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ABSTRACT 
 
Assessing the Cost-Effectiveness of Tumor Necrosis Factor Inhibitors and 








Three new tumor necrosis factor (TNF) inhibitors, adalimumab, etanercept, and 
infliximab, have been approved for use in patients with active RA.  The goals of the 
study were two fold: 1) to perform a cost-effectiveness analysis of the three TNF 
inhibitors in patients with RA that inadequately respond to MTX alone and 2) to assess 
the current prescribing patterns, laboratory monitoring practices, and perceived barriers 
of rheumatologists in prescribing these agents in patients with RA.  Phase I involved 
the development of a Markov simulation model to estimate the health effects and costs 
associated with five treatment strategies in patients with RA that inadequately respond 
to MTX alone: (1) adalimumab plus MTX, (2) etanercept plus MTX, (3) infliximab 
plus MTX, (4) leflunomide plus MTX, and (5) standard therapy of MTX.  A 
hypothetical cohort of 10,000 55-year old women was evaluated using Monte Carlo 
simulation.  The study was conducted from a societal perspective.  The main outcome 
measures were net gains in quality-adjusted life expectancy and incremental cost-
effectiveness ratios, (ICERs) in dollars per quality adjusted life year (QALY) gained.  
Costs and effects were discounted at 3%.  Etanercept plus MTX was the most cost-
effective treatment with an ICER of $49,724/QALY.  Leflunomide plus MTX was the 
second most cost-effective option with an ICER of $52,833/QALY.  One-way and 
probabilistic sensitivity analyses indicated that the conclusions were relatively stable to 
variations in model assumptions.  In phase II, a survey was mailed to a randomly 
selected national sample of rheumatologists, of which 22.3% responded.  The survey 
findings indicated that TNF inhibitor use was not restricted to moderate and severe 
patients with RA.  Also, TNF inhibitor plus one disease modifying anti-rheumatic drug 
was the treatment of choice in patients with severe RA that inadequately respond to 
MTX alone.  Costs to the patient and insurance coverage were perceived as major 
barriers in prescribing TNF inhibitors.  One-fourth of the rheumatologists reported not 
using any monitoring guidelines for the TNF inhibitors indicating a need to revise 
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Clinical features of Rheumatoid Arthritis 
 
Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease that 
affects joints and other tissues.  The disease is characterized by inflammation of 
synovial tissues, joint swelling, stiffness and pain, which may progress to joint and 
bone erosion.  Rheumatoid arthritis generally follows one of three routes of disease 
progression: progressive, intermittent, or malignant.  Around 70% of cases are 
progressive in nature, which follow a chronic pattern with periods of exacerbation and 
remission and significant functional limitation.  Another 25% of cases are intermittent 
in nature and are characterized by brief attacks of inflammation with partial or 
complete remissions.  The remaining 5% have a malignant form of the disease with 





Rheumatoid arthritis affects around one percent of the adult population 
worldwide (Gabriel, 2001) and approximately 2 to 2.5 million people in the United 
States (ACR Guidelines, 2002; Griffiths, Bar-Din, MacLean, Sullivan, Herbert, & 
Yelin, 2001).  The annual incidence of RA diagnosis is about two to four people per 
100,000 (Cimino & O’Malley, 1998).  Like most rheumatic disorders, the prevalence of 
RA is higher in women than men, with a reported female to male ratio of 2.5 to 1.  The 
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incidence of RA is found to increase with age, with peak occurrence ranging from the 
fourth to sixth decade (Terebelo, 2003).   
 
Burden of Illness 
 
Rheumatoid arthritis is associated with pain, deformity, decreased quality of life 
and disability; the disease affects patients’ ability to work, and hence, their 
socioeconomic status.  In addition to causing significant morbidity and mortality, RA 
results in substantial medical resource use and costs.  The combined direct and indirect 
costs resulting from RA in the United States are estimated to be approximately $26 to 
$32 billion per year (1998 values; Pugner, Scott, Holmes, & Hieke, 2000).  A recent 
study by Michaud and colleagues (2003) examined costs of patients with RA after the 
introduction of tumor necrosis factor (TNF) inhibitors.  A sample of 7,527 patients with 
RA responded to semi-annual questionnaires from January 1999 to December 2001.  
Direct medical costs were calculated based on physician and other health professional 
visits, laboratory tests, radiological examinations, outpatient surgeries, hospitalizations, 
and medications.  Patients on TNF inhibitors or other RA drugs reported a mean direct 
cost of $9,519 (2001 values), where 66% was due to drug costs, 16% due to hospital 
costs, and 17% due to outpatient costs.  A sub analysis of the mean direct costs revealed 
that the direct cost of patients on TNF inhibitors was almost three times higher 
($19,016) than those not receiving these agents ($6,164).      
 
Patients with RA have a significantly shorter life expectancy compared with the 
general population, with mean life expectancy shortened by seven years in males and 
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three years in females (Pinals, 1987).  Rheumatoid arthritis frequently leads to work 
disability, and the social impact of the disease is profound.  Rates of work disability in 
the United States and Europe range from 22 to 85% and 31 to 80%, respectively 
(Barrett, Scott, Wiles, & Symmons, 2000).  Income loss is reported to be 50% for men 
and 63% for women and the divorce rate in patients with RA is 70%, higher than that of 
the general population (Allaire, Prashker, & Meenan, 1994; Doyle, 2001).    
 
Etiology and Pathophysiology 
 
  Despite extensive epidemiologic research, the etiology of RA is poorly 
understood.  Rheumatoid arthritis appears to be a multi-factorial disease and a number 
of risk factors have been postulated in the development or progression of RA.  The 
familial nature of this disease indicates that genetic factors are important risk factors in 
the etiology of this disease (Gabriel, 2001).  Other suspected risk factors include 
infectious factors such as helicobacter pylori (Zentilin et al., 2002), Epstein Barr virus 
(Silman & Pearson, 2002), and environmental factors such as cigarette smoking 
(Gabriel, 2001).  Sex hormones are also implicated in the etiology of RA as there is an 
increased incidence in women (Jobanputra, Barton, Bryan, & Burls, 2002). 
   
Rheumatoid arthritis begins as a synovial microvasculature injury.  This is 
accompanied by proliferation of inflammatory exudate into the joint cavity.  The 
synovial fluid in RA is highly cellular and contains lymphocytes, macrophages, T- and 
B- cells.  The normal joint layer consists of one to two layers of thick fibroblastic-like 
cells.  In disease, the layer increases to a ten-cell thick layer and forms a pannus that 
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actively destroys the periarticular bone and cartilage.  Erosions can be seen in x-rays, 
which are very useful for diagnosis.   
 
Role of Tumor Necrosis Factor (TNF)   
  Almost all biological processes involve cytokines.  Cytokines are low molecular 
weight soluble proteins synthesized by different types of cells that play a key role in the 
function and regulation of the immune system.  The most prominent cytokines include 
interleukins (IL-1α, IL-1β) and TNF- α and β (Toussirot & Wendling, 2004).  
Interleukins and TNF play a prominent role in the mechanisms of inflammation and 
joint degradation as they can activate different cells in the synovium and can regulate 
the cartilage and bone turnover.  It has been demonstrated that blocking TNF results in 
down regulation of pro-inflammatory cytokines such as IL-1 as well as other cytokines 
and angiogenic factors.  Thus, TNF plays a pivotal role in the pathogenic mechanisms 
of RA and is a major therapeutic target in the disease treatment.   
 
Goals of RA Management 
 
 According to the guidelines for the management of RA issued by the American 
College of Rheumatology (ACR), the goals of RA treatment is to prevent or control 
joint damage, prevent loss of function, and decrease pain (ACR Guidelines, 2002).  
Figure 1 depicts the RA treatment algorithm.  The long-term treatment plan for RA 
requires a comprehensive coordinated care and the expertise of a number of health care 
providers.  In addition, the care provided has to be reevaluated in light of clinical 
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parameters and patient preferences.  Clinicians incorporate various factors when 
choosing treatment protocols with/for their patients: 
a) Therapeutic options including drug and non-drug treatments as well as their risk and 
benefits. 
b) Modes of drug administration and monitoring for safe use of these drugs. 
c) Educational needs of patients and care-givers. 
d) Patient co-morbidities that may influence drug use and prognosis.  For example, a 
number of RA patients have coexisting cardiovascular disease at diagnosis. 




Figure 1. Rheumatoid arthritis treatment algorithm (ACR Guidelines) 
Classification of RA 
Mild disease with no disease 
progression 




2. Low dose corticosteroids 
3. Non pharmacologic treatment (rest, 
occupational therapy, physical 
therapy, use of assisted device) 
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Assessment of Response to Treatments 
 
  The ultimate goals of treatment are to prevent or control joint damage, prevent 
loss of function, and decrease pain.  In short, the goal is complete remission; this may 
be somewhat unrealistic in RA.  The ACR has developed criteria to define 
improvement and clinical remission in RA.  The ACR criteria of a 20% clinical 
response is defined as a decrease of at least 20% in the number of swollen joints, a 
decrease of at least 20% in the number of tender joints, and a 20% improvement in 
three of the following five criteria: patients’ global assessment of disease status, 
patients’ assessment of pain, health assessment questionnaire estimate of disability, 
physicians’ global assessment of disease status, and erythrocyte sedimentation rate 
(ESR) or C-reactive protein (CRP) concentration.  These criteria have been expanded to 






Pharmacotherapy for active RA may include one or a combination of the 
following four classes of drugs: nonsteroidal anti-inflammatory drugs (NSAIDs), 
analgesics, corticosteroids (prednisolone and methylprednisolone), and disease 
modifying anti-rheumatic drugs (DMARDs) including sulfasalazine, methotrexate, gold 
preparations, penicillamine, azathioprine, hydroxychloroquine, leflunomide, and 




 The treatment of RA has evolved over the past few years.  Four pathways of 
drugs for RA have been identified in the literature (Wolfe, Rehman, Lane, & Kremer, 
2001):  
1) Time-based pyramid: In this approach, NSAIDs are the first line of therapy and 
disease modifying anti-rheumatic drugs (DMARDs) are used in the end with caution. 
2) Severity-based pyramid: In this approach, the most effective treatment is given to 
those with more active disease.  
3) Cost-based approach: The primary goal of this approach is to contain cost.  Criteria 
are established which allow less expensive drugs to be used before more expensive 
ones.  Additionally, use of some DMARDs and TNF inhibitors are restricted for use in 
patients based on severity of the disease.  Thus, the severity-based approach is tied with 
cost considerations. 
4) Patient preference: The treatment is based on the patient’s needs and wishes 
regardless of the severity. 
   
Studies in the literature indicate that time-based and severity-based pathways 
are no longer used and patients with varying severity and disease duration are treated 
aggressively with DMARDs and TNF inhibitors (Wolfe et al., 2001).  Modern RA 
management stresses the importance of early diagnosis and treatment with DMARDs, 
particularly methotrexate (MTX) which is considered to be the “gold standard.”  
However, several problems exist with the use of traditional DMARDs.  The duration of 
treatment is often limited to intervals of less than two years.  Patients usually 
discontinue the usage of these drugs either due to toxicity or lack of effectiveness.  The 
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next step in the management is to administer combinations of DMARDs to patients 
who do not respond to higher doses of single agents.  Combinations include 
cyclosporine with MTX or hydroxychloroquine with MTX.  If favorable outcomes are 
not achieved with these combinations, another DMARD is added to the combination, 
e.g. sulfasalazine with hydroxychloroquine and MTX (Kremer, 2001).   
   
A significant number of patients (around 10%) fail to respond to traditional 
DMARDs, either alone or in combination (Cairns & Taggart, 2002).  These patients 
appear to be resistant to conventional approaches including MTX, that is, they have 
used at least three DMARDs including MTX (> 15 mg/week) and sulfasalazine (dose > 
2 g/day) for a minimum of six months (unless there was toxicity) and have persistent 
active disease despite therapy.  Thus, it is apparent that further therapeutic advances are 
required for better treatment of the disease for those patients who do not respond to 
conventional approaches.   
 
The treatment of patients with RA has changed dramatically in the last few 
years (Kremer, 2001;Yazici, Erkan, & Paget, 2003).  Tumor necrosis factor (TNF) has 
become an attractive target for treatment in patients with RA.  As a result, three new 
TNF inhibitors, adalimumab, etanercept, and infliximab, have been approved for use in 
patients with RA that inadequately respond to MTX alone (Hochberg, Tracy, Holt-
Hawkins, & Flores, 2003).  Infliximab is given in combination with MTX, while 
etanercept and adalimumab are administered either alone or in combination with MTX.  
Clinical trials of these drugs have shown that they may be more effective than 
9 
 
traditional agents because of their ability to alter joint remodeling as well as attenuate 
symptoms (Louie, Park, & Yoon, 2003).  Leflunomide, a dihydroorotate dehydrogenase 
inhibitor, is another addition to the list of DMARDs, which in combination with MTX 
has been effective in improving signs and symptoms of patients with inadequate 
response to MTX (Kremer, 2001).  
 
 
Economics of Treatments in Patients with RA that Inadequately Respond to MTX 
 
 A systematic literature search was conducted among literature published from 
January 1996 to October 2004 through MEDLINE, EMBASE, and the Cochrane library 
databases to identify studies that addressed the cost-effectiveness of all three TNF 
inhibitors and leflunomide in RA patients with inadequate response to MTX.  The 
search yielded 14 articles of which nine were published in peer-reviewed journals and 
five were abstracts presented at various conferences.  A study by Kavanaugh and 
colleagues (1996) used a six-month decision model to determine and compare the costs 
and effectiveness of three single agents (a hypothetical novel biologic agent, MTX, and 
parenteral gold.  The authors reported that the total cost of MTX and parenteral gold 
were substantially lower than those of the hypothetical biological agent.  However, 
sensitivity analyses indicated that by increasing the clinical efficacy of the hypothetical 
biological agent, total cost decreased due to the accrual of fewer indirect costs.  In 
another study, which also employed a six-month decision model, triple therapy (a 
combination of hydroxychloroquine, sulfasalazine, and MTX) was the least expensive 
option and had the lowest incremental cost-effectiveness ratio (ICER) per ACR 20 or 
ACR 70 weighted response (US $1,500 and US $3,100, respectively).  The most 
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efficacious option was the combination of etanercept with MTX with ICERs of 
$42,600/ACR 20 response and $34,800/ACR 70 weighted response, respectively (Choi, 
Seeger, & Kuntz, 2000).  A major limitation of these studies was that early withdrawal 
of patients from treatments was not built into the six-month model.  
 
Despite promising short-term results for newer TNF inhibitors, very few 
economic studies have addressed the long-term effectiveness of these drugs.  A cost-
effectiveness study employing a Markov Model by Wong and colleagues (2002) 
demonstrated that infliximab plus MTX, when compared with MTX alone, decreased 
the likelihood of having advanced disability from 23% to 11% at the end of 54 weeks; 
this projected to a lifetime marginal cost-effectiveness ratio of $30,500 per discounted 
quality-adjusted life-year (QALY) gained.  A study conducted in the Netherlands, 
which also employed a Markov Model, reported that a treatment strategy starting with 
leflunomide followed by TNF inhibitors, in case of non-response with MTX, was the 
most cost-effective strategy (Welsing, Severens, Hartman, van Riel, & Laan, 2004).   
 
  A UK cost-utility analysis indicated that etanercept was more cost-effective 
than infliximab in the treatment of patients who had failed DMARD therapy (Brennan, 
Bansback, Conway et al., 2001).  A study by Bansback and colleagues (2004) looked at 
the cost-utility of adalimumab in treating patients with moderate to severe RA who 
have failed at least two traditional DMARDs.  The cost per QALY for both 
adalimumab and etanercept was estimated to be between 35,000-42,000 euros 
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suggesting that adalimumab was at least as cost-effective as the other TNF inhibitors.  
These studies are discussed in more detail in Chapter 2.  
  
 
STATEMENT OF PROBLEM 
 
 The management of patients with RA that inadequately respond to MTX alone 
has changed markedly with the introduction of TNF inhibitors.  These agents have been 
shown to decrease pain, joint swelling, inflammatory arthritis, and rates of radiologic 
damage.  Despite the benefits, these treatments are expensive and the annual cost of 
therapy with these drugs is approximately $16,000 (Kavanaugh, Cohen, & Cush, 2004).  
Given the chronic nature of RA, the economic costs associated with the disease, and the 
high costs of the newer treatments, economic evaluations of the costs and benefits of 
these new agents could be very useful for optimal resource allocation.  Given the 
current financial constraints on health care, the ability to demonstrate cost-effectiveness 
of new treatments is a critical factor in determining the acceptability of a new therapy 
(Tugwell, 2000). 
   
One of the major concerns about economic studies in RA is the duration for 
which a study may be conducted.  Most existing economic models determine cost-
effectiveness over a short period of time, since the duration of most clinical trials in RA 
are six months.  This ignores the possibility that varying duration of efficacy in 
treatments can affect cost-effectiveness over a longer time horizon.  Since patients with 
RA continue to take medications indefinitely, as long as the medication does not have 
any side effects, costs and outcomes continue to accumulate over a longer time horizon.  
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Tumor necrosis factor inhibitors have been shown to slow down the radiological 
progression of the disease and thereby the downstream economic consequences.  Thus, 
lifetime models are the most accurate way of estimating the cost-effectiveness of RA 
therapy.  These lifetime models may also assess the impact of the treatment on the 
disease course, which might not be apparent in the short-term.  
   
A few studies are reported in the literature that have conducted economic 
evaluations of TNF inhibitors using lifetime models (Brennan, Bansback, Reynolds, & 
Conway, 2003; Kobelt, Jonsson, Lindgren, Young, & Eberhardt, 2003; Wong et al., 
2002).  These studies have mainly compared one TNF inhibitor with the standard 
treatment (MTX) or a placebo.  A major limitation of these long-term studies, however, 
is that none have looked at the effect of etanercept or infliximab on surgery-related 
hospitalizations.  Disability represents a major cost-driver in RA treatment and clinical 
trials of these drugs have shown evidence of slowing disease progression and 
eventually disability (Keystone et al., 2004; Maini et al., 1999; Weinblatt et al., 2003; 
Weinblatt, Kremer, Bankhurst et al., 1999).   
   
In the absence of any study evaluating the cost-effectiveness of all three TNF 
inhibitors in patients with RA that inadequately respond to MTX alone, there is a need 
to assess the impact of these agents on long-term outcomes and on disease and drug-
related morbidity and mortality.  Also, it is important to determine the cost-
effectiveness of these new drugs in order to assess the appropriateness of their use in an 
increasingly cost-conscious environment.  Thus, Phase I of the proposed study will 
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examine the incremental cost-effectiveness of TNF inhibitors (adalimumab, etanercept, 
and infliximab) and leflunomide used in combination with MTX modeled over a 
lifetime in patients with RA that inadequately respond to MTX alone.  The analysis will 
be conducted from a societal perspective.  
 
Even though infliximab, etanercept, and adalimumab belong to the same class 
of drugs, they have distinct clinical, pharmacokinetic, and pharmacodynamic properties 
that must be considered when selecting any one of them for therapy.  A number of 
factors have been found to affect a physician’s decision-making process regarding 
choice of therapy.  These include patient preference, the disease itself (for example, 
disease duration and symptom severity), the drug chosen (for example, potential 
adverse events, cost, and route of administration), and published evidence documenting 
the overall experience with each drug (Schwartzman, Fleischmann, & Morgan, 2004; 
Schwartzman & Morgan, 2004).   
 
Physicians have been prescribing etanercept and infliximab for over four years.  
Although adalimumab has recently been introduced, the experience is greatest with the 
use of etanercept and infliximab.  However, physicians’ preference for these TNF 
inhibitors in patients with RA that inadequately respond to MTX have not been well 
studied.  Another issue with these drugs is identifying the patient population that should 
be treated with TNF inhibitors.  In their original labeling, all three TNF inhibitors were 
approved for patients with moderate to severely active RA.  However, their actual uses 
have varied according to local availability, standards of practice, and monitoring 
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guidelines (Kavanaugh et al., 2004).  It is not known whether rheumatologists are using 
these agents very early in the disease course to induce remissions or for patients with 
active RA as indicated in the labeling of the three agents.  Also, very limited data is 
available about the issues physicians confront in the use of these drugs or while making 
choices among the three TNF inhibitors.  Thus, one of the goals of phase II of the 
proposed study is to investigate rheumatologists’ current prescribing patterns for the 
three TNF inhibitors.   
 
There are very few data available on these agents’ possible side effects and 
there are no well-defined laboratory monitoring guidelines.  Since the introduction of 
these agents, there have been concerns about the potential for adverse events as a result 
of inhibiting TNF.  Clinical studies report that the frequency of infections and 
lymphomas among patients with RA treated with TNF inhibitors may be higher than in 
the general population.  Thus, there is a need for routine screening of patients using 
these agents (Kavanaugh et al., 2004).  However, there are currently no guidelines for 
blood tests to monitor patients on these agents.  Studies indicate that rheumatologists 
using these agents seem to monitor patients based on their experience with DMARDs, 
particularly MTX.  Also, there is no consensus as to how often the monitoring tests 
should be performed (Yazici et al., 2003).  Hence, another goal of Phase II of the 
proposed study is to determine what laboratory monitoring protocols rheumatologists 




The selection of the most appropriate agent in RA treatment is a complex 
clinical decision.  The TNF inhibitors have been shown to achieve a marked 
improvement in clinical outcomes in patients with RA.  However, there are a number of 
concerns regarding their use by rheumatologists.  These include the potential for 
adverse events (such as injection and infusion-site reactions, upper respiratory tract 
infections), severe infections, high cost of TNF inhibitors, route of administration, and 
patient preference (Fleischmann & Yocum, 2004).  Thus, one of the goals of Phase II of 
the proposed study is to investigate the different factors that rheumatologists perceive 
as problematic in prescribing specific TNF inhibitors for patients with RA.  
  
In summary, Phase I of the proposed study will examine the incremental cost-
effectiveness of the three TNF inhibitors and leflunomide in combination with MTX in 
patients with RA that inadequately respond to MTX alone.  In Phase II of the study, 
rheumatologists’ current prescribing patterns, laboratory monitoring protocols, and 




   This study will be conducted in two phases.  Phase I will involve the 
construction of an economic model to compare the incremental cost-effectiveness of 
the three TNF inhibitors and leflunomide in combination with MTX in patients with 
RA that inadequately respond to MTX alone.  Phase II will assess the current 
prescribing patterns of rheumatologists using TNF inhibitors in treating patients with 
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RA.  Information on laboratory monitoring practices, frequency of tests ordered, and 




  Phase I involves developing a decision analytic model to compare the total costs 
and effects of each of the three TNF inhibitors (etanercept, infliximab, and 
adalimumab), and leflunomide used in combination with MTX in patients with RA that 
inadequately respond to MTX alone.  Economic analysis utilizing decision analytic 
models is a comparative analysis of different therapeutic options in terms of their costs, 
efficacy, and safety parameters.  The end result of this analysis is to summarize the 
benefits and harms (both clinical and financial) of the different therapeutic options and 
identify those options that deliver maximum benefits in the most cost efficient manner 
(Homik & Suarez-Alamor, 2004).   
 
The decision analytic model in the proposed study will assume that a base-case 
population of 55 year-old women have already failed at least two DMARDs, one of 
which is MTX.  The selection of the base-case population is because it is the patient 
population that has been studied in the majority of the randomized clinical trials 
(RCTs), and is therefore most representative of the patients with RA receiving TNF 
inhibitors and leflunomide.  Since it is assumed that the patients will inadequately 
respond to MTX, the five treatment options to be considered in the analysis will include 
combination of each of the three TNF inhibitors (adalimumab, etanercept, infliximab) 
with MTX, leflunomide plus MTX and standard therapy of MTX.        
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The decision model to be employed in the analysis will be a Markov Model 
with six-month cycles.  Since the current study involves extrapolating results from 
short-term RCTs over a patient’s lifetime to quantify the effects of introducing the 
treatments, Markov models are particularly suited to handle both costs and outcomes 
simultaneously over chronic time intervals (Briggs & Sculpher, 1998; Sonnenberg & 
Beck, 1993).  Details on the actual working of Markov models are presented in Chapter 
2.  In each six-month cycle of the model, the patient will either continue with the 
treatment or will withdraw due to severe adverse events or lack of efficacy.  In the 
event of withdrawal, the patients will be switched to palliative care where they will be 
treated with a combination of MTX, NSAIDs, and corticosteroids.  The effectiveness 
measures will consist of American College of Rheumatology 20% response criteria 
(ACR 20).  Those who will continue with the treatment may respond to treatment by at 
least 20% (ACR 20) or may experience adverse events (mild and moderate) minor 
enough to continue with the treatment.  Thus, at the end of each cycle, patients will be 
redistributed in the model based on the transition rates derived from the RCTs of the 
respective treatments.  The model will run until all the patients are dead.   
 
Rheumatoid arthritis, like other chronic diseases, has a continuous effect on 
several functions over a long period of time and therefore several outcome measures 
are used.  However, RA-specific outcomes like ACR 20 cannot be used to make 
absolute statements about whether a given option is cost-effective compared with other 
widely accepted cost-effective interventions in medicine (Choi et al., 2000).  Thus, a 
generic measure of effectiveness such as quality-adjusted life years (QALYs) will also 
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be used in the study.  Quality-adjusted life years combines QoL with time by adjusting 
life-years with a quality weight, measured as utility.  Utilities, to calculate QALYs in 
the present study, will be derived from a study by Bansback and colleagues (2004).   
 
A societal perspective will be taken in the estimation of costs in the base-case 
analysis.  The total cost of treatment with each agent is composed of direct costs 
associated with treating patients with RA that inadequately respond to MTX, combined 
with the indirect costs (for example, loss of productivity and premature mortality) 
incurred by the patient as a result of the disease.  Incremental cost-effectiveness ratios 
will be calculated as additional cost per patient achieving outcomes, compared with the 




  As noted earlier, treatments for RA have evolved over time.  Randomized 
clinical trials are considered as the “gold standard” for assessing the value of a therapy.  
However, the short-term data derived from RCTs may not be applicable to long-term 
effectiveness of controlling the disease, especially in a chronic and complex disease 
like RA.  Long-term observational studies are also used to evaluate therapies but these 
require investment in terms of time and money.  A third approach, in addition to RCTs 
and long-term observation studies, is to survey rheumatologists regarding their opinions 




Since the TNF inhibitors have recently been introduced in the market, there is 
not enough data available regarding their safety and effectiveness.  Also, there are no 
recommended treatment guidelines available for rheumatologists to consult, while 
using these drugs.  The selection of etanercept, infliximab, or adalimumab depends on a 
number of factors.  They have different routes of administration, which can affect a 
patient’s preference for the drugs.  Safety (severe adverse events, moderate events, and 
mild events like injection- and infusion-related reactions) is another factor which 
physicians may consider to make their choice.  In terms of reimbursement issues, 
intravenous (IV) dosing (infliximab) may hold an advantage over subcutaneous (SC) 
dosing (etanercept and adalimumab), especially in patients with Medicare coverage.  
This information can only be clarified with the availability of more data from a clinical 
trial or from evaluation of physician practice experiences.  
 
Phase II of the proposed study will assess the current prescribing patterns of 
rheumatologists using TNF inhibitors in treating patients with RA through a national 
mail survey.  The survey will be useful in providing data on the clinical experiences of 
rheumatologists.  In addition, information on laboratory monitoring practices, 
frequency of tests ordered, and perceived barriers of rheumatologists in prescribing 
TNF inhibitors will also be collected. 
 
STUDY GOALS AND RESEARCH QUESTIONS 
 
  The goals of the study are two fold: 1) to conduct an incremental cost-
effectiveness analysis of TNF inhibitors (adalimumab, etanercept, and infliximab) and 
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leflunomide used in combination with MTX in the treatment of patients with RA that 
inadequately respond to MTX alone using a Markov simulation model, and 2) to assess 
the current prescribing patterns, laboratory monitoring practices, and perceived barriers 




  Phase I will involve the development of a Markov simulation model to calculate 
the incremental cost-effectiveness ratios of TNF inhibitors (adalimumab, etanercept, 
and infliximab) and leflunomide used in combination with MTX in the treatment of 
patients with RA that inadequately respond to MTX alone 
 
Objectives for Phase I: 
Objective 1: To develop a Markov simulation model to assess the long-term costs and 
consequences of TNF inhibitors (adalimumab, etanercept, and infliximab) and 
leflunomide used in combination with MTX in the treatment of patients with RA that 
inadequately respond to MTX alone  
Rationale: Decision analysis modeling is a powerful simulation technique and is being 
increasingly used to assess the economic outcomes of new drugs.  Decision analysis 
modeling can be an inexpensive and effective way of synthesizing existing data and 
evidence available on costs and outcomes of alternative treatments, and can be used to 
extrapolate beyond the follow-up period of a clinical trial, or from an intermediate 
outcome to a final health outcome (Brennan & Akehurst, 2000).  These analytic models 
can assist decision makers until more definitive information is made available about 
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outcomes and costs in actual clinical settings.  Rheumatoid arthritis is a chronic, 
debilitating, and lifelong disease and any decision analytic model developed to evaluate 
the cost-effectiveness of the new drugs needs to take into account the lifetime costs of 
the therapies.  Decision tree models are not appropriate since they report the outcomes 
over one to two-year time frame.  Also, there is a limit to the manageable size of the 
decision tree.  Markov models overcome this hurdle and provide a better way of 
simulating the progression of RA over time and the possible impact of treatments.   
 
Objective 2: To develop cost-effectiveness models based on the Markov simulation 
model that determine the incremental costs and consequences of TNF inhibitors 
(adalimumab, etanercept, and infliximab) and leflunomide used in combination with 
MTX in the treatment of patients with RA that inadequately respond to MTX alone 
Rationale: When considering a drug therapy for RA, several factors appear to be 
predictive of positive cost-effectiveness.  Disability is a major determinant of expense 
in RA and any drug that slows joint destruction and thus delays the onset of disability 
has the potential to be cost-effective.  Another determinant of RA expense is the cost 
associated with treating drug-related adverse events.  Thus, a drug with good safety 
profile will probably be more cost-effective than a drug with similar efficacy but 
causing more side effects.  Finally, RA being a chronic disease, the longer the drug 





The introduction of TNF inhibitors (adalimumab, etanercept, and infliximab) 
represents a significant advance in the available treatments for patients with RA.  These 
agents have demonstrated good efficacy and tolerability in clinical trials (Keystone et. 
al., 2004; Kremer et. al., 2002; Maini et. al., 1999; Weinblatt et al., 2003; Weinblatt et. 
al., 1999).  These agents have also been shown to be more effective than traditional 
agents because of their ability to slow disease progression and to improve disability 
scores.  While all these attributes suggest that these agents will be cost-effective, only 
appropriate analyses that examine both efficacy and total costs can provide a true 
assessment of cost-effectiveness (Tugwell, 2000). 
 
A few studies have been conducted to evaluate the cost-effectiveness of these 
agents.  A study by Choi and colleagues (2000) that used a six-month decision model 
failed to account for early withdrawals by patients who did not respond to the 
treatments.  Similarly, two studies that used long-term models, let non-responders stay 
on treatment for one full year (Kobelt et al., 2003; Wong et al., 2002).  Neglecting to 
incorporate early withdrawals potentially biases the results because patients that fail to 
respond to treatment will show little gain in health improvement but will continue to 
accrue large costs associated with one-year treatment with TNF inhibitors.  In addition, 
most of the studies failed to include the decrease in future risk of disability, which 
could improve the cost-effectiveness of treatments.  Conversely, the adverse effects of 
TNF inhibitors (including high risk of serious infections), which may increase health 
care costs, were not included in most analyses.  Simply demonstrating the efficacy of a 
treatment does not necessarily establish its economic benefits.  Economic evaluation of 
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the TNF inhibitors should include their ability to prevent disability and safety profiles, 
and should be conducted over a patient’s lifetime thereby determining the true cost-




  The primary goal of phase II will be to assess rheumatologists’ current 
prescribing patterns for the three TNF inhibitors.  Secondary goals will include 
determining rheumatologists’ laboratory monitoring practices, practice of switching 
patient from one TNF inhibitor to another TNF inhibitor, and identifying perceived 
barriers to prescribing these drugs.  
The specific objectives are as follows: 
 
Objectives for Phase II: 
Objective 1:  To describe rheumatologists’ prescribing patterns for the three TNF 
inhibitors: adalimumab, etanercept, and infliximab. 
Rationale:  Recent surveys have shown that combinations of DMARDs are preferred in 
practice especially to treat patients with moderate or severe RA (Jobanputra, Wilson, 
Douglas, & Burls, 2004; Maetzel, Bombardier, Strand, Tugwell, & Wells, 1998; Pope, 
Hong, & Koehler, 2002).  With the introduction of new TNF inhibitors, it is important 
to investigate the current prescribing patterns of rheumatologists.  The labeling of these 
drugs indicates their use in moderate to severe patients.  But whether these drugs are 
being prescribed as first-line therapy in RA alone or used in conjunction with other 
traditional DMARDs is not known. 
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An indirect comparison of the three TNF inhibitors by Hochberg and colleagues 
(2003) indicated similar efficacies in RA.  Thus, a reasonable question for clinicians is 
whether patients who have failed one TNF inhibitor could be given a trial with another 
TNF inhibitor.  A few studies conducted in rheumatology clinics have reported 
switching patients from one TNF inhibitor to another TNF inhibitor, but it is not known 
if rheumatologists in different practice settings are doing the same and their reasons for 
switching patients from one TNF inhibitor to another TNF inhibitor (Haraoui, 2004; 
Yazici & Erkan, 2004). 
 
Objective 2:  To determine if the rheumatologists have any preference for a particular 
TNF inhibitor. 
Null Hypothesis A: Rheumatologists do not have any preference for any of the TNF 
inhibitors. 
 
Objective 3:  To assess if there are any differences in demographic (age, gender) and 
practice-related characteristics (number of years in practice as a rheumatologist, 
primary practice site, average number of RA patients seen per week) and perceived 
barriers in prescribing TNF inhibitors among rheumatologists who prefer adalimumab, 
etanercept, or infliximab as their first choice agent. 
Null Hypothesis B: There are no significant differences in demographic (age, gender), 
practice-related characteristics (number of years in practice as a rheumatologist, 
primary practice site, average number of RA patients seen per week), and perceived 
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barriers in prescribing TNF inhibitors among rheumatologists who prefer adalimumab, 
etanercept, or infliximab as their first choice agent. 
 
Objective 4:  To describe the laboratory monitoring practices and the frequency of tests 
ordered by the rheumatologists for patients on TNF inhibitors. 
Rationale: There are no known monitoring guidelines established for TNF inhibitors.  
There are a number of reports on the safety profile of these agents and at the same time 
a dearth of information regarding their long-term outcomes.  According to the only 
study conducted to find whether or not rheumatologists follow monitoring guidelines, 
results indicated that rheumatologists seem to continue their practice of monitoring 
based on their experience with earlier traditional DMARDs.  However, there seems to 
be a significant variation in laboratory tests ordered, and the frequency of ordering 
these tests (Yazici et al., 2003).  This research question is a follow-up on this study to 
determine if the practice is the same or has changed over the years. 
 
Objective 5: To determine if the rheumatologists are following any recommended 
monitoring guidelines for patients with RA on adalimumab, etanercept, and infliximab. 
Null Hypothesis C: Rheumatologists are not following any recommended monitoring 
guidelines for patients with RA on adalimumab, etanercept, and infliximab. 
 
Objective 6:  To assess if there are any differences in demographic (age, gender) and 
practice-related characteristics (number of years in practice as a rheumatologist, 
primary practice site, average number of RA patients seen per week) and perceived 
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barriers in prescribing TNF inhibitors between rheumatologists who follow monitoring 
guidelines and those who do not follow any guidelines. 
Null Hypothesis D: There are no significant differences in demographic (age, gender) 
and practice-related characteristics (number of years in practice as a rheumatologist, 
primary practice site, average number of RA patients seen per week) and perceived 
barriers in prescribing TNF inhibitors between rheumatologist’s who follow guidelines 
and those who do not follow any guidelines. 
 
Objective 7:  To assess if there are any differences in rheumatologists’ perceptions of 
barriers (insurance coverage, route of administration, patient compliance, patient 
preference, side effects, costs to the patient, age of the patient, efficacy of the drugs, 
and support needed for administration of drugs) to prescribing the three TNF inhibitors. 
Null Hypothesis E:  There are no significant differences in rheumatologists’ perceptions 
of barriers (insurance coverage, route of administration, patient compliance, side 
effects, costs to the patient, age of the patient, efficacy of the drugs, and support needed 
for administration of drugs) to prescribing the three TNF inhibitors. 
       
SIGNIFICANCE OF THE STUDY 
 
 
  Recent therapeutic advances in the treatment of RA have demonstrated 
improvement in inflammatory arthritis and stabilization of radiographic progression, 
but these new therapies are expensive due to high acquisition costs, potential toxicity, 
and associated monitoring.  The costs of not treating RA are also very high due to 
increased medical and long-term costs associated with uncontrolled disease.  The cost-
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effectiveness of TNF inhibitors is presently unclear.  The results of Phase I of the study 
can help determine if etanercept, infliximab, adalimumab, or leflunomide used in 
combination with MTX in patients with RA that inadequately respond to MTX alone is 
cost-effective or not.  The TNF inhibitors have been shown to prevent and delay 
disability.  At the same time, they have also been shown to cause serious adverse 
events.  The results of the study may also determine if the reductions in nondrug costs 
can help offset the high acquisition costs of these agents and the high health care costs 
due to higher risk of infections.   
 
However, as discussed earlier, the choice of an optimal agent by a 
rheumatologist is based not only on cost but also on accumulated clinical experience, 
patient preference, convenience, route of administration, and safety profile of a drug.  
The most widely accepted and used guidelines are for MTX and published by the ACR.  
For the newer TNF inhibitors, risks exist and infections, neoplasms, and autoimmune 
disorders have been reported in patients using these agents.  It is important that drug 
toxicity is discovered as early as possible by appropriate laboratory monitoring before 
serious events become clinically evident.  Currently, very little information exists with 
regards to the rheumatologists’ prescribing patterns for TNF inhibitors, laboratory 
monitoring protocols, and their perceived barriers in prescribing these agents.  
Consequently, Phase II of the study was developed to study rheumatologists’ use of the 
TNF inhibitors.  Results of phase II study will help provide valuable insight into the 
prescribing patterns of rheumatologists using these agents for treatment of patients with 






The limitations of each phase of the study are discussed below: 
The main limitation of Phase I of the study relates to the data available.  An 
ideal source would have been a very long-term, randomized study with a large sample 
size examining the efficacy and resources utilized by all the therapeutic options in RA 
patients who have inadequate response to MTX.  In the absence of such a study, 
evidence has to be assembled from a range of sources and these sources have their 
advantages and disadvantages from a health economic perspective.  Data from clinical 
trials do not have high external validity.  In addition, data on actual use of etanercept, 
infliximab, and adalimumab are not yet available.  Thus, the results of any modeling 
study need to be treated with some degree of caution. 
 
Another limitation in Phase I is that the base-case analysis in the decision 
analytic model assumes that the baseline characteristics of the study patients across the 
source RCTs are comparable based on their close similarities in important baseline 
demographic and clinical characteristics.  It is a general view that absolute 
comparability across different treatments can be established through randomization.  
Currently, such data does not exist and it appears doubtful that all the treatment options 
considered in the analysis would be evaluated using a single head-to-head randomized 




The efficacy data for each treatment option (except for adalimumab plus MTX) 
comes from a single respective RCT.  Therefore, there will be generalizability issues 
with the base-case estimate used in the Phase I of the study.  However, sensitivity 
analyses will be conducted to address this limitation. 
 
As discussed in the introduction, the significant portion of health services costs 
incurred by RA patients is due to surgery-related hospital admissions.  It is possible that 
effective disease control with more effective therapy could prevent or reduce hospital 
admissions.  A study by Yelin and Wanke (1999) reported that almost 52% of the direct 
costs of RA was due to hospital admissions, of which 95.2% came from surgical 
admissions.  The authors also reported that functional status measured by Health 
Assessment Questionnaire (HAQ) disability score was the only consistent and strong 
predictor for the total direct costs.  The surgery-related costs for each treatment strategy 
was calculated based on an exponential relationship between HAQ score reported from 
clinical trials and inpatient surgery costs used by Choi and colleagues (2000).  
However, since the data may not be reliable, the study will report results both by 
including and excluding surgery-related costs in the model. 
 
The three TNF inhibitors and leflunomide have different modes of 
administration.  However, the potential impact of compliance was not considered in the 
model.  No data is available indicating differing rates of compliance among the 




In RA, indirect costs can be divided into morbidity costs (lost production) and 
mortality costs (present value of lost production due to premature death).  In the present 
study, indirect cost was estimated as being one to three fold higher than direct costs, 
which may limit its accuracy.  
 
Phase II of the study will use a mail survey to elicit current treatment practices 
of rheumatologists.  The study therefore will have all the limitations associated with 
cross-sectional survey design methodology. 
 
This chapter gave a brief description of underlying health problem, the need for 
the study, the research questions, the significance and the limitations of the study.  The 
next chapter will give an extensive review of the existing literature associated with RA 







REVIEW OF LITERATURE 
 
 The first section of this chapter will describe the techniques of economic 
evaluation and will provide an overview of the use of Markov models in performing 
these evaluations.  A review of the clinical effectiveness and available 
pharmacoeconomic evaluations of tumor necrosis factor inhibitors and leflunomide in 
RA patients that inadequately respond to MTX alone will be discussed next.  Finally, 
studies investigating rheumatologists’ prescribing patterns for specific TNF inhibitors 
and their use of monitoring protocols will be reviewed.   
 
Types of Economic Analyses 
 
Rheumatoid arthritis (RA) is a chronic systemic disorder and is associated with 
pain, functional limitations, physical disability, and decreased QoL (Blumenauer, 
Coyle, & Tugwell, 2002).  As a chronic debilitating disease with a progressive course, 
RA has an economic impact that is disproportional to its prevalence.  Several studies 
have been conducted to quantify the economic costs of interventions that delay or 
prevent disability and reduce the associated morbidity and mortality in RA.  However, 
these studies need to include both costs and the consequences to establish the economic 
benefit of the therapy. 
 
Studies that consider both costs and consequences are termed as “full’ economic 
evaluation and include cost-benefit analyses, cost-effectiveness analyses, and cost-
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utility analyses.  These studies consider the total direct, indirect, and intangible costs.  
Direct costs include physician services, hospitalizations, medication costs, diagnostic 
procedures (laboratory and radiological costs), costs of treating of adverse events, 
patient and caregiver time, and rehabilitation and nursing care.  Indirect costs include 
loss of income due to loss of workdays or loss of employment, house-remodeling costs, 
and the intangible costs of impact on social life, pain, deformity, and decreased QoL 
(Blumenauer et al., 2002; Drummond, O’Brien, Stoddart, & Torrance, 1998; Emery, 
2004; Homik & Suarez-Almazor, 2004).   
 
Cost-benefit analyses express both costs and consequences in monetary terms.  
These methods are less commonly used, as they require the consequences of the 
treatment to be expressed in dollar terms.  The most commonly used economic 
evaluations in RA are cost-effectiveness and cost-utility analyses.  Cost-effectiveness 
analyses measure costs in terms of a defined measure of a clinical outcome; cost-utility 
analyses measure costs in relation to an outcome, and take QoL into consideration (e.g. 
Quality adjusted life years or QALYs).  These types of analyses are more appropriate 
since they not only include the total costs of the therapy but also the costs of the disease 
process.  Patients with active RA may have major disabilities resulting in loss of 
workdays, decreased QoL, and other outcomes; cost-effectiveness analyses account for 





As opposed to full economic evaluations, “partial” economic evaluations 
consider only the cost of intervention (direct and indirect) and not the outcome (clinical 
effectiveness or economic benefit) of the intervention (Drummond et al., 1998; Emery, 
2004; Homik & Suarez-Almazor, 2004).  Cost analyses are considered as partial 
economic evaluations and are useful in evaluating the impact of drugs with similar 
efficacies.  However, cost analyses of the TNF inhibitors against the traditional 
DMARDs might not favor the TNF inhibitors due to their high acquisition costs 
(Lipsky & Kavanaugh, 1999).  A full economic evaluation of TNF inhibitors and 
traditional DMARDs, on the other hand, may indicate TNF inhibitors to be cost-
effective since these evaluations take into account the downstream economic savings 
(e.g., surgery-related hospitalizations) that might offset the high acquisition costs of 
TNF inhibitors.  Thus, cost-effectiveness and cost-utility studies are the most 




 One key issue when performing cost-effectiveness analyses of new treatments 
in chronic conditions like RA is that the randomized clinical trials to date are for short 
time periods compared to the lifetime duration of the disease.  Also, clinical trials 
exhibit modest external validity due to exclusion of certain age groups or comorbidities 
and protocol driven costs (Brennan & Akehurst, 2000).  Observation studies may 
provide useful data.  However, there is limited data available on the use of new 




One approach in performing economic analyses is to apply modeling techniques 
to available data.  Economic modeling can be an inexpensive and effective way of 
synthesizing existing data and evidence available on costs and outcomes of alternative 
treatments, and can be used to extrapolate beyond the follow-up of a trial or from an 
intermediate to a final health outcome (Brennan & Akehurst, 2000).  A number of 
decision models such as decision trees and Markov models have been reported in the 
literature for conducting cost-effectiveness analyses of TNF inhibitors.  The following 
is a brief description providing a rationale for choosing a Markov model over a decision 
tree in the proposed study.   
  
The decision tree is the simplest structure used to represent possible patient 
treatment pathways.  These pathways can be modeled using probabilities of events and 
relevant outcome measures.  Decision trees are usually employed when the time frame 
of the model is short and there is no difference in mortality across treatment strategies.  
This, however, ignores the possibility that varying duration of efficacy in treatments 
can affect cost-effectiveness over a longer time horizon.  Rheumatoid arthritis is a 
chronic, debilitating, and lifelong disease and patients with RA continue to take 
medications indefinitely as long as the medication does not have any side effects.  
Thus, costs and outcomes continue to accumulate over a long time horizon and any 
decision model developed to evaluate the cost-effectiveness of the new drugs need to 
take into account the lifetime costs of the therapies (Emery, 2004).  If a decision tree 
model is used to report the outcomes over a very long period of time, the tree structure 
may become unmanageable; with the presence of repetitive outcomes, the structure of 
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the decision tree can get complicated.  A Markov model overcomes this hurdle by 
allowing incorporation of time-dependent events.  
 
Markov models are used in decision analysis to represent stochastic processes, 
which evolve over time (Briggs & Sculpher, 1998; Sonnenberg & Beck, 1993).  As a 
result, they are particularly suited to modeling chronic diseases.  The disease in 
question is divided into a finite number of health states usually defined by the severity 
of the disease.  The individual is assumed to be in any one of the health states referred 
to as Markov states.  All events are then considered as transitions of individuals from 
one health state to another.  The time horizon in Markov models is divided into equal 
increments of time, referred to as Markov cycles, and the length of the cycles are 
chosen to represent a clinically meaningful time interval.   
 
During each cycle of the model, transitions are assumed to take place and the 
net probability of making a transition from one state to another during one cycle is 
called a transition probability.  It is assumed that a patient in a given state can make 
only a single state transition during a cycle.  A patient may remain in one state for a 
number of cycles or may transition to a different state.  There are states in the Markov 
model from which it is impossible for patients to leave; these are called absorbing 
states.  The most common example of an absorbing state is death.   
 
An important limitation of the Markov model is that the probability of moving 
out of the state is not dependent on the state or states a patient may have experienced 
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before entering the current state.  In other words, a Markov state does not depend on 
history.  This is often referred to as the ‘Markovian assumption’ and it can be 
accounted for by using a combination of distinct states or time-dependent transition 
probabilities (Briggs & Sculpher, 1998; Sonnenberg & Beck, 1993).   
 
Markov models are categorized into two different types of models based on 
whether the state transition probabilities are constant over time or not.  Markov chains 
are models in which the transition probabilities are constant over time.  Markov models 
where transition probabilities vary with time are called time-dependent Markov 
processes and are more flexible in modeling a chronic disease.   
 
In order to complete a Markov model, it is important to attach weights to the 
model for costs and consequences to be estimated.  For example, the calculation of 
QALYs or costs over the lifetime of the model will involve weighting the length of 
time spent in a particular health state by a value representing either QoL experienced in 
that state or the costs incurred in that state.  A QALY is an effectiveness measure that 
includes both quantity and QoL, by assigning a “utility” weight to life-years.   
 
In economic analyses, utility refers to preferences which individuals or society 
place on particular health outcomes and is measured on a scale between zero (dead) and 
one (perfect health).  Utility can be elicited directly by using techniques such as 
standard gamble, time trade-off, and rating scale or can be elicited indirectly by using 
questionnaires such as EuroQol (EQ-5D) or the Health Utility Index (HUI-2, HUI-3) 
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(Bansback et al., 2005).  By running the model over a number of cycles, a QALY score 
or total costs can be calculated.  However, there are two types of adjustments to costs 
and consequences that have to be considered: discounting and a half-cycle correction.   
   
It is a standard practice to adjust costs and consequences for differential timing 
by applying a discount rate of three percent based on the recommendation of the “Panel 
on Cost-effectiveness in Health and Medicine” which was convened by the United 
States Public Health Service (Gold, Russell, Siegel, & Weinstein, 1996).  Discounting 
allows comparison of costs and consequences in terms of net present value.  That is, 
discounting costs and effects captures the economic theory that people prefer to 
consume more goods in the present than in the future.  This notion of time preference 
could significantly affect cost-effectiveness ratios, especially given the disability and 
time path of disease associated with RA (Bansback et al., 2005).  Markov models 
assume that transition occurs between cycles and that patient membership is constant 
for the duration of the cycle.  However, in reality, patients are moving between 
different phases of the disease continuously.  Thus, instead of assuming that patients 
transition between states at the end of the cycle, a half-cycle correction is employed.  
The half-cycle correction is based on the assumption that, on average, patients will 
transition between states half way through the cycle.   
 
To evaluate a Markov model, matrix algebra is used as a cohort simulation or as 
a first order Monte Carlo simulation.  Cohort simulation considers a hypothetical cohort 
of patients all beginning the process in the initial disease state at time zero, or with 
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some distributions between the model states.  At each cycle, based on the appropriate 
transition probabilities, distribution of patients in each state of the Markov model is 
adjusted.  By running the model for many cycles, one can predict the number of 
patients in each state of the model over time.  As discussed earlier, weights based on 
QALYs and costs are attached to different states for each cycle.  Summing the cycle 
QALYs and costs across all cycles of the model gives QALYs and cost estimates for 
the overall cohort of patients.   
   
Unlike cohort simulation, in first order Monte Carlo simulation, a large number 
of patients are followed through the model individually.  The transition probabilities for 
cohort simulation and individual patients are the same but since an individual patient 
can be in only one state at a given time, s/he may or may not transit between states in 
any given cycle.  Hence, the path of individual patients will differ based on random 
variation.  Thus, the sum of results of n simulations of the individual patients through 
the model will give estimates for costs and outcomes of the model (Briggs & Sculpher, 
1998; Sonnenberg & Beck, 1993).  Although mean costs and outcomes obtained in a 
first order Monte Carlo simulation will be similar to those obtained by cohort 
simulation, an advantage of Monte Carlo simulation is that estimates of variance may 
also be determined generating a degree of uncertainty associated with the derived costs 
and outcomes.   
 
 
Markov models for Rheumatoid Arthritis 
 
  Two studies have used Markov models to study the progression of RA.  Kobelt 
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and colleagues (2002) used a Markov simulation model to assess the cost-effectiveness 
of treatments that affect progression of RA.  Hypothetical treatment interventions were 
simulated to illustrate the model.  Costs were calculated from data of resource 
utilization and patients’ work capacity while utilities were assessed using the EuroQol 
instrument.  The authors concluded that the model was a valuable tool in assessing the 
cost-effectiveness of different interventions in RA.  A similar study used decision 
modeling and Markov methods to model treatment strategies for patients with RA 
(Albert, Aksentijevich, Hurst, Fries, & Wolfe, 2000).  Only traditional DMARDs were 
compared for their effectiveness.  MTX was found to be superior to other DMARDs.  
The authors agreed that Markov analysis generated a more realistic appraisal of the 
outcome of the drugs as compared to standard decision tree analysis.  
 
Effectiveness of TNF Inhibitors (adalimumab, etanercept, and infliximab) and 
leflunomide 
 
 Among the traditional DMARDs used to treat RA, MTX has increasingly 
become the treatment of choice because of its early onset of action and superior 
efficacy and tolerability (Weinblatt et al., 2003; Weinblatt et al., 1999).  Even though 
MTX has been found to be effective in RA, many patients continue to have persistent 
disease and experience less than 50% improvement despite receiving therapeutic doses 
of MTX.  To increase the clinical response in such patients, rheumatologists frequently 
add another DMARD (Kremer, 2001).  A number of studies have reported the clinical 
efficacy of new agents such as adalimumab, etanercept, infliximab, and leflunomide in 
combination with MTX.     




Two double blind RCTs investigating the clinical efficacy of adalimumab in 
patients with RA and an inadequate response to MTX have been published (Keystone 
et al. 2004; Weinblatt et al., 2003).  A 24-week, randomized, double-blind, placebo-
controlled study (ARMADA Trial: Anti-TNF Research Study Program of the 
Monoclonal Antibody [D2E7] in Patients with RA) involved 271 patients with active 
RA (Weinblatt et al., 2003).  The primary efficacy end point was the ACR criteria for 
20% improvement (ACR 20) at 24 weeks.  Secondary efficacy endpoints were ACR 50 
and ACR 70 response rates.  The patients were randomized to one of the four treatment 
groups, adalimumab 20 mg (n=69), 40 mg (n=67), or 80 mg (n=73) or placebo (n=62) 
administered as a SC injection every other week.  The patients continued to take their 
long-term stable dosage of MTX (12.5-25 mg).  An ACR 20 response at week 24 was 
achieved by a significantly greater proportion of patients in 20 mg (47.8%), 40 mg 
(67.2%), and 80 mg (65.8%) than in placebo plus MTX group (14.5%, p< .001).  ACR 
50 response rates with all three doses of adalimumab and ACR 70 response rates with 
40 and 80 mg of adalimumab were significantly greater than placebo (Weinblatt et al., 
2003).   
 
A second study by Keystone and colleagues (2004) was a multicenter, 52-week, 
double-blind, placebo-controlled study involving 619 patients with active RA with an 
inadequate response to MTX.  Patients were randomized to receive adalimumab 20 mg 
SC every week (n=212), 40 mg SC every other week (n=207), or placebo (n=200) plus 
concomitant MTX (12.5-25 mg).  Adalimumab (20 mg and 40 mg) was more effective 
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than placebo at inhibiting the progression of structural joint damage (p< 0.001).  At 
week 24 and 52, patients receiving 40 mg of adalimumab achieved ACR 20 response 
rates of 65% and 59%, respectively, versus 30% and 24% in the placebo group.  Also, 
there was an improvement in physical function in patients receiving adalimumab.  
Discontinuations were lower in the adalimumab group (22%) compared with placebo 
group (30%).  However, proportion of patients reporting serious infections was higher 
in adalimumab (3.8%) compared to placebo (0.5%).   
 
Etanercept     
  Three clinical studies support the efficacy of etanercept in patients with RA 
with an inadequate response to MTX.  In a 24-week, double-blind study, Weinblatt and 
colleagues (1999) randomly assigned 89 patients to placebo or etanercept (25 mg SC 
twice a week) plus concomitant MTX.  At week 24, an ACR 20 response was achieved 
by a significantly greater proportion of patients taking etanercept 25 mg (71%) than in 
the placebo plus MTX group (14.5%; p< .001).  Also, the intervention group achieved 
ACR 50 and 70 response rates of 39% and 15%, respectively, compared with 3% and 
0%, respectively, for the placebo group.  All measures of disease activity were 
significantly improved in the etanercept group, and the only adverse events associated 
with this therapy were injection-site reaction. 
 
 In another double-blind, randomized trial (TEMPO: Trial of Etanercept and 
Methotrexate with radiographic Outcomes) 686 patients were randomly allocated to 
receive etanercept (25 mg SC twice a week), MTX (up to 20 mg every week) or a 
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combination of etanercept and MTX (Klareskog et al., 2004).  The combination of 
etanercept and MTX was significantly better in reduction of disease activity, 
improvement in functional disability, and inhibition of radiographic progression 
compared with MTX and etanercept alone.  The number of patients reporting infections 
or adverse events was similar in all groups.  
 
 Lan and colleagues (2004) evaluated etanercept 25 mg given SC twice a week 
in patients with active RA who were maintained on MTX therapy (12.5-20 mg per 
week).  Patients were randomized in the 12-week, double-blind study to receive 
etanercept (n=29) or placebo (n=29).  Results for the overall improvement in disease 
activity assessed by ACR 20 (90% vs. 34%), ACR 50 (66% vs. 10%), and ACR 70 
(24% vs. 0%) all favored the etanercept plus MTX group.  The number of patients 
reporting adverse events was comparable between the two treatments.  
 
Infliximab 
 The efficacy of infliximab was studied using a large multi-center, double-
blinded, placebo-controlled trial (ATTRACT: Anti-Tumor Necrosis Factor Trial) 
involving 428 patients with active RA not responding to MTX therapy (Maini et al., 
1999).  Patients were randomized to receive infliximab (3mg/kg or 10 mg/kg) or 
placebo every four to eight weeks, in addition to a stable dose of MTX (15 mg per 
week).  After 30 weeks of therapy, 50% of patients treated with infliximab plus MTX 
(3mg/kg every eight weeks) achieved the ACR 20 response criteria compared with 20% 
of patients receiving placebo IV injections (p<0.001).  Clinical response was rapid and 
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over half the responders attained 20% improvement by the second week of follow-up.  
Headaches and upper respiratory tract infections were the most frequently reported 
adverse events, and infusion reaction was seen in 16-20% of the patients receiving 
infliximab plus MTX compared with placebo (10%).   
 
 The patients in the ATTRACT trial were followed for 54 weeks to determine 
the effect of infliximab and MTX on radiographic progression of the disease (Lipsky et 
al., 2000).  Results of the study indicated that the combination provided sustained 
clinical benefit and halted the progression of joint damage not only in patients with 
limited joint damage, but also in those with extensive damage.  The combination was 
also well tolerated and safe.   
 
Leflunomide 
 The combination of leflunomide and MTX was studied in a 30-patient open-
label study (Weinblatt, Kremer, Coblyn, et al., 1999).  Patients reported an ACR 20 
response rate of 56% and ACR 50 response rate of 36%.  These responses were 
sustained at week 48.  The leflunomide plus MTX combination was well tolerated 
although an increase in hepatic enzymes was observed.   
  
The results of the open label study were confirmed in a randomized, double-
blind placebo-controlled study (Kremer et al., 2002).  Addition of leflunomide to MTX 
provided substantial therapeutic benefit compared with adding placebo and it was 
generally well tolerated.  Following this study, additional information on efficacy and 
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safety data on the combination drug was gathered using a 24-week open-label extension 
study.  Response to therapy was maintained through 48 weeks of treatment in patients 
who continued on leflunomide and MTX during the extension.  ACR 20 response rates 
after 24 weeks of leflunomide therapy were similar between patients switched from 
placebo to leflunomide.       
 
In summary, these agents have been proven to be effective and safe in 
appropriate and well-conducted clinical trials.  In addition, the combination of 
adalimumab, etanercept, infliximab, or leflunomide with MTX have been shown to be 
better in reducing disease activity, improving functional disability, and inhibiting 
radiographic progression.  Only one observational study has been reported comparing a 
combination of TNF inhibitor plus MTX with TNF inhibitor alone or MTX alone.  
Analysis of the Stockholm TNF-α Follow-Up Registry (STURE) data showed that 
patients receiving combination of etanercept and MTX had better outcomes compared 
with those patients receiving etanercept alone, thereby indicating that for patients 
receiving etanercept as monotherapy and having only partially satisfactory responses, 
adding MTX might give additional benefits (van Vollenhoven, Ernestam, Harju, and 
Klareskog, 2003).  
 





   A study by Nuijten and colleagues (2001) conducted in the Netherlands 
estimated the total cost of etanercept therapy to be lower than those of infliximab (US 
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$12,648 vs. US $18,046, respectively).  The efficacy of the two drugs was assumed to 
be equivalent.  The difference in the cost was mainly due to the additional costs of 
administration of infliximab in outpatient clinics and concomitant use of MTX although 
the annual drug costs was similar for both the drugs NLG 31,334 (US $12,534) for 
etanercept and NLG 31,526 (US $12,610) for infliximab.  As discussed earlier, this 
type of analysis is a partial evaluation and ignores the long-term outcomes.     
 
Cost-effectiveness studies: Short-term studies 
  In the Cost Evaluation of Novel Therapeutics in Rheumatoid Arthritis 
(CENTRA) study, a six-month decision tree model was designed to determine and 
compare the costs and effectiveness of three single agents (a hypothetical novel 
biologic agent, MTX, and parenteral gold) for the treatment of patients with established 
RA (Kavanaugh et al., 1996).  Both direct costs of treating RA and indirect costs 
incurred by patients as a result of the disease were included in the evaluation.  The 
authors reported that the total costs of MTX and parenteral gold were substantially 
lower than those of the hypothetical biological agent.  However, sensitivity analyses 
indicated that by increasing the clinical efficacy of the hypothetical biological agent, 
total costs decreased due to the accrual of fewer indirect costs.   
   
Another study by Choi and colleagues (2000) assessed the relative cost-
effectiveness of six different treatment options for patients with RA in whom MTX 
therapy had failed: etanercept monotherapy, etanercept plus MTX, cyclosporine plus 
MTX, triple therapy with hydroxychloroquine, sulfasalazine and MTX, continued MTX 
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monotherapy, and no second-line therapy.  A decision tree model with a time horizon 
of six months was used and an incremental cost-effectiveness ratio (ICER) for 
achieving ACR 20 and 70 responses were calculated.  Etanercept plus MTX, the most 
efficacious therapy, had a higher incremental cost compared with MTX therapy.  Triple 
therapy had the lowest ICER per ACR 20 or ACR 70 response (US $1,500 and US 
$3,100, respectively).  The next less costly and more effective treatment option, 
etanercept plus MTX, was the most effective.  The ICER was estimated to be US 
$42,600 and US $34,800, respectively.  A limitation of this study was that it did not 
account for patients withdrawing from the treatments.  As mentioned earlier, neglecting 
to incorporate early withdrawals could potentially bias the results.    
  
Two studies evaluated the cost-effectiveness of TNF inhibitors with and without 
concomitant MTX using ACR response criteria (ACR 20 and ACR 50) as the endpoint 
over one year.  The first study evaluated the cost-effectiveness of etanercept and 
adalimumab with and without concomitant MTX in RA patients.  Etanercept was found 
to be more cost-effective than adalimumab.  The cost per patient achieving ACR 20 and 
ACR 50 response criteria for etanercept monotherapy (25mg twice weekly) was US 
$29,369 and US $43,319, respectively, and for adalimumab (40 mg once every other 
week) US $40,672 and US $78,643, respectively.  The cost per patient achieving ACR 
20 and ACR 50 response criteria for etanercept plus MTX was US $26,167 and US 
$47,636, respectively; and adalimumab plus MTX was US $29,468 and US $47,605, 




The second study reported similar results in the cost-efficacy analysis of 
etanercept, infliximab, adalimumab, and anakinra with and without concomitant MTX.  
Etanercept with and without concomitant MTX was more cost-effective followed by 
adalimumab, anakinra, and infliximab (Chiou et al., 2003).  As pointed out earlier, the 
short study duration of the four studies mentioned above is a major limitation.  A long-
term model that considers the downstream economic costs is necessary to determine the 
most cost-effective treatment in patients who inadequately respond to MTX alone.   
 
Cost-effectiveness studies: Long-term studies 
  Despite promising short-term results from RCTs for newer TNF inhibitors that 
have demonstrated significant effects on functional status and radiographic progression, 
very few economic studies have addressed the issue of effectiveness of these drugs in 
RA (Brennan et al., 2003; Kobelt et al., 2003; Wong et al., 2002).  This could be 
attributed to the lack of sufficient longitudinal data to determine whether such an 
increased expenditure will eventually be offset by lower total costs of the disease.  A 
recent cost-effectiveness analysis based on the ATTRACT trial demonstrated that 
infliximab plus MTX was more cost-effective in the treatment of patients with RA than 
MTX alone (Wong et al., 2002).  A Markov simulation model was used to project the 
54-week results from the ATTRACT trial into lifetime economic and clinical outcomes 
based on the Arthritis, Rheumatism and Aging Medical Information System 
(ARAMIS).  When compared with MTX alone, infliximab plus MTX decreased the 
likelihood of having advanced disability from 23% to 11% at the end of 54 weeks that 
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projected to a lifetime marginal cost-effectiveness ratio of $30,500 per discounted 
QALY gained.   
 
Another study by Kobelt and colleagues (2003) used the results from the 
ATTRACT trial to examine the cost per QALY of infliximab plus MTX compared with 
MTX alone in patients with RA.  A Markov simulation model assessed the progression 
of RA using ten-year data from two epidemiological studies conducted in Sweden and 
the United Kingdom (UK).  The results indicated that one or two years of infliximab 
treatment reduced direct and indirect resource consumption in both countries.  The cost 
per QALY gained was Swedish Krone (SEK) 32,000 (3,440 Euros) in Sweden and 
Great Britain Pounds (GBP) 21,600 (34,800 Euros) in UK for one-year treatment.  The 
respective QALY gains were 0.248 and 0.298.  With two years of treatment, the costs 
per QALY gained were SEK 150,000 (16,100 Euros) in Sweden and GBP 29,900 
(48,200 Euros) in the UK.  However, the problem with both studies was that they 
modeled nonresponders to stay on infliximab for one entire year.  This potentially 
biased the results since the patients were not responding to infliximab treatment yet 
were accruing high costs associated with one year of infliximab treatment.  
   
A UK cost-utility analysis indicated that etanercept was more cost-effective 
than infliximab in the treatment of patients who had failed DMARD therapy.  The 
primary clinical outcome used in the study was the HAQ disability score.  The study 
model defined success as the achievement of ACR 20 responses and this was 
extrapolated beyond the time horizon of the clinical trial, to the expected lifetime of the 
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cohort, by incorporating withdrawal rates from other clinical investigations.  The 
discounted cost per QALY for etanercept therapy was £18,938 (US $27,271) when 
direct costs were considered and £8,439 (US $12,152) when indirect costs were 
considered (Brennan et al., 2001).   
 
Cost-effectiveness studies: Comparing treatment strategies 
  Although a number of economic analyses demonstrate average trends for 
populations and provide some direction for prescribing, they are based on a number of 
assumptions such as similarity in baseline characteristics of patient population, 
clinically relevant outcome measures, variation in treatment practice, and other 
generalizations which may or may not be correct (Emery, 2004).  In RA modeling, it is 
essential that time-dependent variables such as age, duration, and severity of disease be 
matched between data sources (Bansback et al., 2005).  Thus, to find the most cost-
effective option for an individual patient, studies that investigate the relative cost-
effectiveness of long-term strategies can be useful.   
   
A study conducted in the Netherlands determined the cost-effectiveness of five 
different treatment strategies over five years.  A Markov simulation model was used 
with Markov states based on a Disease Activity Score (DAS).  The treatment strategies 
compared included: (1) usual treatment (MTX); (2) treatment with leflunomide (in case 
of non-response, start usual treatment); (3) TNF inhibitors (in case of non-response, 
start usual treatment); (4) treatment with leflunomide (in case of non-response, start 
TNF inhibitors, in case of non-response, start usual treatment); (5) TNF inhibitors (in 
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case of non-response, start with leflunomide, in case of non-response, start usual 
treatment).  Expected costs and QALYs were compared between strategies and the 
ICER was calculated.  The expected effect on QALY and disease activity was better for 
strategies three, four, and five than for strategies one and two.  A treatment strategy 
starting with leflunomide followed by TNF inhibitors in case of non-response was the 
most cost-effective (Welsing et al., 2004).   
   
A study by Brennan and colleagues (2003) looked at the cost-effectiveness of 
etanercept monotherapy under British Society for Rheumatological guidelines.  The 
study compared a traditional DMARD sequence with etanercept third line against the 
same sequence excluding etanercept.  The method involved simulating HAQ disability 
scores for 10,000 patients’ lifetimes (Monte Carlo Simulation) using clinical trial data 
and other published data.  The primary analysis included drug costs, monitoring and 
hospitalization.  The cost per QALY was estimated to be £16,330 (US $23,515) 
suggesting that etanercept was cost-effective when compared with non-biologic agents.  
Sensitivity analysis (£7,800 to £42,000, US $11,232 to $60,480) showed that long term 
HAQ progression for etanercept, DMARDs, and being a nonresponder were the most 
sensitive variables.  
 
Using a method similar to that described by Brennan and colleagues (2003), 
Bansback and colleagues (2004) looked at the cost-utility of adalimumab in treating 
patients with moderate to severe RA who have failed at least two traditional DMARDs.  
The study implemented Swedish unit costs and treatment guidelines from a lifetime 
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perspective and compared adalimumab with traditional DMARDs and other TNF 
inhibitors.  The primary outcome measure, QALYs, was calculated from the 
adalimumab trial results.  The method involved simulating the experiences of 10,000 
hypothetical moderate to severe RA patients for each strategy using clinical trial data 
and other published data.  The cost per QALY for both adalimumab and etanercept was 
estimated to be between 35,000-42,000 euros suggesting that adalimumab was at least 
as cost-effective as the other TNF inhibitors.   
   
Two more studies have been conducted by the National Coordinating Center for 
Health Technology Assessment (NCCHTA; Barton, Jobanputra, Wilson, Bryan, & 
Burls, 2004; Jobanputra et al., 2002) to assess the additional costs and QALY gain 
associated with the use of either etanercept or infliximab as the third DMARD in a 
sequence of traditional DMARDs.  The first study resulted in an ICER of 
approximately £83,000 (US $119,520) per QALY for etanercept and approximately 
£115,000 (US $165,600) per QALY for infliximab.  However, the effects of DMARDs 
on joint replacement, hospitalization, mortality, and QoL were not studied.  The model 
used in the previous study was restructured in a subsequent study and the analysis was 
conducted again based on the DMARDs strategies used by rheumatologists in the UK.  
An ICER of approximately £59,289 (US $85,376) per QALY for etanercept and 
approximately £76,233 (US $109,775) per QALY for infliximab was reported. 
 
  In summary, none of the studies have evaluated the incremental cost-
effectiveness of the TNF inhibitors (adalimumab, etanercept, and infliximab) and 
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leflunomide used in combination with MTX in the treatment of patients with RA who 
inadequately respond to MTX alone.   
 
Rheumatologists’ Preferences Regarding TNF Inhibitors 
 
  In the past, few studies have been conducted to ascertain the prescribing 
patterns of rheumatologists.  The results of these studies reflect the changing 
prescribing patterns of the rheumatologists, indicating a shift from time- and severity-
based approaches to patient preference-based approach.  Disease modifying anti-
rheumatic drugs have been the standard treatment for RA.  Studies to determine the 
prescribing patterns of DMARDs show wide variations in dosing and monitoring 
schedules (Pope et al., 2002).  Because of its favorable efficacy/toxicity trade-off, MTX 
has been rated as substantially more effective than any other DMARD by 
rheumatologists (Maetzel et al., 1998; Wolfe et al., 1998).  A recent study determined 
the current DMARD preferences of UK consultant rheumatologists and confirmed 
earlier findings that MTX was the drug of choice while newer agents such as TNF 
inhibitors and leflunomide had replaced the older traditional DMARDs (Jobanputra et 
al., 2004).  However, with a growing number of patients not responding to MTX, 
coupled with the development of highly effective TNF inhibitors, researchers have yet 
to assess how rheumatologists are prescribing these new drugs.   
  
 A number of questions remain unanswered regarding the use of TNF inhibitors 
in clinical practice.  It is not clear in which patients with RA that the TNF inhibitors are 
being used.  The approved indication for these drugs is in patients with moderate to 
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severe RA.  However, with their ability to reduce radiographic damage, it is not clear if 
these drugs are being used in patients with early RA (Kavanaugh et al; 2004).  Another 
question should address how these powerful, new agents are being used.  A number of 
RCTs (ARMADA, ATTRACT, and TEMPO) have shown that a combination of TNF 
inhibitors with MTX is superior to either drug as monotherapy in patients with active 
RA, but no long-term follow-up data is available to confirm the findings.  Another 
important question a clinician faces is whether to prescribe a new TNF inhibitor if the 
patient has failed one such agent.  A review by van Vollenhoven (2004) on switching 
among TNF inhibitors indicated that even though a majority of studies conducted in 
rheumatology clinics supported the use of alternative TNF inhibitors, caution has to be 
exercised in interpreting the results.  The study samples were small and there were 
differences in the concurrent use of MTX in patients enrolled in the studies.  Thus, until 
studies are designed to identify the predictors of response, use of TNF inhibitors will be 
governed by clinical judgment and accumulated experience.  
  
 Another concern regarding the use of TNF inhibitors is the potential for adverse 
events such as infections and lymphomas in patients who are using these drugs.  
Appropriately screening and monitoring patients can minimize these complications.  
But there are no monitoring protocols established for these drugs   One study has 
investigated the monitoring practices of rheumatologists for MTX-, etanercept-, 
infliximab-, and anakinra-associated adverse events (Yazici et al., 2003).  A majority 
(76% to 78%) of rheumatologists reported that they ordered ACR recommended 
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screening tests for MTX but were not aware of any guidelines for monitoring TNF 
inhibitors.    
 
Despite the clinical effectiveness of TNF inhibitors, there are a number of 
factors which influence the choice of these drugs.  The drug cost is significant and their 
reimbursement varies greatly depending on the age of the patient, section of the 
country, and third party payer.  Drug cost was reported to play a dominant role in 
rheumatologists’ choice of treatment regimens (Erkan, Yazici, Harrison, & Paget, 
2002).  Additionally, the different routes of administration of etanercept, infliximab, 
and adalimumab have resulted in different coverage and reimbursement policies 
(Gallup, 2001).  Medicare covers only infliximab since it reimburses for intravenous 
infusion performed in the physicians’ office.  However, for patients under 65, insurance 
plans insist on documentation for MTX failure before etanercept, infliximab or 
adalimumab can be used (Kremer, 2001).  Medicaid also restricts payment for these 
drugs to those patients who do not demonstrate an adequate clinical response to a full 
dose of MTX.  Self-injectable drugs such as etanercept and adalimumab are covered by 
pharmacy benefits (Gallup, 2001).  Due to these requirements, physicians and their 
staff are compelled to spend more time on paper work and phone calls.   
 
Despite the increasing use of TNF inhibitors in clinical practice, there are no 
studies conducted that report the current rheumatologists’ prescribing patterns and the 
potential barriers they face in terms of using these drugs or making a choice among the 








The study was conducted in two phases.  In phase I, a lifetime model was 
constructed using decision analytic techniques to evaluate the total costs and effects of 
the TNF inhibitors (adalimumab, etanercept, and infliximab) and leflunomide, used in 
combination with MTX, in patients with RA that inadequately respond to MTX alone.  
In phase II, the study assessed the current prescribing patterns of rheumatologists using 
TNF inhibitors to treat patients with RA through a national mail survey.  The survey 
also assessed laboratory monitoring practices, frequency of tests ordered, and perceived 
barriers of rheumatologists prescribing these drugs. 
 
Phase I  
 
The following sections describe the design of the economic model, 
operationalizing the model, data used in the model, analytical methods, model 
assumptions and rationale that were utilized in this phase of the study.  
 
Design of the Model 
The study involved the development of a Markov model using DATA 4.0 
TreeAgeTM software (Data TreeAge Software, Inc., 2002).  This model was used to 
evaluate the incremental cost-effectiveness of different treatment strategies in patients 




The five treatment strategies compared using a decision analytic method 
included 1) adalimumab plus MTX, 2) etanercept plus MTX, 3) infliximab plus MTX, 
4) leflunomide plus MTX, and 5) a standard therapy of MTX alone.  The main 
analytical plan was to calculate incremental cost-effectiveness ratios.  This approach 
involved combining cumulative measures of costs over time with a cumulative measure 
of effectiveness, resulting in incremental costs per clinical benefit gained.  A societal 
perspective was taken in the estimation of costs in the base-case analysis.  The total 
costs of therapy with each agent was composed of direct costs associated with treating 
MTX-resistant RA combined with indirect costs incurred by patients as a result of the 
disease.   
 
The effectiveness measure consisted of American College of Rheumatology 
20% response criteria (ACR 20) and quality adjusted life years (QALYs).  An 
advantage of using ACR outcomes in cost-effectiveness analysis is their availability 
from publications of RCTs, and that these outcomes can be used to compare 
interventions within RA.  However, it is difficult to make an absolute statement about 
whether any given option is cost-effective compared with other widely accepted cost-
effective interventions in medicine.  To overcome this limitation, a generic measure of 
effectiveness such as QALY was used.  The QALY combines QoL with time by 







Operationalizing the Model 
Outcomes Measure in Rheumatoid Arthritis Clinical Trials (OMERACT) 
acknowledges that the underlying characteristics of a clinical trial population define 
which population the economic analysis is applicable to (Bansback et al., 2005).  Most 
reported efficacy data pertain to subjects in the 50- to 60-year-old age group since this 
patient population is most representative of the patients with RA receiving TNF 
inhibitors and leflunomide.  Therefore, a cohort of 55-year-old women was selected as 
the base-case population.  The hypothetical cohort included 10,000 women who had 
already failed two DMARDs, one of which was MTX.       
     
The efficacy data were based on five double blinded, randomized controlled 
trials conducted in patients with inadequate responses to MTX (Keystone et al., 2004; 
Kremer et al., 2002; Maini et al., 1999; Weinblatt et al., 2003; Weinblatt et al., 1999).  
The baseline patient characteristics across the RCTs were similar, especially the 
duration of RA, HAQ disability score, and the number of previous traditional 
DMARDs used (Table 1).  
 
 American College of Rheumatology 20% response data (ACR 20) for all 
treatment options were available in each clinical trial.  The efficacy represents the 
probability of achieving ACR response on each drug subtracting the effect of placebo 
from among those who have not improved on placebo (Choi, Seeger, & Kuntz, 2002; 
Choi et al., 2000).  Thus, efficacy estimates were calculated for all treatment options.  
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Table 1. A review of published RCT results for TNF inhibitors and leflunomide 
 
  N Baseline   HAQ at Previous no. Disease     Avg.           Females     % Patients       Reference 
   HAQ    24 weeks  DMARDs duration    age                (%)      Responding 
  (0-3)    (0-3)    (yrs)     (yrs)   ACR20  
 
Adalimumab 
40mg eow+MTX   67 1.6    0.9  2.9  12.2     55.5  76.8        67  Weinblatt et al., 2003 
40mg eow+MTX 207 1.5    0.9  2.4  11.0     56.1  76.3        62  Keystone et al., 2004 
 
Etanercept 
25mg 2 x wkly+MTX   59 1.5    0.8  2.7  13.0     48.0  90.0        71  Weinblatt et al., 1999 
25mg 2 x wkly+MTX 231 NA    NA  2.3    6.8     52.5  74.0        85  Klareskog et al., 2004 
 
Infliximab 
3mg/8 week+MTX   86 1.8    1.5  2.8    8.4     56.0  81.0        50  Maini et al., 1999 
 
Leflunomide 
20mg a day+MTX 130 1.5    1.1  NA  10.5     55.6  76.2        46  Kremer et al., 2002 
 
N= number of patients enrolled in the trial 
NA=Data not available 
eow=every other week 
Avg.= average 
Wkly=weekly 
RCT= randomized clinical trial 
HAQ = Health Assessment Questionnaire (0 = No disability, 3=severely disabled) 
DMARDs = Disease modifying anti-rheumatic drugs 
ACR 20: American College of Rheumatology Response Rate 
MTX = Methotrexate 
 
 
Since more than one trial provided the efficacy estimates of adalimumab plus MTX and 
standard therapy of MTX, average of the estimates were used in the analysis.  
  
 Treatment withdrawal rates were calculated from all RCTs by determining the 
proportion of patients withdrawing from the studies due to severe adverse events, lack 
of efficacy, or withdrawing due to other reasons.  Severe adverse events included 
sepsis, pneumonia, or any diseases requiring hospitalization.  In addition, studies were 
also screened for information on mild and moderate adverse events, in particular the 
number of patients suffering one or more mild and moderate adverse events.  Mild 
adverse events included injection or infusion site reactions, headache, rhinitis, 
dizziness, abdominal pain, rash, and dyspepsia.  Moderate adverse events included 
upper respiratory infection, pharyngitis, respiratory disorder, and sinusitis.  Rate of 
mild and moderate adverse events was then calculated as the number of patients 
experiencing a mild and moderate event per patient year of follow-up for each drug. 
 
Utilities for Markov states, such as being on medication, palliative care, and 
post-joint replacement were calculated from a study by Bansback and colleagues 
(2004).  The clinical trials for all the treatments in RA report baseline and six-month 
HAQ disability scores.  In addition, adalimumab clinical trials use Health Utility Index-
3 (HUI-3) as an indirect measure of health utility.  Thus, an analysis of adalimumab 
trial data of almost 2,000 patients permitted transformation from HAQ disability scores 
to HUI-3 using the equation: 
   HUI-3 utility = 0.76 – 0.28*HAQ-DI + 0.05* Female 
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This transformation was necessary since etanercept, infliximab, and leflunomide trials 
do not report any health utility measures (Bansback et al., 2004). 
 




 The clinical efficacy of adalimumab in combination with MTX was assessed in 
two randomized, double-blinded studies in RA patients greater than or equal to 18 years 
of age with an inadequate response to MTX alone.  Adalimumab (40 mg) was 
administered every other week subcutaneously.  The results of both studies were 
similar; patients achieved ACR 20 rates of 63.3 to 67.2% (Keystone et al., 2004; 
Weinblatt et al., 2003).  As described earlier, the efficacy represents the probability of 
achieving ACR response on each drug subtracting the effect of placebo from among 
those who have not improved on placebo.  Thus, efficacy estimate for ACR 20 response 
of adalimumab in one trial was calculated to be 0.616 (0.672-0.145/1-0.145) and in 
another was 0.479 (0.633-0.295/1-0.295).  An average of these two efficacy estimates 
(0.548) was used as the baseline probability of achieving ACR 20 improvements for 
adalimumab.   
  
 The proportion of patients withdrawing from the study (23.2%) and the subset 
of withdrawals due to severe adverse events, lack of efficacy, and due to other reasons 
were estimated from the study by Keystone and colleagues (2004).  The rate of mild 
and moderate adverse events for adalimumab was calculated to be 1.85 patients per 
patient-year (331 patients experiencing an event/ 179.2 patient-years of follow-up).  
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Event rates cannot be directly used in the model and have to be converted to 
probabilities (risks) which represent the actual transitions by the cohort of individuals 
over a period of time (Miller et al., 1994).  Probabilities (risks) are estimated in one of 
three ways: (1) simple cumulative method (2) actuarial method and (3) density method.   
 
Density method was used to convert rates into probabilities (risks).  This 
method uses group-specific rates (incidence densities (ID)) to estimate probabilities 
(risks) for a specified time interval (Kleinbaum, Kupper, & Morgenstern, 1982).  Thus, 
the ∆-year probability (risk) [P (to, t)] can be estimated as a function of the estimated 
average rate (ID) by using the following expression: 
P (to, t)  = 1 – (N t / No) = 1 – exp [-ID (∆)] 
 where N t  = number of subjects remaining at time t during the follow-up 
No = number of disease free subjects at time to
ID = estimated average rate 
∆ = elapsed time (t - to) 
 
Etanercept 
The clinical efficacy of etanercept in combination with MTX was assessed in a 
randomized, double-blinded study involving patients with RA that responded 
inadequately to MTX alone.  Etanercept (25 mg) was administered twice every week 
subcutaneously.  Almost 71% of patients reported achieving ACR 20 response rates 
(Weinblatt et al., 1999).  Subtracting the placebo effect, the efficacy estimate for ACR 
20 response was calculated to be 0.603.  The proportion of patients withdrawing from 
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the studies (9.7%) and the subset of withdrawals due to severe adverse events, lack of 
efficacy, or due to other reasons were estimated from two studies (Klareskog et al., 
2004; Weinblatt et al., 1999).  The rate of mild and moderate adverse events for 
etanercept was calculated to be 3.92 patients per patient-year.  
 
Infliximab 
The randomized, double-blinded trial assessing the clinical efficacy of 
infliximab (3mg/kg every 8 weeks, IV) in combination with MTX in patients with RA 
that inadequately respond to MTX alone reported an ACR 20 response rate of 50% 
(Maini et al., 1999).  After accounting for the placebo effect, the efficacy estimate for 
ACR 20 response was calculated to be 0.375.  The proportion of patients withdrawing 
from the study (26.7%) and the subset of withdrawals due to severe adverse events, 
lack of efficacy, and due to other reasons were estimated from the same study.  The rate 
of mild and moderate adverse events for infliximab was calculated to be 2.79 patients 
per patient-year.
 
Leflunomide   
The 24-week randomized, double-blinded trial assessing the clinical efficacy of 
leflunomide (20 mg once a day, orally) in combination with MTX reported an ACR 20 
response rate of 52% (Kremer et al., 2002).  Subtracting the placebo effect, the efficacy 
estimate for ACR 20 response was calculated to be 0.332.  The proportion of patients 
withdrawing from the study was 23.1% and the rate of mild and moderate adverse 




All the RCTs included a control group receiving MTX plus placebo.  The ACR 
20 response rates were pooled for the five trials and, after accounting for the placebo, 
an average efficacy estimate of 0.19 was calculated for MTX.  There was 31.2% 
withdrawal (pooled estimate) and the rate of mild and moderate adverse events for 
MTX was calculated to be 2.3 patients per patient-year.  To calculate the efficacy due 
to MTX, the probability of achieving an ACR response due to placebo had to be 
calculated.  The estimate for efficacy of placebo (0.11) was taken from the study by 
Choi and colleagues (2000) who had calculated the value from an etanercept 
monotherapy trial.    
 
Operationalizing the Model for Joint Replacement Therapy 
The need for a joint replacement therapy is generally perceived to reflect a 
failure of medical treatments.  Data from short-term clinical trials of TNF inhibitors and 
leflunomide indicate a decrease in radiological progression of the disease; however, 
nothing is known about the potential long-term impact of these drugs in preventing 
joint replacement surgeries.  A study by Wolfe and Zwillich (1998), using a database of 
1,600 patients with RA, reported that 25% of the patients had joint replacement within 
22 years of disease onset.  The age of the study cohort was 54 years; like the baseline 
population in RCTs used in this study, the cohort had a baseline HAQ disability score 
of 1.5, disease duration of over 10 years, and had failed two to three DMARDs.  Since 
very little published evidence is available, an assumption was made that one-fourth of 




from the disease onset) in the model.  A one-time cost of $19,490 (adjusted to 2004 
dollars) was applied each time joint replacement occurred and this cost was varied by + 
20% in the sensitivity analysis (Kremer, 2001).  
 
Operationalizing the Model for Mortality 
The OMERACT statement recommends that risk of mortality be included in 
decision-analytical modeling studies (Bansback et al., 2005).  However, there are 
conflicting reports regarding the effect of RA on the risk of mortality.  Some 
epidemiologic studies have shown an increased mortality in patients with severe RA 
with mean standardized mortality ratio (SMR) of 1.87 to 2.26 (Guedes, 1999; Wolfe et 
al., 1994).  However, more recent studies have not found any effect of RA on mortality 
(Kobelt et al., 2003).  For the baseline model, an SMR of two was considered for RA.  
Since some studies report that with aggressive therapy, RA mortality may be similar to 
that of the general population, an alternative possibility was also tested where SMR was 
designated as one (Wong, Ramey, & Singh, 2001; Wong et al., 2002).        
 
Model Structure and Simulation 
The transition state model for rheumatoid arthritis is illustrated in Figure 2.  The 
model used transition probabilities to move 10,000 different patients randomly through  
different Markov states over time.  The time horizon of the analysis was divided into 
equal increments, referred to as Markov cycles, during which a patient was allowed to 
transition from one Markov state to another.  A cycle length of six months was chosen.   
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ACR=American college of rheumatology 
RA=Rheumatoid arthritis 
           = Markov states 
 







 RA patient 
 
 
By following patients until death, the model estimated the costs and QALYs for each 
treatment.  The analysis assumed a societal perspective (direct and indirect costs) and 
followed the reference case recommendations of the panel on Cost-effectiveness 
Analysis in Healthcare and Medicine (Gold et al., 1996).  Future costs and benefits 
were discounted at a three percent annual rate (Gold et al., 1996).  
 
Figure 3 shows the model structure for each strategy.  The model structure for 
each of the five treatment arms was identical.  The first branch point on the decision 
tree was a decision node indicating a choice of treatment being made: adalimumab plus 
MTX, etanercept plus MTX, infliximab plus MTX, leflunomide plus MTX, or standard 
therapy of MTX.  Subsequent to the decision node, a Markov cycle is shown and is 
identical for all five treatments options.   
 
The model had four Markov states: on medication, palliative care, post-joint 
replacement, and death state.  In the model, individual patients started in the Markov 
state ‘on medication’.  After applying the age- and sex-adjusted mortality rate (U.S. 
Census Bureau, 2004), the patients experienced two events: they either continued 
taking the treatment or stopped the treatment.  These transitions were based on pre-
specified transition probabilities.  If the patients continued the medication, they may or 
may not respond to medication by at least ACR 20% response criteria.  In both cases,  
the patients could experience mild and/or moderate adverse events that were minor 
enough to continue treatment. 
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  Patients who stopped the treatment did so because of the following reasons: 
severe adverse events, lack of efficacy, or withdrawal due to other reasons.  These 
patients then entered the ‘palliative care’ state where they were treated with a 
combination of MTX, NSAIDs, and corticosteroids.  Patients in this state were assumed 
to be at an increased risk of RA episodes and experienced one event: joint replacement 
surgery.  Joint replacement surgery in patients with RA is widely perceived to result 
from inadequate disease control (Jobanputra et al., 2002).  Once a patient had 
undergone joint replacement surgery, she then entered the ‘post-joint replacement’ state 
and stayed in this state for the remainder of their lifetime, eventually moving to the 
death state.   
 
In the model, all the patients ultimately transitioned into the “death” state.  Once 
the patient entered the “death” state, she could not leave that state.  This, “death” state 
was called the absorbing state.  Ideally, the model should be terminated when the entire 
cohort of patients are dead.  However, since the Markov process is evaluated 
probabilitistically, the proportion of people in “non-dead” state approaches zero but is 
never equal to zero.  Thus, an approximation was introduced to artificially terminate the 
cohort such that the approximation error would be minimal.   Thus, in the current study, 
the cohort was followed until 99.999% was in the “dead” state; the remainder was 




Model Assumptions and Rationale 
1. The patients enrolled in the clinical trials of adalimumab, etanercept, infliximab, 
and leflunomide reported a previous use of two to three DMARDs.  It was assumed 
that effectiveness and toxicity of these DMARDs were captured as a consequence 
on costs through increased use in health care resources and thus would be consistent 
across the five treatment strategies.  
 
2. The use of NSAIDs in patients with RA was not included in the current analysis, 
because previous studies have shown that such use did not differ significantly 
between different levels of disease severity, and costs were minimal (Kobelt et al., 
2003).  The simulation model was focused on estimating the effects of treatments 
that influence the progression of the disease, rather than on calculating the precise 
costs of illness.  Markov models are driven by the differences in costs and utilities 
between states and by the transition probabilities between the states.  Thus, 
increasing or decreasing costs by the same amounts in all health states of the model 
will not affect the cost-effectiveness calculation.  Since small costs such as NSAID 
use is identical in all states, these will not change the total cost of the disease 
significantly. 
 
3. It was assumed that patients who did not respond to the treatments were switched to 
palliative care.  Patients who responded, continued to stay on the medication until 
they experienced any severe adverse event, lack of efficacy, or withdrawal due to 
other reasons.  Currently, there is no data to show the actual distribution of time a 
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patient spends on each of these drugs.  Clinical trials have reported the efficacy of 
these drugs over a six-month or one year period.  Also, in actual clinical settings, if 
the patient fails to respond to one agent, rheumatologists may switch the patient to a 
different DMARD or to a TNF inhibitor.  Patients switched to palliative care will be 
at an increased risk of RA episodes.  
 
4. Clinical trials of the TNF inhibitors have shown that these drugs may cause 
radiological stabilization of structural joint damage.  This indicates a likely decrease 
in future risk of joint replacement and disability.  However, for those patients who 
stopped taking TNF inhibitors or leflunomide, there is an increased future risk of 
joint replacement and disability.  A study by Wolfe and Zwillich (1998), using a 
database of 1,600 patients with RA, had reported that 25% of the patients had joint 
replacement within 22 years of disease onset.  Since the base-case population of the 
model was 55 years old and had disease duration of 10 years, it was assumed that 
one-fourth of the population who withdrew from the TNF inhibitors and 
leflunomide underwent joint surgery after 12 years.  A one-time joint replacement 
cost was applied for patients reaching this stage. 
 
5. The evidence regarding the effect of RA on life expectancy is conflicting.  Some 
epidemiologic studies have shown increased mortality in patients with severe RA 
while more recent studies have not demonstrated any effect of RA on mortality 
(Guedes, 1999; Kobelt et al., 2003; Wolfe et al., 1994).  The study model assumed 




general population, was the same.  An alternative possibility was also tested where 
the risk of mortality was considered twice as compared with a normal age-, sex-, 
and race-matched general population (Wong et al., 2001; Wong et al., 2002).    
 
Data for the Model 
Three different types of data were used to populate the model: 
 
Probabilities 
 The six-month transition probabilities were obtained from a formal review of 
the literature.  The transition probabilities used in the model were calculated directly 
from patient-level data from active and placebo groups of the RCTs.  The model 
assumed that after one cycle, the patients experienced the same disease progression and 
clinical outcomes as seen in the RCTs.  Probabilities for other outcomes such as 
mortality and joint replacement therapy were also derived from the literature.   
 
The base-case estimates for each variable and ranges used for sensitivity 
analysis are shown in Table 2.  The base-case estimate for the probability of achieving 
ACR improvements for adalimumab was calculated from the efficacy estimate of each 
component using the formula:  
PPlacebo + (1-PPlacebo) * Efficacy of drug 1 + (PPlacebo + (1-PPlacebo) * Efficacy of drug 1) * Efficacy of drug 2 
Where PPlacebo is the proportion of patients achieving ACR response with any drug,  
Drug 1 = MTX (MTX is used in combination with other drugs used in all trials) 
Drug 2 = either adalimumab, etanercept, infliximab, or leflunomide
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Table 2. Base-case estimates (efficacy and percent probability of achieving ACR 20 response) and their ranges for sensitivity 
analyses: 6-month data 
 
Variable      Baseline estimate (range)   References 
 
Efficacy of individual drug+ (ACR 20)  
MTX        19.0 (16.5-21.0)   Choi et al., 2000, Moreland et 
              al., 2001; Strand et al., 1999 
Adalimumab       54.8 (47.9-61.6)   Keystone et al., 2004; 
              Weinblatt et al., 2003 
Etanercept       60.3 (+ 20%)    Weinblatt et al., 1999 
Infliximab       37.5 (+ 20%)    Maini et al., 1999 
Leflunomide       33.2 (+ 20%)    Kremer et al., 2002 
 
Percent probability of achieving ACR 20 response++
Placebo        11.0 (9.0-13.0)    Choi et al., 2000 
MTX        27.9 (25.7-29.7)   Choi et al., 2000, Moreland et 
              al., 2001; Strand et al., 1999 
Adalimumab       67.4 (62.4-72.3)   Keystone et al., 2004; 
              Weinblatt et al., 2003 
Etanercept       71.4 (+ 20%)    Weinblatt et al., 1999 
Infliximab       54.9 (+ 20%)    Maini et al., 1999 
Leflunomide       51.8 (+ 20%)    Kremer et al., 2002 
 
MTX = Methotrexate 
ACR 20: American College of Rheumatology Response Rate 
+ The efficacy data is the net drug effect after adjusting for the placebo effect in each trial 
Efficacy represents the probability of achieving ACR response on each drug subtracting the effect of placebo from among those who have not improved on 
placebo (Choi et al., 2000)  
(Drug –Placebo)/ (1-Placebo) 





For example, when treated with adalimumab and MTX, the proportion of patients 
achieving ACR 20 response was 0.674 [0.11 + (1-0.11) * 0.19 + (0.11 + (1-0.11) * 
0.19) * 0.548].  This method of calculating the ACR response implicitly assumed the 
additive pharmacologic effect of each component in a therapeutic option (Choi et al., 
2000).  The same formula was applied to calculate the proportion of patients achieving 
ACR 20 responses for etanercept, infliximab, leflunomide, and MTX.   
 
 Probabilities of withdrawal from treatment and the subset of withdrawals due to 
severe adverse events, lack of efficacy, and due to other reasons were estimated from 
the respective clinical trials (Table 3).  In RCTs, both the mild and moderate adverse 
events (reported as number of patients with events), and the total number of patient-
years of follow-up, are reported.  Rate of mild and moderate adverse events were 
calculated from the information (number of patients with events / patient-years) and 
this was converted to probabilities using the density method described earlier (Table 4).     
 
Utilities 
Utilities are numerical values assigned to health states, which reflect the 
desirability of living in a given state.  Health state utilities range from perfect health 
(weighted 1.0) to death (weighted 0).  The weights are multiplied by the amount of time 
spent in each health state, and these products are summed over the patient’s lifetime in 
the different states to obtain an estimate of QALYs.  Utilities for different states in the 
Markov model were derived from a study by Bansback and colleagues (2004) and are 
reported in Table 5. 
 
Table 3. Base-case estimates (total withdrawals and subset of withdrawals) and their ranges for sensitivity analyses: 6-month 
data 
 
Variable       Baseline estimate (+ 20%)  References 
 
Total withdrawals, % 
 
Adalimumab       23.2    Keystone et al., 2004 
  Adverse events (%)     54.2    Weinblatt et al., 2003  
Lack of efficacy (%)     12.5   
Other reasons (%)     33.3 
 
Etanercept        9.7    Klareskog et al., 2004 
Adverse events (%)     31.6    Weinblatt et al., 1999 
Lack of efficacy (%)       7.9   
Other reasons (%)     60.5 
 
Infliximab       26.7    Maini et al., 1999 
Adverse events (%)     21.7   
Lack of efficacy (%)     73.9   
Other reasons (%)       4.3 
 
Leflunomide       23.1    Kremer et al., 2002 
Adverse events (%)     53.3   
Lack of efficacy (%)     30.0   
Other reasons (%)     16.7 
 
MTX        31.2    Choi et al., 2000, Moreland et 
Adverse events (%)     55.8    al., 2001; Strand et al., 1999 
Lack of efficacy (%)     20.4   




Table 4. Base-case estimates (mild/moderate adverse event) and their ranges for sensitivity analyses: 6-month data 
 
Variable        Baseline estimate (+ 20%)   References 
 
    Rate#         Probability 
 
Mild/moderate adverse event 
 
Adalimumab   1.85   0.6035    Keystone et al., 2004 
   
Etanercept   3.92   0.8591    Weinblatt et al., 1999 
 
Infliximab   2.79   0.7522    Maini et al., 1999 
 
Leflunomide   3.71   0.8435    Kremer et al., 2002 
 
MTX    2.30   0.6830     Choi et al., 2000, Moreland et 
             al., 2001; Strand et al., 1999 
 









Table 5. Utilities for Markov states used in the decision analysis model #
 
Markov States       Utilities (+20%)     
 
 On Medication 
 Adalimumab+MTX      0.558 (0.446-0.669) 
 Etanercept+MTX      0.586 (0.469-0.703) 
 Infliximab+MTX      0.460 (0.368-0.552) 
 Leflunomide+MTX      0.502 (0.402-0.602) 
 Standard MTX Therapy     0.446 (0.357-0.535) 
 
Palliative Care        0.283 (0.227-0.340) 
 
Post-Joint Replacement      0.152 (0.122-0.182) 
 
# Utilities were estimated using an equation derived by Bansback and Colleagues (2004):  HUI-3 = 0.76 – 0.28*HAQ DI + 0.05* Female 




Utilities for the five different treatments were calculated based on the HAQ 
disability score at six-months derived from their respective RCTs using the equation: 
HUI-3 utility = 0.76 – 0.28*HAQ-DI + 0.05* Female 
HUI-3 = Health Utility Index-3 
HAQ-DI= Health Assessment Questionnaire Disability Score 
  
 Since the patients who withdrew from the treatments and moved to the 
palliative care or post-joint replacement states were assumed to experience an increase 
in RA episodes, it was decided that after six months there will be a 25% increase in 
their baseline HAQ disability score.  For the palliative care state, the baseline HAQ 
disability score was assumed to be 1.50; for the post-joint replacement state, the 
baseline HAQ disability score was assumed to be 1.88.  The increase in the HAQ 
disability score at six months was then substituted in the above equation to generate 
utilities for each of these two states.  
 
Costs 
Direct costs: The costs of each of the TNF inhibitors, leflunomide, and MTX included 
the drug costs, costs of monitoring, costs of treating mild and/or moderate and severe 
adverse events arising from the treatment, and the cost of joint replacement therapy 
(Table 6).  Drug costs were calculated from Drug Topics Red Book (2004).  The Red 
Book lists the average wholesale price (AWP) for prescribed medications.  Drug costs 
were based on the standard dose derived from the package insert of the drug.  In 
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Table 6. Costs: 6-month data used in the decision analysis model for each drug 
 
Variables   Methotrexate  Adalimumab  Etanercept         Infliximab               Leflunomide  
           
Dose    15 mg/week  40 mg every  25 mg twice  3 mg/kg   20 mg/  
       other week  every week  every 8 weeks   day 
Direct Costs ($) #
 
Medication costs§  $714.8 (+20%)  $7,894.8 (+20%) $7,894.8 (+20%) $8,520.6*(+20%)     $2,233.9 (+20%) 
 
Administration cost +  -   -   -   $848.6 ($663.6-$1,033.6)    - 
 
Monitoring costs§§    $707.7   $996.5   $996.5   $996.5    $670  
(First 6-month)    ($488.4-$927)   ($730.5-$1,262.5)  ($730.5-$1,262.5)  ($730.5-$1,262.5)      ($487.4-$852.5) 
 
Monitoring costs§§   $404.4   $354.5   $354.5   $354.5   $473.2 
(After 6-month)   ($299.6-$501.2) ($240.2-$468.8)  ($240.2-$468.8)  ($240.2-$468.8)      ($347.9-$598.4) 
 
Costs of treating severe  $8,500 (+20%)  $8,500 (+20%)  $8,500 (+20%)  $8,500 (+20%)         $8,500 (+20%) 
Adverse Event  
  
Costs of treating mild/   $165.3   $165.3   $165.3   $165.3   $165.3 
moderate adverse event   ($126.2-$204.3) ($126.2-$204.3) ($126.2-$204.3)  ($126.2-$204.3)  ($126.2-$204.3) 
 
# All costs adjusted to 2004 dollars
§ Based on Drug Topics Red Book  (AWP 2004) 
§§ Based on Medicare and Managed Care reimbursement rates 
* Mean dose per infusion = 2.8 vials, number of infusion per 6-month = 4.4 
+ Medicare rate (2004) $150.8 per infusion (First hour infusion rate=$117.79, Every additional hour = $33.02); Administration cost = 150.8*4.4=$663.6 






addition, infliximab is administered as an infusion and the administration cost was 
added to the treatment costs.  All five drugs required intensive monitoring in the first 
six months, after which routine monitoring was required.  Thus, the model incorporated 
higher monitoring costs in the first six months and lower constant monitoring costs 
after the first six months.   Monitoring costs were identified by applying Medicare and 
managed care current laboratory fees to the recommended laboratory schedule.  An 
average of the two costs was included in the model (Tables 6 and 7).   
 
The cost of drug-related severe adverse events was based on the cost of treating 
pneumonia, which is the most commonly reported severe adverse event due to 
treatment with TNF inhibitors.  The cost of treating pneumonia ($8,500) was derived 
from the reimbursement rates paid by Medicare.  Treatment of mild and/or moderate 
events was assumed to result in an office visit, a complete blood count test (CBC), one 
liver function test (LFT), one urine analysis, a chest X-ray, and a ten day antibiotic 
treatment.  The costs of physician visit and laboratory tests were identified by applying 
Medicare and managed care current lab fees.  The antibiotic cost was calculated from 
the Drug Topics Red Book (2004).  
 
Joint replacement therapy was treated as an event and a one-time cost was 
applied at the time of joint replacement.  The estimate ($19,490) came from the 
published literature (Kremer, 2001).  For patients in palliative care, there was no start-
up cost, but a constant cost of $1,141 per six-months was applied.  This cost included 
the six-month average cost of NSAIDs, corticosteroids, and MTX.  The costs of   
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Table 7. Monitoring costs: 6-month data used in the decision analysis model for each drug 
 
Variables  CPT   Unit Rate ($)  Methotrexate Adalimumab Etanercept Infliximab        Leflunomide  
         Managed care/ Medicare  (Frequency)  (Frequency)  (Frequency)  (Frequency)     (Frequency) 
    Reimbursement Rates  1st 6-mth/ 1st 6-mth/ 1st 6-mth/ 1st 6-mth/ 1st 6 mth/ 
        After 6-mth After 6-mth After 6-mth After 6-mth After 6-mt 
 
Chest X-ray  71020  $65.6/$36.3  1  1  1  1  1 
 
Complete blood count 85007  $9.6/$4.8  7/6  13/6  13/6  13/6  7/6 
 
Urine analysis  81005  $6.1/$3.0  2  13  13  13  - 
 
Creatinine  82575  $26.4/$13.2  7  13  13  13  7 
 
LFTs 
 ALT  84460  $7.3/$7.4  7/6  1/1  1/1  1/1  7/6 
AST  84450  $7.1/$7.2  7/6  1/1  1/1  1/1  7/6 
Albumin  82040  $11.5/$6.9  7/6  1/1  1/1  1/1  7/6 
 
Protein purified test 86580  2$2.07/-   -  1  1  1  - 
 
Antinuclear antibody 86039  $31.2/$15.6  2  13/1  13/1  13/1  -/1 
 
Rheumatologist (visits)   $72.1/$35.5  3.3/3.3  3.3/3.3  3.3/3.3  3.3/3.3  3.3/3.3 
 
Nonrheumatologist (visits)  $72.1/$35.5  1.6/1.6  1.6/1.6  1.6/1.6  1.6/1.6  1.6/1.6 
Total monitoring costs (First 6-month, Range)   $488.4-$927 $730.5-$1,262.5 $730.5-$1,262.5 $730.5-$1,262.5   $730.5-$1,262.5 
Average monitoring costs (First 6-month)    $707.7  $996.5  $996.5  $996.5  $670 
Total monitoring costs (After 6-month, Range)   $299.6-$501.2 $240.2-$468.8  $240.2-$468.8   $240.2-$468.8       $347.9-$598.4 
Average monitoring costs (First 6-month)    $404.4  $354.5  $354.5  $354.5    $473.2 
LFT=Liver function test, ALT=Alanine transferase test, AST= Aspartame transferase test 
Medicare:http://www.cms.hhs.gov/providers/pufdownload/default.asp? 




NSAIDs and corticosteroids were calculated from the Drug Topics Red Book (2004).  
Patients in the post-joint replacement state were assumed to have the same cost of 
treatment as those in the palliative care state.  The costs of hospitalizations due to RA-
related surgeries were calculated by using an exponential equation which is a function 
of the HAQ disability score (Choi et al., 2000; Table 8). 
Cost of surgery = 635.5 e1.0935 (HAQ score) 
 
where HAQ score is the score at 24 week  
 
  
Indirect costs: Indirect costs were included to capture potential savings associated with 
improvement in RA with each treatment.  Studies have shown that indirect costs in RA 
patients are one to three times the direct costs (Meenan, Yelin, Henke, Curtis, & 
Epstein, 1978; Stone, 1984).  In the present study, indirect costs was calculated as one 
to three times that of direct costs. 
 
Adjusting Costs 
When costs are taken from the literature or from electronic datasets, they often 
require adjustments before they can be included in the cost-effectiveness analysis.  
When older costs are used, they underestimate the cost of medical care in present-day 
terms, unless they are adjusted for inflation (Muennig, 2002).  Thus, all the costs that 
were taken from the literature in this study were adjusted to 2004 dollars.  The annual 
changes in medical inflation between 1990 and 2004 are reported by the Bureau of 
Labor Statistics.  The proportional increase in the prices was then calculated using the 
formula: (high year index value – low year index value)/low year index value   
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Variables     Baseline estimate (range )    References 
Table 8. Base-case estimates and their ranges for sensitivity analyses: 6-month data 
 
Hospitalization costs  +++          Choi et al., 2000 
 
MTX      $1302.7 (+20%) 
 
Adalimumab       $859.8 (+20%) 
    
Etanercept       $762.0 (+20%) 
   
Infliximab     $1639.1 (+20%) 
  
Leflunomide       $928.2 (+20%)  
 
 
Joint replacement cost     $19,490.0 (+20%)    Kremer, 2001 
 
Palliative care cost        $1141.0 (+20%) 
 
+++Hospitalization costs calculated using the formula:  
     Cost of surgery = 635.5 e1.0935 (HAQ score) where HAQ score is the score at 24 week 
     MTX = methotrexate 
     All costs adjusted to 2004 dollars
 
 
Discounting Future Costs 
  Medical interventions often result in decreased future medical costs that must be 
accounted for in present-day terms.  Based on the recommendation of the “Panel on 
Cost-effectiveness in Health and Medicine” which was convened by the United States 
Public Health Service, all future costs and outcomes were discounted into their net 
present value by three percent before they were included in the cost-effectiveness 
analysis (Gold et al., 1996).  The general formula for discounting future costs used was: 
    Cost of future event/ (1+ discount rate) years  
 
Analysis 
The base-case analysis represented the expected average effectiveness and costs 
per patient population, discounted at three percent for a hypothetical cohort of 10,000 
patients.  A Markov Model can be evaluated by using a Markov cohort simulation 
where the patients in the cohort are followed as they move among the predetermined 
Markov states.  Also, the Markov Model can be evaluated by using a first order Monte 
Carlo simulation.  In the first order Monte Carlo simulation, a large number of patients 
are followed through the model individually.  A single simulation trial will randomly 
select a path at each uncertainty, based on the probability of each outcome’s 
occurrence.  Thus, the path followed by different patients will differ by chance (Shaw 
& Zachary, 2002).   
 
The baseline model in this study was analyzed using a first order Monte Carlo 
simulation.  Even though costs and outcomes estimated by the two methods are similar, 
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an advantage of using a first order Monte Carlo simulation is that estimates of variance 
associated with costs and outcomes in each arm of the model are also determined, 
giving a measure of uncertainty of the derived costs and outcomes.  Estimated average 
costs and QALYs were then used to calculate an incremental cost-effectiveness ratio 
(ICER).  An ICER was calculated as the additional cost per patient achieving a 
particular outcome, compared with the next more expensive option.  
 
The use of tracker variables in the Markov Model also dictated the use of a first 
order Monte Carlo simulation.  A tracker variable is a special type of variable that can 
only be used in Monte Carlo simulation trials and not during Markov cohort simulation.  
The primary function of a tracker variable is to serve as a memory within a Markov 
process.  For example, if a patient encounters a node containing the tracker variable 
definition numEvents=numEvents+1, DATA will take the current global value of 
numEvents for that patient’s trial, add one to it, and store the new global value (DATA 
TreeAge Software manual).  Two tracker variables were created in the model.  The 
tracker variable ‘Number_JR’ was created to count the number of joint replacements a 
patient underwent in the model.  Another tracker variable ‘Number_JRage’ was created 
to estimate the age at which the patient underwent joint replacement.     
 
Sensitivity analysis is used to deal with uncertainty in the model parameters.  
Sensitivity analysis was performed by varying baseline variables over a plausible range 
to test the robustness of the model over a range of assumptions and probability 
estimates.  One-way sensitivity analysis was used to vary one parameter at a time from 
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its baseline value and the analyses used a first order Monte Carlo simulation to observe 
the effect on the choice of strategy.  Because the overall variability of a model is poorly 
characterized by one-way sensitivity analysis, a second order Monte Carlo simulation 
(probabilistic sensitivity analysis) was also used to characterize this variability.   
 
In second order Monte Carlo simulation, each parameter in the model, instead 
of taking on a single value, was assumed to be a variable quantity with a known range 
of possible values and an associated range of distribution functions.  For a cohort of 
patients, all the model parameters were allowed to vary within assigned ranges 
according to an assigned distribution and the average cost and effect of each treatment 
strategy was calculated.  This process was repeated a large number of times to generate 
empirical distributions for mean costs and effects of each treatment strategy (Shaw & 




Primary data for phase II was collected using a survey instrument.  The survey 
was developed to determine rheumatologists’ current prescribing patterns, laboratory 
monitoring practices, and perceived barriers in prescribing the three TNF inhibitors.  
The following section describes selection of the study population, development and 
administration of the survey instrument, data collection, and data analytical techniques 
that were used for this phase of the study.    
 
Study Population and Sample Selection 
 The research design used for this phase of the study was a cross-sectional 
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survey design.  The population of interest was a national sample of rheumatologists.  A 
mailing list of all the rheumatologists in the United States was obtained from SK&A 
Information Services Inc., a private mailing list firm.  The total number of 
rheumatologists obtained from SK&A was 3,008.   
 
Sample Size Calculation 
  The sample size for the study was determined on the basis of getting an estimate 
of the true proportion of a variable of interest in the population within + 5% points with 
95% confidence (Kalton, 1987).  The sample size necessary was determined using the 
following formula: 
   n = Z2 * Π (1 - Π) 
                      E2 
 
 
n: estimate of appropriate sample size 
 
Z: the number of standard errors away from the mean, or the Z score for the confidence  
 
     interval chosen, and equals 1.96 
 
Π: True population proportion and is equal to 33% (considering that all three TNF  
 
      inhibitors are being equally prescribed by the rheumatologists) 
 
E: acceptable level of error in estimation of population proportion, and is equal to 5%.   
 
Substituting the values in the equation gave a sample size of 340 
rheumatologists that need to be surveyed from the study population.  Assuming a 20% 
response rate for physician mail surveys, a total of 1,700 rheumatologists were needed 
to achieve the required sample size. After excluding trainees, non-clinical, and pediatric 
rheumatologists (n = 45), a total of 1,970 rheumatologists were randomly selected from 
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3,008 rheumatologists and mailed a survey questionnaire.  To assess the nonresponse 
bias, a one-page non-response questionnaire was mailed to 200 randomly selected non-
responding rheumatologists. 
   
Instrument Development and Content 
A self-administered survey was used for this phase of the study.  Surveys allow 
information to be collected from a sample group and to be generalized to the population 
at large.  Mail surveys are used more frequently than telephone and face-to-face 
interviews because they are easy to implement, incur relatively low cost, and have been 
found to be more reliable than telephone and face-to-face interviews (Dillman, 1999; 
DeLeeuw, 1992).   
 
The survey questionnaire was designed to investigate rheumatologists’ current 
prescribing patterns for the three TNF inhibitors in patients with RA.  Specifically, the 
survey was designed to gather information on rheumatologists’ preference for any 
particular TNF agent, to identify the patient population in which these agents were 
being used, to determine what laboratory monitoring protocols were being followed, 
and to identify rheumatologists’ perceived barriers in prescribing these agents. 
 
  The first section of the survey questionnaire was focused on exploring 
rheumatologists’ prescribing patterns of the three TNF inhibitors.  Rheumatologists 
were asked to identify the patient population (newly diagnosed, mild RA, moderate 
RA, or severe RA) in which they prescribed each of the TNF inhibitors.  
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Rheumatologists were also asked to rank, in order of preference, the TNF inhibitor they 
were more likely to prescribe in patients with RA.  The next question in this section 
asked the rheumatologists to indicate how they used TNF inhibitors in patients who 
responded inadequately to MTX alone.  The last question in this section asked the 
rheumatologists if they had switched any patient to a different TNF inhibitor if the first 
TNF inhibitor had not worked.  A follow-up question required the respondents to 
indicate the reasons for switching. 
 
The second section of the survey questionnaire was designed to investigate the 
use of adalimumab, etanercept, and infliximab by rheumatologists in their clinical 
practice.  For each drug, respondents were asked to provide the dose and frequency of 
dosing they prescribed in patients with newly diagnosed, mild, moderate, and severe 
RA.  The respondents were also asked about the laboratory tests ordered for each drug 
and the frequency of ordering these tests.  Respondents could select from a list of five 
laboratory tests.  These tests included anti-nuclear antibody test, complete blood count 
test, creatinine test, chest x-ray, and purified protein derivative test.        
   
  The third section of the questionnaire was designed to measure rheumatologists’ 
perceived barriers in prescribing each of the TNF inhibitors.  Respondents were asked 
to rate factors such as insurance coverage, cost, safety and efficacy of these drugs, and 
route of administration, on a one to seven Likert-type scale where one was ‘no 
problem’ and seven was ‘major problem’. 
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Demographic and practice-related information were obtained in the last section 
of the questionnaire.  Data collected included age in years, gender, number of years in 
practice as a rheumatologist, primary practice site, average number of patients with RA 
seen per week, average number of prescriptions written per week for each of the drugs, 
and the monitoring guidelines (ACR, EULAR, both, or none) used by the respondents 
in treating patients with TNF inhibitors. 
 
Instrument Validation 
 Faculty members from a School of Pharmacy and a School of Medicine were 
approached to assess the clarity, readability levels, and appropriateness of the 
instrument.  All the comments provided were incorporated in order to enhance the face 
and content validity of the survey questionnaire.  Feedback on the content of the 
questionnaire was also obtained from rheumatologists practicing at West Virginia 
University Hospital.  This process helped determine the relevance of questions and 
clarity of instructions included in the survey.  It also helped determine if any important 
variables were omitted or if any information was redundant. 
 
Instrument Administration 
Approvals for all survey related documents (survey questionnaire, cover letters, 
and non-response survey) were sought from the West Virginia University’s Institutional 
Review Board (WVU-IRB).  Once approved, the survey process was initiated by 
mailing a cover letter, the survey instrument, and a business reply envelope to a 
randomly selected national sample of rheumatologists.  The cover letter (Appendices A 
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& B) explained the study, noting the importance of determining the prescribing patterns 
of rheumatologists and their perceived barriers in prescribing the TNF inhibitors.  In 
addition to the purpose of the study, the letter also emphasized voluntary participation 
and assured confidentiality of responses.  Respondents were asked to return the 
completed survey (Appendix C) in a self-addressed business reply envelope.  The 
surveys were coded for follow-up purposes only. 
 
A second mailing followed after a period of four weeks.  This consisted of a 
cover letter, the survey instrument, and a business reply envelope; and this second 
packet was mailed only to those rheumatologists who did not respond to the first 
mailing.  Finally, about ten weeks after the first mailing, a one page non-response 
questionnaire was mailed to a randomly selected sample of non-responding 
rheumatologists to assess non-response bias.  The non-response survey (Appendix D) 
was conducted to determine if there is a difference between respondents and non-
respondents.  The non-response survey assessed the reasons for not participating in the 
study and also collected critical demographic and prescribing-related information on 
the use of TNF inhibitors. 
 
Data Handling and Analysis  
  All the returned surveys were checked for completeness.  Incomplete responses 
were not included in the analyses.  Data entry and statistical analyses were performed 




Descriptive statistics such as means and standard deviations (SDs) were used to 
report data.  Independent t-tests, analysis of variance (ANOVA), and repeated measures 
ANOVA were used to assess differences among groups.  Frequency distributions were 
generated for demographic and practice characteristics of the respondents. 
 
This chapter discussed in detail the methodology employed to meet the study 
goals and to address the research questions of both phases I and II.   The next chapter 











In phase I, a Markov model was constructed to evaluate the total costs and 
effects of five treatments: adalimumab plus MTX, etanercept plus MTX, infliximab 
plus MTX, leflunomide plus MTX, and a standard therapy of MTX in patients with RA 
that inadequately respond to MTX alone.  The model was evaluated using a first order 
Monte Carlo simulation.  The patients entered the model at age 55 and moved through 
the three Markov states of  ‘on medication, ‘palliative care’, and ‘post-joint 
replacement’.  Each state was associated with some events such as response to 
treatment, withdrawal from drug therapy, or experiencing joint replacement surgery.  
Finally the patients entered the absorbing state (death state).  Estimates of population 
mean costs and mean effects (e.g. QALYs) were obtained using first order Monte Carlo 
simulation, which were then used to calculate the ICERs.   
 
The transition from Markov states to ‘death’ state can be considered as a 
function of two independent forces: disease-specific mortality and all-cause mortality 
excluding the disease under consideration.  As described earlier, there are conflicting 
reports regarding the effect of RA on the risk of mortality.  For the baseline model, a 
standardized mortality ratio (SMR) of one was considered for RA and therefore, age-, 
sex-, race-adjusted all-cause mortality rates were used.  Since some studies report that 




adjusted all-cause mortality rates was adjusted by a factor of two to reflect the increase 
in risk of mortality due to RA.  The probability of dying based on age, sex, and race 
were obtained from the Statistical Abstract of the United States (U.S Census Bureau, 
Vital Statistics, 2004).  These probabilities and the adjusted probabilities to reflect the 





Table 9. Probability of dying based on age-, sex-, and race-adjusted all-cause mortality rates  
Age Probability  Age Probability  Age Probability  Age  Probability  
55 0.0041   67 0.0125   79 0.0392   91 0.1357 
56 0.0047   68 0.0141   80 0.0438   92 0.1485 
57 0.0046   69 0.0151   81 0.0491   93 0.1620 
58 0.0055   70 0.0169   82 0.0533   94 0.1764 
59 0.0060   71 0.0186   83 0.0621   95 0.1915 
60 0.0069   72 0.0199   84 0.0645   96 0.2075 
61 0.0072   73 0.0220   85 0.0753   97 0.2242 
62  0.0080   74 0.0242   86 0.0836   98 0.2417 
63 0.0088   75 0.0266   87 0.0925   99 0.2599 
64 0.0097   76 0.0295   88 0.1022   100 0.2788 
65 0.0107   77 0.0321   89 0.1126   >101 1.0000 
66 0.0117   78 0.0356   90 0.1238 
Source: Statistical Abstract of the United States (U.S Census Bureau, Vital Statistics, 2004) 
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Age Probability  Age Probability  Age Probability  Age  Probability  
55 0.0082   67 0.0248   79 0.0769   91 0.2530 
56 0.0094   68 0.0280   80 0.0857   92 0.2749 
57 0.0092   69 0.0300   81 0.0958   93 0.2978 
58 0.0110   70 0.0335   82 0.1038   94 0.3217 
59 0.0120   71 0.0369   83 0.1203   95 0.3463 
60 0.0138   72 0.0394   84 0.1248   96 0.3719 
61 0.0143   73 0.0435   85 0.1449   97 0.3981 
62  0.0159   74 0.0478   86 0.1602   98 0.4250 
63 0.0175   75 0.0525   87 0.1764   99 0.4523 
64 0.0193   76 0.0581   88 0.1939   100 0.4799 
65 0.0213   77 0.0632   89 0.2125   >101 1.0000 
66 0.0233   78 0.0699   90 0.2323 
Table 10. Probability of dying based on RA-adjusted mortality rates  




Base-case Analysis Results 
Ten thousand hypothetical patients were sampled for all the five treatments 
using a first order Monte Carlo simulation.  Natural mortality (adjusted for age, gender, 
and race) was incorporated into the model via standard life tables for a United States 
(US) population (U.S Census Bureau, Vital Statistics, 2004).  A discount rate of three 
percent, applied to costs and benefits in the base-case analysis, was based on the 
recommendation of the “Panel on Cost-effectiveness in Health and Medicine” which 
was convened by the United States Public Health Service (Gold et al., 1996).  As 
discussed earlier, the indirect costs due to RA are estimated to be one to three times that 
of the direct costs.  In the base-case analysis, we assumed that the indirect costs were 
the same as the direct costs.  Analyses were also performed assuming indirect costs at 
two and three times the direct costs and these results are reported later in this chapter. 
 
Estimated lifetime mean total costs and QALYs for each treatment are reported 
in Table 11.  The standard MTX treatment was the least expensive ($82,956 for a 
lifetime treatment) and etanercept plus MTX was the most expensive treatment 
($314,895).  The two other TNF inhibitors, infliximab plus MTX ($189,145) and 
adalimumab plus MTX ($187,748) were less expensive than etanercept plus MTX but 
were more expensive than leflunomide plus MTX ($116,991).  Etanercept plus MTX 
had the highest gain of 15.84 QALYs followed by adalimumab plus MTX (13.28 
QALYs), leflunomide plus MTX (12.94 QALYs), infliximab plus MTX (12.51 
QALYs), and standard MTX treatment (12.29 QALYs).   
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Table 11. Base-case results for total costs and effectiveness using Monte Carlo simulations of 10,000 hypothetical patients with 
RA that inadequately respond to MTX (using age-, sex- race-adjusted all-cause mortality rates) 
 
 
      Total Costs* ($)     Effectiveness (QALYs) 
Treatment Strategy           Mean $ (+SD)  Min $  Median $   Max $  Mean (+SD) Min Median   Max 
               
Standard MTX      82,956   (+25,567) 1,362    86,420 168,706 12.29 (+2.93) 0.22 13.12  19.00  
Leflunomide+MTX    116,991   (+52,012) 2,276  107,578 338,463 12.94 (+3.18) 0.25 13.55  23.24  
Infliximab+MTX    189,145 (+123,914) 6,360  157,079 853,187 12.51 (+3.00) 0.23 13.26  20.96 
Adalimumab+MTX    187,748 (+113,828) 5,232  157,689 701,482 13.28 (+3.35) 0.28 13.74  25.32 
Etanercept+MTX     314,895 (+193,655) 5,184  272,060 888,545 15.84 (+4.88) 0.29 15.49  36.05 
* Total costs = Direct costs + Indirect costs (Indirect costs calculated the same as direct costs) 
QALYs = Quality adjusted life years 
MTX = Methotrexate 
SD = Standard deviation 
Min = Minimum 




An incremental cost-effectiveness analysis was performed to determine whether 
costs incurred due to the addition of a TNF inhibitor or leflunomide to standard MTX 
treatment achieved any additional benefits.  This involved determining the ICERs.  The 
ICERs were calculated for both total costs and direct costs only of the treatments and 
are reported in Table 12. 
 
Under base-case assumptions using total costs, etanercept plus MTX provided 
more health benefits and was more costly than standard MTX treatment, with a 
resulting cost-effectiveness ratio of $49,724/QALY.  The second most cost-effective 
treatment was leflunomide plus MTX with an ICER of $52,833/QALY.  Infliximab 
plus MTX was less effective and more costly than adalimumab plus MTX (i.e., 
dominated), and adalimumab plus MTX had a higher ICER and costs compared with 
leflunomide plus MTX (i.e., ruled out through extended dominance).  The results for 
total costs are also represented graphically in Figure 4 where the X-axis represents the 
effectiveness in QALYs and the Y-axis gives the total costs in dollars. 
 
In the analysis including only direct costs, the dominance status of each 
considered treatments remained the same as in the base-case analysis using total costs 
consideration.  In the analysis including only direct costs, the ICER of etanercept plus 
MTX compared with standard MTX treatment was $24,333/QALY, while the ICER of 
leflunomide plus MTX compared with standard MTX treatment was $27,717/QALY.  
Infliximab plus MTX was dominated by leflunomide plus MTX and adalimumab plus 
MTX was ruled out through extended dominance.           
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Table 12. Base-case direct costs, total costs, effectiveness, and incremental cost-effectiveness ratios of different treatments for 
patients with RA that inadequately respond to MTX (using age-, sex-, and race-adjusted all-cause mortality rates) 
 
Treatment Strategy    Direct costs   Effectiveness Incremental   Total costs*  Effectiveness Incremental  
          ($)   (QALYs)  cost-effectiveness ($)  (QALYs) cost-effectiveness 
           Ratios ($/QALYs)     ratios ($/QALYs)  
Adalimumab+MTX   129,066  13.19  Extended Domination++ 187,748  13.28  Extended Domination## 
Etanercept+MTX   192,080  15.78  24,333   314,895 15.84  49,724 
Standard MTX     73,016  12.21  -     82,956 12.29  - 
Leflunomide+MTX     90,866  12.86  27,717   116,991 12.94  52,833 
Infliximab+MTX   128,553  12.43  Dominated+  189,145  12.51  Dominated# 
All treatments compared to the reference case: Standard MTX treatment 
MTX= Methotrexate 
* Total costs = Direct costs + Indirect costs (Indirect costs calculated as same as direct costs) 
+ Infliximab+MTX dominated by Leflunomide+MTX 
++Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.623   and 0.884. 
# Infliximab+MTX dominated by Adalimumab+MTX 




Figure 4. Total costs and effectiveness of different treatments for patients with RA 
that inadequately respond to MTX (using age-, sex-, race-adjusted all-cause 
mortality rates) 

















Continue with MTX 
MTX = methotrexate 
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Since the baseline estimates were obtained by analyzing the model using a first 
order Monte Carlo simulation, one-way sensitivity analysis also employed first order 
Monte Carlo simulation.  One-way sensitivity analysis was conducted by vary one 
input parameter at a time from their baseline values to observe the effect on the choice 
of treatment strategy.  Probabilities and costs were varied between ranges or +20%.  
Results of one-way sensitivity analyses on different input parameters and their effect on 
total costs, effectiveness, and ICERs are reported in Tables 13-23.  The first row in the 
tables gives the base-case results which serve as a benchmark against which all the 
subsequent derived values from the sensitivity analysis can be compared. 
Sensitivity analysis is used to deal with uncertainty in the model parameters.  
These analyses are performed to determine the robustness of the base-case results with 
regards to variation in the base-case estimates, both costs and effectiveness.  A 
comparison between the original cost-effectiveness ratios and the sensitivity analysis 
cost-effectiveness ratios of an input parameter provides an indication of how sensitive 
the overall model results are to changes in that particular parameter.  Thus, if the results 
are found to be stable over a wide range of input parameter, the model’s conclusions 
are considered to be robust (Gold et al., 1996). 






     
 
Table 13. One-way sensitivity analyses - Probability of withdrawals 
 
Parameter/range        MTX       Lef+MTX    Inf+MTX   Ada+MTX   Eta+MTX    MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX       
 
 Total Cost Total Cost     Total Cost Total Cost      Total Cost QALYs      QALYs QALYs       QALYs QALYs 
 
Base Case         82,956 116,991        189,145 187,748        314,895 12.29        12.94 12.51        13.28 15.84 
Adalimumab (-20%)    82,499 116,093        187,601 216,493       314,416 12.16        12.84 12.38        13.61 15.75 
        (+20%)   82,182 116,204        188,814 165,245        316,414 12.18        12.84 12.41        12.86 15.78 
Etanercept    (-20%)    82,135 115,559        187,091 185,609       355,238 12.17        12.80 12.39        13.15 16.60 
        (+20%)   82,589 116,712        188,123 187,416        284,419 12.24        12.89 12.45        13.24 15.18 
Infliximab     (-20%)    81,625 115,323        220,212 185,035       313,359 12.12        12.78 12.62        13.12 15.68 
        (+20%)   82,558 116,043        164,589 186,139        315,450 12.25        12.88 12.29        13.23 15.78 
Leflunomide (-20%)    82,332 127,693        185,981 183,786       316,044 12.23        13.24 12.45        13.20 15.82 
        (+20%)   82,463 107,378        188,157 185,473        315,450 12.22        12.62 12.44        13.20 15.77 
MTX            (-20%)    85,645 116,062        187,318 186,467       312,632 12.41        12.86 12.42        13.21 15.72 
        (+20%)   80,064 116,341        188,468 187,076        315,830 12.07        12.87 12.44        13.22 15.80 
MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX 
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Table 14. One-way sensitivity analyses - Probability of withdrawals due to severe adverse events 
Parameter/range        MTX       Lef+MTX      Inf+MTX   Ada+MTX   Eta+MTX    MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX  
 
 Total Cost Total Cost     Total Cost Total Cost     Total Cost  QALYs      QALYs QALYs       QALYs QALYs 
Base Case         82,956 116,991        189,145 187,748        314,895 12.29        12.94 12.51        13.28 15.84 
Adalimumab (-20%)    82,333 116,246        188,343 185,137        317,377 12.22        12.86 12.42        13.20 15.81 
        (+20%)   81,806 115,694        187,136 187,456        312,667 12.14        12.81 12.35        13.15 15.71 
Etanercept    (-20%)    82,380 115,541        186,667 185,096        312,606 12.19        12.82 12.40        13.14 15.73 
        (+20%)   82,361 116,108        187,831 186,072        317,839 12.29        12.86 12.42        12.21 15.84 
Infliximab     (-20%)    82,245 116,005        188,077 186,325        314,690 12.19        12.82 12.40        13.17 15.74 
        (+20%)   82,381 115,791        189,164 185,566        315,083 12.23        12.86 12.43        13.20 15.80 
Leflunomide (-20%)    82,498 115,521        189,128 186,815        316,097 12.22        12.88 12.45        13.22 15.78 
        (+20%)   82,320 116,663        188,163 185,758        314,707 12.19        12.83 12.41        13.18 15.74 
MTX            (-20%)    81,528 116,556        189,915 187,414        318,828 12.22        12.86 12.44        13.21 15.84 
        (+20%)   82,678 115,206        186,861 184,440        312,838 12.13        12.79 12.36        13.13 15.70 







Table 15. One-way sensitivity analyses - Probability of mild/moderate adverse event 
Parameter/range        MTX       Lef+MTX      Inf+MTX    Ada+MTX   Eta+MTX    MTX        Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX       
          Total Cost Total Cost     Total Cost Total Cost     Total Cost  QALYs      QALYs QALYs       QALYs QALYs 
Base Case         82,956 116,991        189,145 187,748        314,895 12.29        12.94 12.51        13.28 15.84 
Adalimumab (-20%)    82,125 115,716        186,652 185,383        313,820 12.20        12.85 12.42        13.19 15.77 
        (+20%)   82,115 115,637        186,411 185,091        311,861 12.18        12.85 12.40        13.18 15.69 
Etanercept    (-20%)    82,120 115,228        185,102 183,887        312,504 12.19        12.84 12.41        13.18 15.78 
        (+20%)   82,683 116,092        188,138 185,677        315,641 12.25        12.89 12.47        12.23 15.80 
Infliximab     (-20%)    81,796 115,506        186,065 185,258        314,397 12.14        12.80 12.36        13.15 15.70 
        (+20%)   81,911 115,602        185,984 185,479        316,197 12.17        12.82 12.38        13.16 15.77 
Leflunomide (-20%)    82,175 116,170        188,102 187,249        314,811 12.16        12.83 12.37        13.17 15.75 
        (+20%)   82,249 116,413        188,178 187,017        314,545 12.21        12.85 12.42        13.20 15.77 
MTX            (-20%)    81,725 115,359        186,556 184,491        312,368 12.16        12.82 12.38        13.16 15.71 
        (+20%)   82,333 116,608        189,036 187,461        315,370 12.19        12.85 12.41        13.20 15.77 





Table 16. One-way sensitivity analyses – Probability of joint replacement and discount rate 
Parameter/range        MTX       Lef+MTX      Inf+MTX   Ada+MTX   Eta+MTX    MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX       
          Total Cost Total Cost     Total Cost Total Cost     Total Cost  QALYs      QALYs QALYs       QALYs QALYs 
Base Case         82,956 116,991        189,145 187,748        314,895 12.29        12.94 12.51        13.28 15.84 
Probability of joint replacement 
 (0.1)           79,246 112,750        183,244 182,448        311,608 12.56        13.22 12.80        13.57 16.14 
(0.5)            83,420 116,666        189,199 186,113        313,172 12.01        12.65 12.23        12.98 15.53 
Discount rate  
(0%)             14,962 187,978        266,748 266,251        444,484 20.91        21.66 21.18        22.04 25.79 
(5%)            61,465   92,971        159,864 158,538        264,591 19.37          9.98   9.58        10.31 12.41 
MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX 
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Table 17. One-way sensitivity analyses – Utilities: on medication, palliative care, and post-joint replacement 
Parameter/range        MTX       Lef+MTX      Inf+MTX   Ada+MTX   Eta+MTX     MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX       
          Total Cost Total Cost     Total Cost Total Cost     Total Cost  QALYs      QALYs QALYs       QALYs QALYs 
Base Case         82,956 116,991        189,145 187,748        314,895 12.29        12.94 12.51        13.28 15.84 
On medication Utilities 
Adalimumab (-20%)        82,968 116,414        188,832 186,252         317,218 12.29        12.91 12.50        12.56 15.85 
      (+20%)       82,497 116,409        188,808 186,937         314,330 12.23        12.87 12.44        13.91 15.76 
Etanercept    (-20%)        82,044 115,569        186,640 185,492         315,142 12.16        12.81 12.38        13.16 14.09 
      (+20%)       82,673 115,934        186,438 185,119         313,793 12.24        12.88 12.46        13.22 17.38 
Infliximab     (-20%)       81,471 115,652        186,241 186,061         313,641 12.14        12.80 11.86        13.15 15.72 
      (+20%)      82,159 115,767        187,125 185,503         313,890 12.21        12.85 12.90        13.19 15.72 
Leflunomide (-20%)       82,397 116,099        188,336 186,637         315,912 12.20        12.22 12.43        13.20 15.78 
      (+20%)      82,103 115,862        188,141 186,145         313,873 12.19        13.46 12.40        13.18 15.72 
MTX            (-20%)       82,222 115,709        188,063 185,661         314,782 11.80        12.84 12.42        13.18 15.73 
      (+20%)      81,917 115,516        187,661 185,018        315,897 12.57        12.83 12.39        13.17 15.78 
UPall. Care   (-20%)      82,305 116,314        188,827 187,033        315,317 10.51        11.27 10.79        11.16 14.60 
       (+20%)     81,822 115,485        187,255 185,455        314,426 13.84        14.40 14.01        14.74 16.91 
UPost-JR      (-20%)      82,036 115,638        187,336 185,503        316,368 11.82        12.46 12.04        12.81 15.46 
       (+20%)     82,389 116,234        188,648 186,658        316,882 12.58        13.22 12.80        13.56 16.13 
MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX 
UPall.care = Palliative care utilities, UPost-JR = post-joint replacement utilities 
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Table 18. One-way sensitivity analyses - medication costs and infliximab administration costs  
Parameter/range        MTX       Lef+MTX     Inf+MTX    Ada+MTX   Eta+MTX    MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX       
          Total Cost Total Cost     Total Cost Total Cost     Total Cost QALYs      QALYs QALYs       QALYs QALYs 
Base Case         82,956 116,991        189,145 187,748        314,895 12.29        12.94 12.51        13.28 15.84 
Medication costs 
Adalimumab (-20%)    82,206 116,013        187,189 167,384        316,082 12.21        12.85 12.41        13.19 15.80 
        (+20%)   82,656 116,745        188,589 206,667        317,777 12.24        12.88 12.44        13.23 15.86 
Etanercept    (-20%)    81,961 114,731        188,132 183,286        272,391 12.19        12.81 12.39        13.15 15.76 
        (+20%)   82,392 116,026        187,046 186,003        358,282 12.21        12.85 12.43        13.19 15.78 
Infliximab     (-20%)    82,285 115,950        169,784 185,710        314,081 12.20        12.84 12.42        13.18 15.76 
        (+20%)   82,369 116,215        205,646 186,682        316,016 12.21        12.86 12.42        13.20 15.82 
Leflunomide (-20%)    81,897 110,672        188,814 186,646        318,205 12.18        12.84 12.39        13.18 15.83 
        (+20%)   82,059 120,755        186,701 184,826        313,864 12.18        12.84 12.41        13.18 15.76 
MTX            (-20%)    81,617 114,708        186,923 185,126        310,428 12.24        12.88 12.45        13.23 15.78 
        (+20%)   83,344 118,521        190,856 189,643         319,301 12.20        12.87 12.43        13.22 15.79 
Infliximab infusion administration costs 
      ($663.6)    82,222 115,866        185,702 186,068        315,605 12.18        12.82 12.40        13.16 15.75 
      ($1,033.6) 82,281 115,901        190,038 186,002        314,196 12.20        12.85 12.43        13.19 15.78 
MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX 
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Table 19. One-way sensitivity analyses - Costs of monitoring in first six months 
Parameter/range        MTX       Lef+MTX      Inf+MTX    Ada+MTX   Eta+MTX   MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX       
          Total Cost Total Cost     Total Cost Total Cost     Total Cost QALYs      QALYs QALYs       QALYs QALYs 
Base Case           82,956 116,991        189,145 187,748       314,895 12.29        12.94 12.51        13.28 15.84 
Adalimumab ($730)      81,782 115,293        185,304 184,320       313,735 12.17        12.82 12.38        13.15 15.72 
        ($1,262)    81,767 115,349        186,791 185,420       314,904 12.13        12.78 12.34        13.12 15.71 
Etanercept    ($730)       81,782 115,293        185,304 184,320       313,735 12.17        12.82 12.38        13.15 15.72 
        ($1,262)    81,767 115,349        186,791 185,420       314,904 12.13        12.78 12.34        13.12 15.71 
Infliximab     ($730)      81,782 115,293        185,304 184,320       313,735 12.17        12.82 12.38        13.15 15.72 
        ($1,262)    81,767 115,349        186,791 185,420       314,904 12.13        12.78 12.34        13.12 15.71 
Leflunomide ($487)       82,533 115,877        187,278 185,844       314,059 12.25        12.88 12.45        13.22 15.79 
        ($852)       82,050 116,057        188,246 186,393       316,781 12.18        12.82 12.40        13.17 15.79 
MTX            ($488)        81,846 116,127        187,559 186,872       316,117 12.15        12.81 12.36        13.16 15.76 
        ($927)        82,251 115,767        187,139 185,321       312,891 12.20        12.86 12.43        13.21 15.73 




Table 20. One-way sensitivity analyses - Costs of monitoring after six months  
 Parameter/range        MTX       Lef+MTX      Inf+MTX    Ada+MTX   Eta+MTX   MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX       
          Total Cost Total Cost     Total Cost Total Cost     Total Cost  QALYs      QALYs QALYs       QALYs QALYs 
 Base Case         82,956 116,991        189,145 187,748        314,895 12.29        12.94 12.51        13.28 15.84 
Adalimumab ($240)      82,054 115,798        186,126 184,532       310,690 12.17        12.83 12.40        13.17 15.74 
        ($468)      82,378 116,040        188,697 187,627       318,616 12.20        12.84 12.40        13.18 15.80 
Etanercept    ($240)      82,054 115,798        186,126 184,532       310,690 12.17        12.83 12.40        13.17 15.74 
        ($468)      82,378 116,040        188,697 187,627       318,616 12.20        12.84 12.40        13.18 15.80 
Infliximab     ($240)      82,054 115,798        186,126 184,532       310,690 12.17        12.83 12.40        13.17 15.74 
        ($468)      82,378 116,040        188,697 187,627       318,616 12.20        12.84 12.40        13.18 15.80 
Leflunomide ($347)      81,691 113,664        186,649 184,830        311,460 12.12        12.77 12.34        13.12 15.63 
        ($598)      82,190 117,091        187,375 185,751        315,068 12.19        12.83 12.41        13.17 15.70 
MTX            ($299)      81,947 115,987        187,949 185,612        315,163 12.23        12.86 12.45        13.21 15.77 
       ($501)     82,608 116,121        188,349 186,587        313,890 12.17        12.83 12.40        13.18 15.71 
MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX 
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Table 21. One-way sensitivity analyses - Hospitalization costs 
  Parameter/range        MTX       Lef+MTX      Inf+MTX    Ada+MTX   Eta+MTX   MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX           
          Total Cost Total Cost     Total Cost Total Cost     Total Cost QALYs      QALYs QALYs       QALYs QALYs 
Base Case          82,956 116,991        189,145 187,748       314,895 12.29        12.94 12.51        13.28 15.84 
Adalimumab (-20%)    82,013 115,381        186,793 183,197       312,126 12.18        12.80 12.38        13.14 15.65 
        (+20%)   82,545 116,774        188,736 189,783       317,130 12.23        12.88 12.45        13.23 15.83 
Etanercept    (-20%)    81,995 115,718        186,503 185,713       309,141 12.18        12.81 12.39        13.15 15.66 
        (+20%)   81,765 114,929        185,185 183,947       315,162 12.17        12.80 12.39        13.14 15.68 
Infliximab     (-20%)    82,327 115,883        185,401 186,471       314,022 12.18        12.82 12.41        13.17 15.73 
        (+20%)   82,098 115,377        190,159 184,921       313,339 12.19        12.82 12.41        13.16 15.73 
Leflunomide (-20%)    82,316 113,864        188,251 186,741       314,372 12.18        12.83 12.39        13.17 15.77 
        (+20%)   82,323 118,169        188,645 186,157       314,211 12.20        12.84 12.42        13.19 15.75 
MTX            (-20%)    80,778 115,605        187,490 184,951       313,237 12.24        12.87 12.46        13.21 15.73 
        (+20%)   83,701 115,460        187,065 185,153       313,164 12.17        12.81 12.38        13.14 15.72 
MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX 
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Table 22. One-way sensitivity analyses - Costs of treating mild/moderate adverse event, severe adverse event, joint 
replacement, and palliative care treatment 
Parameter/range        MTX       Lef+MTX      Inf+MTX    Ada+MTX   Eta+MTX   MTX      Lef+MTX      Inf+MTX      Ada+MTX      Eta+MTX       
          Total Cost Total Cost     Total Cost Total Cost     Total Cost QALYs      QALYs QALYs       QALYs QALYs 
Base Case         82,956 116,991        189,145 187,748        314,895 12.29        12.94 12.51        13.28 15.84 
Costs of treating mild/moderate adverse event 
        ($126)    82,014 115,240        186,511 185,077        316,321 12.17        12.82 12.39        13.16 15.80 
         ($204)    82,640 116,400        187,147 186,751        316,475 12.24        12.88 12.43        13.22 15.83 
Costs of treating severe adverse event 
                      (-20%)    81,127 114,405        185,071 182,421        312,683 12.20        12.81 12.40        13.15 15.73 
        (+20%)   83,550 117,147        189,318 188,943        315,027 12.23        12.86 12.44        13.21 15.76 
Costs of joint replacement 
   ($15,592)    79,518 113,048        184,607 182,407        310,011 12.21        12.86 12.42        13.20 15.72 
    ($23,388)    85,075 118,490        190,108 188,345        320,584 12.18        12.81 12.39        13.16 15.78 
Costs of palliative care treatment 
   ($912)      73,013 106,675        177,380 176,135        307,692 12.24        12.85 12.43        13.19 15.79 
    ($1,369)   91,585 125,270        198,056 195,972        324,216 12.20        12.86 12.42        13.21 15.82 
MTX: Standard MTX treatment, Lef+MTX: Leflunomide+MTX, Inf+MTX: Infliximab+MTX, Ada+MTX: Adalimumab+MTX, Eta+MTX: Etanercept+MTX
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Table 23. Summary of main results in one-way sensitivity analyses 
Parameter/range      Leflunomide+MTX Infliximab+MTX      Adalimumab+MTX Etanercept+MTX       
      ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) 
Base Case              52,833  Dominated  Extended Domination  49,724 
Probability of Achieving ACR 20 Response 
All Five Treatments (-20%)      52,058  Dominated  Extended Domination  38,033 
        (+20%)      52,058  Dominated  Extended Domination  38,033 
Probability of Total Withdrawals 
Adalimumab  (-20%)      52,058  Dominated  Extended Domination  46,773 
          (+20%)      52,058  Dominated  Extended Domination  38,033 
Etanercept      (-20%)       52,058  Dominated  Extended Domination  40,078 
         (+20%)      52,058  Dominated  Extended Domination  34,986 
Infliximab       (-20%)    52,059  Dominated  Extended Domination  30,371 
          (+20%)    52,059  Dominated  Extended Domination  50,047 
Leflunomide  (-20%)      45,638  Dominated  Extended Domination  38,033 
         (+20%)      63,126  Dominated  Extended Domination  38,033 
MTX              (-20%)      Extended Domination Dominated  Extended Domination  38,033 
          (+20%)     45,256  Dominated  Extended Domination  38,033 





Table 23. Summary of main results in one-way sensitivity analyses 
Parameter/range      Leflunomide+MTX Infliximab+MTX      Adalimumab+MTX Etanercept+MTX       
      ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) 
Base Case              52,833  Dominated  Extended Domination  49,724 
Probability of Withdrawal Due to Loss of Efficacy 
All Five Treatments (-20%)      52,058  Dominated  Extended Domination  38,033 
         (+20%)      52,058  Dominated  Extended Domination  38,033 
Probability of Mild/Moderate Adverse Events 
Adalimumab  (-20%)      52,058  Dominated  Extended Domination  38,033 
          (+20%)      52,058  Dominated  Extended Domination  38,033 
Etanercept      (-20%)       52,058  Dominated  Extended Domination  37,917 
         (+20%)      52,058  Dominated  Extended Domination  38,130 
Infliximab       (-20%)    52,058  Dominated  Extended Domination  38,070 
          (+20%)    52,058  Dominated  Extended Domination  37,996 
Leflunomide  (-20%)      51,802  Dominated  Extended Domination  38,033 
         (+20%)      52,296  Dominated  Extended Domination  38,033 
MTX              (-20%)       52,201  Dominated  Extended Domination  38,033 
          (+20%)     51,916  Dominated  Extended Domination  38,033 
All treatments compared to Standard MTX treatment  
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Table 23. Summary of main results in one-way sensitivity analyses 
Parameter/range      Leflunomide+MTX Infliximab+MTX      Adalimumab+MTX Etanercept+MTX       
      ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) 
Base Case              52,833  Dominated  Extended Domination  49,724 
Probability of Joint Replacement  
(0.1)       52,069  Dominated  Extended Domination  38,193 
 (0.5)       52,058  Dominated  Extended Domination  37,966 
Discount Rate  
(0%)       51,253  Dominated  Extended Domination  38,923 
       (5%)       52,493  Dominated  Extended Domination  37,017 
All treatments compared to the reference case: Standard MTX treatment 
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Table 23. Summary of main results in one-way sensitivity analyses 
Parameter/range      Leflunomide+MTX Infliximab+MTX      Adalimumab+MTX Etanercept+MTX       
      ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) 
Base Case              52,833  Dominated  Extended Domination  49,724 
Utilities – On Medication 
Adalimumab  (-20%)      52,058  Dominated  Dominated   38,033 
          (+20%)      52,058  Dominated   67,246   38,033 
Etanercept      (-20%)       52,058  Dominated  Extended Domination  74,628 
         (+20%)     Extended Domination Dominated  Extended Domination  25,519 
Infliximab       (-20%)    52,058  Dominated  Extended Domination  33,159 
          (+20%)    52,058  Dominated  Extended Domination  44,587 
Leflunomide  (-20%)     Extended Domination Dominated  Extended Domination  38,033 
         (+20%)      26,362  Dominated   Dominated   38,033 
MTX              (-20%)       32,218  Dominated  Extended Domination  38,033 
          (+20%)    Extended Domination Dominated  Extended Domination  50,048 
Palliative Care     (-20%)       44,932  Dominated  Extended Domination  33,377 
          (+20%)     61,872  Dominated  Extended Domination  44,199 
Post-JR              (-20%)       52,047  Dominated  Extended Domination  37,888 
          (+20%)    Extended Domination Dominated  Extended Domination  38,033 
All treatments compared to the reference case: Standard MTX treatment 
Post-JR = Post-Joint Replacement 
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Table 23. Summary of main results in one-way sensitivity analyses 
Parameter/range      Leflunomide+MTX Infliximab+MTX      Adalimumab+MTX Etanercept+MTX       
      ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) 
Base Case              52,833  Dominated  Extended Domination  49,724 
Medication Costs 
Adalimumab  (-20%)      52,058  Dominated  Extended Domination  38,033 
          (+20%)      52,058  Dominated  Extended Domination  42,714 
Etanercept      (-20%)       52,058  Dominated  Extended Domination  25,489 
         (+20%)      52,058  Dominated  Extended Domination  50,577 
Infliximab       (-20%)    52,058  Dominated  Extended Domination  50,047 
          (+20%)      52,058  Dominated  Extended Domination  32,045 
Leflunomide  (-20%)      43,720  Dominated  Extended Domination  38,033 
          (+20%)      60,397  Dominated  Extended Domination  38,033 
MTX              (-20%)       50,822  Dominated  Extended Domination  37,333 
          (+20%)     53,295  Dominated  Extended Domination  38,734 
Infliximab Infusion Administration Costs 
      ($663)       52,058  Dominated  Extended Domination  50,047 
          ($1,033)       52,058  Dominated  Extended Domination  37,470 





Table 23. Summary of main results in one-way sensitivity analyses 
Parameter/range      Leflunomide+MTX Infliximab+MTX      Adalimumab+MTX Etanercept+MTX       
      ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) 
Base Case              52,833  Dominated  Extended Domination  49,724 
Monitoring Costs in First Six Months 
TNF inhibitors  ($730)       52,058  Dominated  Extended Domination  38,033 
          ($1,262)       52,058  Dominated  Extended Domination  38,033 
Leflunomide  ($487)       51,917  Dominated  Extended Domination  38,033 
          ($852)       52,199  Dominated  Extended Domination  38,033 
MTX              ($488)       52,228  Dominated  Extended Domination  38,033 
          ($927)      51,889  Dominated  Extended Domination  38,033 
Monitoring Costs after Six Months 
TNF inhibitors  ($240)       52,058  Dominated  Extended Domination  37,473 
          ($468)       52,058  Dominated  Extended Domination  38,593 
Leflunomide  ($347)       49,823  Dominated  Extended Domination  38,033 
          ($598)       52,199  Dominated  Extended Domination  38,033 
MTX              ($299)           53,022  Dominated  Extended Domination  38,033 
          ($501)       51,168  Dominated  Extended Domination  38,033 





Table 23. Summary of main results in one-way sensitivity analyses 
Parameter/range      Leflunomide+MTX Infliximab+MTX      Adalimumab+MTX Etanercept+MTX       
      ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) 
Base Case              52,833  Dominated  Extended Domination  49,724 
Costs of Hospitalization 
Adalimumab  (-20%)      52,058  Dominated  Extended Domination  38,033 
          (+20%)      52,058  Dominated  Extended Domination  49,248 
Etanercept      (-20%)       52,058  Dominated  Extended Domination  36,822 
         (+20%)      52,058  Dominated  Extended Domination  39,244 
Infliximab       (-20%)    52,058  Dominated  Extended Domination  50,047 
          (+20%)      52,058  Dominated  Extended Domination  37,035 
Leflunomide  (-20%)      48,603  Dominated  Extended Domination  38,033 
          (+20%)      55,514  Dominated  Extended Domination  38,033 
MTX              (-20%)       54,655  Dominated  Extended Domination  38,033 
          (+20%)     49,461  Dominated  Extended Domination  38,033 
Cost of Treating Mild/ Moderate Adverse Events 
      ($126)       51,924  Dominated  Extended Domination  37,938 
          ($204)       52,193  Dominated  Extended Domination  38,129 





          (+20%)      51,625  Dominated  Extended Domination  38,073 
          ($23,388)      52,057  Dominated  Extended Domination  38,008 
          ($1,369)      51,418  Dominated  Extended Domination  37,443 
      ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) ICER (Total Cost/QALY) 
Parameter/range      Leflunomide+MTX Infliximab+MTX      Adalimumab+MTX Etanercept+MTX       
Base Case              52,833  Dominated  Extended Domination  49,724 
      (-20%)      52,492  Dominated  Extended Domination  37,993 
      ($15,592)   52,060  Dominated  Extended Domination  38,058 
      ($912)    52,698  Dominated  Extended Domination  38,623 
Table 23. Summary of main results in one-way sensitivity analyses 
Cost of Treating Severe Adverse Events 
Cost of Joint Replacement 
Costs of Palliative Care Treatment 
All treatments compared to the reference case: Standard MTX treatment
 
 
The total costs were sensitive to changes in the medication costs.  However, the 
dominance status of each considered treatments remained the same as in the base-case 
analysis.  As seen in the results, changes in the cost parameters influenced only the total 
costs and not the effectiveness and resulted in marked changes in the ICERs for the 
treatments.  For example, reducing the medication costs of etanercept and leflunomide 
(the two nondominated treatments) by 20% resulted in an ICER of $25,489/QALY and 
$43,720/QALY, respectively.  Conversely, increasing the medication costs of 
etanercept and leflunomide by 20% resulted in an ICER of $50,577/QALY and 
$60,397/QALY, respectively.      
 
Changes in the utility parameter also resulted in changes in the ICERs.  
Increasing the utilities of etanercept and leflunomide by 20% resulted in an ICER of 
$25,519/QALY and $26,362/QALY, respectively.  Decreasing the utilities of these 
treatments by 20% resulted in an ICER of $74,628/QALY for etanercept and 
leflunomide was ruled out by extended dominance.  Results varied little with changes 
in the utilities associated with palliative care and post-joint replacement care. 
 
The results were most sensitive to changes in medication costs, cost of palliative 
care, and probability of total withdrawals (Figure 5 and 6).  The results were not 
sensitive to the changes in the probability of ACR 20 responses and probability of lack 
of efficacy of treatments.  Also, results varied little with the changes in probability of 
joint replacement, discount rate, monitoring costs, costs of hospitalizations, and costs of 
severe and mild/moderate adverse events.  The ICER for leflunomide plus MTX  
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Figure 5. One-way sensitivity analysis: Etanercept  
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Figure 6. One-way sensitivity analysis: Leflunomide 
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remained fairly stable across the ranges of all variables, except when medication costs 
and utilities of leflunomide were reduced or increased by 20%.  
 
The ICER for etanercept plus MTX was found to be even more favorable in the 
sensitivity results than in the base-case analysis.   The ICER for etanercept plus MTX 
in the sensitivity analysis for a number of variables was around $38,000/QALY 
compared to an ICER of $49,724/QALY reported in the base-case analysis.  This is 
because the total costs of adalimumab plus MTX and infliximab plus MTX are very 
similar to each other.  Varying any of the variables in the sensitivity analysis between  
+20% resulted in a change in position of adalimumab plus MTX and infliximab plus 
MTX in the calculation of incremental costs and this made the ICER for etanercept plus 
MTX even more favorable.  For example, when the treatment cost of adalimumab plus 
MTX is reduced by 20%, the lifetime cost of adalimumab plus MTX is $167,384 while 
that of infliximab plus MTX is $187,189 and etanercept plus MTX is $316,082.  The 
incremental cost of etanercept plus MTX is calculated by subtracting infliximab plus 
MTX cost from etanercept plus MTX cost.  However, when treatment cost of 
adalimumab plus MTX is increased by 20%, the lifetime cost of adalimumab plus MTX 
increases to $206,667 while that of infliximab plus MTX and etanercept plus MTX 
remain approximately the same.  The incremental cost of etanercept plus MTX is now 
calculated from adalimumab plus MTX since the cost of adalimumab plus MTX is 
higher than that of infliximab plus MTX.  This results in a lower ICER for etanercept 





Probabilistic Sensitivity Analysis 
Because the overall variability of a model is poorly characterized by a 
univariate sensitivity analysis, probabilistic sensitivity analysis (second order Monte 
Carlo simulation) was also used to characterize this variability.  As discussed earlier, 
each parameter in the model, instead of taking a single value, was assumed to be a 
variable quantity with a known range of possible values and an associated distribution 
function.  Since all costs, probabilities, and utilities were given ranges, a triangular 
distribution was specified for each of the variable.  Triangular distribution takes into 
consideration the lowest, highest, and the likeliest value of any variable.   
 
The process of resampling from each of the distributions and recalculating the 
cost-effectiveness from the model was repeated 10,000 times to generate the total costs, 
effectiveness, and ICERs of each treatment.  The results are presented in Table 24 and 
are similar to those obtained in the base-case analysis.  Etanercept plus MTX and 
leflunomide plus MTX had an ICER of $49,689/QALY and $51,288/QALY, 
respectively.  Infliximab plus MTX was dominated by leflunomide plus MTX and 
adalimumab plus MTX was ruled out by extended domination.  The advantage of using 
a probabilistic sensitivity analysis is that it instills more confidence in the validity of the 
model by taking into consideration the relevant uncertainty in the parameter; and by 
specifying a prior distribution for a particular parameter that increases the clarity of the 
model.          
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Table 24. Probabilistic sensitivity analysis results for total costs, effectiveness, and incremental cost-effectiveness ratios of 
different treatments for patients with RA that inadequately respond to MTX (using age-, sex-, race-adjusted all-cause 
mortality rate 
 
Treatments       Total costs*  Effectiveness  Incremental            
    ($)   (QALYs)  cost-effectiveness ratios 
          ($/QALY) 
 
Standard MTX        83,003  12.25   - 
Leflunomide+MTX      116,506  12.91   51,288 
Infliximab+MTX      186,868  12.47   Dominated# 
Adalimumab+MTX      187,352  13.25   Extended Domination## 
Etanercept+MTX   316,468  15.85   49,689 
All treatments compared to the reference case: Standard MTX treatment 
MTX=methotrexate 
* Total costs = Direct costs + Indirect costs (Indirect costs calculated as same as direct costs) 
# Infliximab+MTX dominated by Leflunomide+MTX 





Effect of RA-adjusted Mortality Rate on ICERs 
There are uncertainties relating to the available data on the effects of RA on the 
risk of mortality.  To examine the effect of increased risk of mortality due to RA, it was 
assumed that mortality was two-fold greater compared with an age-, sex-, and race- 
matched general population.  Results of the analyses comparing the direct costs, total 
costs, effectiveness, and ICERs of the five treatments are shown in Tables 25 and 26. 
 
The dominance status of each treatment remained the same as in the base-case 
analysis using total costs and direct costs.  The standard MTX treatment was the least 
expensive (direct costs = $62,504, total costs = $71,867) and lowest QALY gain (10.9 
QALY).  Etanercept plus MTX was the most expensive treatment (direct costs = 
$177,197, total costs = $297,171) and highest QALY gain (14.3 QALY).  This 
treatment provided more health benefits and was more costly than standard MTX 
treatment, with resulting cost-effectiveness ratios of $24,421/QALY (direct costs) and 
$50,782/QALY (total costs).  The second most cost-effective option was leflunomide 
plus MTX with an ICER of $28,127/QALY (direct costs) and $51,905/QALY (total 
costs).  Infliximab plus MTX was dominated by adalimumab plus MTX and 
adalimumab plus MTX was ruled out through extended dominance.        
 
Table 25. Results for total costs and effectiveness using Monte Carlo simulations of 10,000 hypothetical patients with RA that 
inadequately respond to MTX (using RA-adjusted mortality rates) 
 
      Total Costs* ($)     Effectiveness (QALYs) 
Treatment Strategy           Mean (+SD) $ Min $  Median $ Max $  Mean (+SD) Min Median   Max 
               
Standard MTX       71,867  (+28,069) 1,362    77,196 153,563 10.91 (+3.40) 0.22 12.00  18.61  
Leflunomide+MTX    104,865   (+53,091) 2,276    97,161 343,265 11.55 (+3.65) 0.25 12.46  23.46  
Infliximab+MTX    173,920 (+122,090) 6,360  135,807 858,419 11.13 (+3.47) 0.23 12.16  21.08 
Adalimumab+MTX    173,314 (+112,921) 5,233  142,950 731,753 11.88 (+3.81) 0.28 12.68  25.85 
Etanercept+MTX     297,171 (+190,522) 5,184  256,584 851,614 14.32 (+5.22) 0.29 14.29  33.88 
All treatments compared to the reference case: Standard MTX treatment 
MTX=methotrexate 
* Total costs = Direct costs + Indirect costs (Indirect costs calculated the same as direct costs) 
QALYs = Quality adjusted life years 
MTX = Methotrexate 
SD = Standard deviation 












Table 26. Direct costs, effectiveness, total costs, and cost-effectiveness of different treatments for patients with RA that 
inadequately respond to MTX (using RA-adjusted mortality rates) 
 
Treatment Strategy     Direct costs Effectiveness  Incremental   Total costs* Effectiveness  Incremental       
          ($)  (QALYs)  cost-effectiveness ($)  (QALYs) cost-effectiveness 
Adalimumab+MTX  118,383 11.87  Extended Domination++ 173,314 11.88  Extended Domination## 
           ratios       ratios 
       ($/QALY)      ($/QALY) 
 
Standard MTX     62,504 10.90  -     71,867 10.91  - 
Leflunomide+MTX     80,254 11.53  28,127   104,865 11.55  51,905 
Infliximab+MTX  118,205 11.14  Dominated+  173,920 11.13  Dominated# 
Etanercept+MTX  177,197 14.28  24,421   297,171 14.32  50,782 
All treatments compared to the reference case: Standard MTX treatment 
MTX=methotrexate 
* Total costs = Direct costs + Indirect costs (Indirect costs calculated as same as direct costs) 
+ Infliximab+MTX dominated by Adalimumab+MTX 
++Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.609 and 0.878. 
# Infliximab+MTX dominated by Adalimumab+MTX 




Effect of Indirect Costs on ICERs 
 Additional analyses were conducted to determine if there was any change in the 
dominance of treatments with regards to changes in the indirect costs.  Indirect costs 
were calculated as two and three times that of direct costs.  Tables 27 and 28 give the 
total costs, effectiveness, and ICERs for each treatment using both age-, sex-, and race-
adjusted mortality rate and RA-adjusted mortality rates. 
 
 When indirect costs were considered as twice that of direct costs, etanercept 
plus MTX had the lowest ICER of $75,502 to $75,577/QALY followed closely by 
leflunomide plus MTX with an ICER of $75,688 to $77,398/QALY.  However, when 
indirect costs were considered as three times that of direct costs, leflunomide plus MTX 
had the lowest ICER of $101,704 to $101,919/QALY followed by etanercept plus 
MTX by with an ICER of $101,875 to $102,548/QALY.  In both scenarios, infliximab 
plus MTX and adalimumab plus MTX were ruled out by dominance and extended 
dominance, respectively.      
      
 
Table 27. Total costs, effectiveness, and incremental cost-effectiveness ratios of different treatments for patients with RA that 
inadequately respond to MTX 
 
 
   ASR-adjusted All-cause Mortality Rates   RA Adjusted All-cause Mortality Rates 
 
Treatment Strategy Total costs*  Effectiveness  Incremental  Total costs*  Effectiveness  Incremental   
  ($)  (QALYs)  cost-effectiveness  ($)  (QALYs)  cost-effectiveness 
       ratios       ratios 
      ($/QALY)      ($/QALY) 
 
Standard MTX    92,428  12.25  -     81,565  10.93  - 
Leflunomide+MTX 141,666  12.90  75,688   130,099  11.55  77,398 
Infliximab+MTX  246,826  12.47  Dominated#  230,437  11.15  Dominated§ 
Adalimumab+MTX 243,493  13.25  Extended Domination## 234,753  11.89  Extended Domination§§ 
Etanercept+MTX  440,085  15.86  75,502   418,168  14.38  75,577 
All treatments compared to the reference case: Standard MTX treatment 
MTX=methotrexate 
ASR = Age, Sex, Race 
* Total costs = Direct costs + Indirect costs (Indirect costs calculated as two times that of direct costs) 
# Infliximab+MTX dominated by Adalimumab +MTX 
##Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.659 and 0.882. 
§ Infliximab+MTX dominated by Adalimumab +MTX 






Table 28. Total costs, effectiveness, and incremental cost-effectiveness ratios of different strategies for patients with RA that 
inadequately respond to MTX 
 
   Normal ASR-adjusted All-cause Mortality Rates  RA Adjusted All-cause Mortality Rates 
 
Treatment Strategy Total costs*  Effectiveness  Incremental  Total costs*  Effectiveness  Incremental   
  ($)  (QALYs)  cost-effectiveness  ($)  (QALYs)  cost-effectiveness 
       ratios       ratios 
      ($/QALY)      ($/QALY) 
Adalimumab+MTX 297,229  13.27  Extended Domination## 280,414  11.81  Extended Domination§§ 
 
Standard MTX  102,224  12.30  -    90,509  10.87  - 
Leflunomide+MTX 165,852  12.93  101,704   152,332  11.48  101,919 
Infliximab+MTX  305,123  12.52  Dominated#  290,420  11.09  Dominated§ 
Etanercept+MTX  557,684  15.82  101,875   530,070  14.25  102,548 
All treatments compared to the reference case: Standard MTX treatment 
MTX=methotrexate 
ASR = Age, Sex, Race 
* Total costs = Direct costs + Indirect costs (Indirect costs calculated as three times that of direct costs) 
# Infliximab+MTX dominated by Adalimumab +MTX 
##Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.665 and 0.883. 
§ Infliximab+MTX dominated by Adalimumab +MTX 





There are uncertainties relating to the available data on the effects of TNF 
inhibitors, leflunomide, or methotrexate on hospitalization costs.  Unlike the base-case 
analysis that included hospitalization costs, this analysis was carried out by excluding 
the hospitalization costs and studying its effect on the ICERs.  The results of the 
analysis using age-, sex-, race-adjusted all-cause mortality rates and RA-adjusted 
mortality are shown in Table 29.  Etanercept plus MTX had the lowest ICER followed 
by leflunomide plus MTX.  Infliximab plus MTX and adalimumab plus MTX were 
ruled out by dominance and extended dominance, respectively.  The ICERs reported in 
Table 29 are similar to those obtained in the base-case analysis.  
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Table 29. Total costs, effectiveness, and cost-effectiveness of different strategies for patients with RA that inadequately 
respond to MTX (without hospitalization costs) 
 
   ASR-adjusted All-cause Mortality Rates   RA Adjusted All-cause Mortality Rates 
 
Treatment Strategy Total costs*  Effectiveness Incremental  Total costs*  Effectiveness Incremental   
  ($)  (QALYs) cost-effectiveness  ($)  (QALYs) cost-effectiveness 
       ratios       ratios 
Adalimumab+MTX 176,335  13.25  Extended Domination## 163,854  11.83  Extended Domination§§ 
       ($/QALY)      ($/QALY) 
 
Standard MTX    74,487  12.29  -     63,207  10.86  - 
Leflunomide+MTX 105,296  12.91  50,246     93,788  11.49  48,013 
Infliximab+MTX  171,508  12.49  Dominated#  159,098  11.07  Dominated§ 
Etanercept+MTX  295,922  15.82  46,529   274,493  14.20  46,714 
All treatments compared to the reference case: Standard MTX treatment 
MTX=methotrexate 
ASR = Age, Sex, Race 
* Total costs = Direct costs + Indirect costs (Indirect costs calculated as same as direct costs) 
# Infliximab+MTX dominated by Leflunomide+MTX 
##Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.627 and 0.882. 
§ Infliximab+MTX dominated by Leflunomide+MTX 
§§ Adalimumab+MTX dominated by a blend of Leflunomide+MTX and Etanercept+MTX with a coefficient of inequity between 0.612 and 0.874.
 
 
Effect of Joint Replacement Therapy 
 The Markov model included two tracker variables that provided information 
regarding the proportion of people undergoing joint replacement therapy and the mean 
age at which people underwent joint replacement therapy.  As seen from the results 
presented in Table 30, the proportion of patients undergoing joint replacement therapy 
is the lowest for the combination of MTX and TNF inhibitors followed by standard 
MTX treatment and leflunomide plus MTX.  Among the TNF inhibitors, the lowest 
proportion of patients undergoing joint replacement therapy was seen with etanercept 
plus MTX.  Also, the mean age (68.58 years) and maximum age of undergoing joint 
replacement (83.5 years) is the highest for etanercept plus MTX indicating that more 
patients stay on the treatment before moving on to palliative care where they may 
undergo joint replacement.  Thus, patients continue to stay on etanercept plus MTX for 
a longer time period compared with the other treatments thereby accumulating higher 




Table 30. Proportion of patients undergoing joint replacement and age at which 
joint replacement occurs for each treatment  
 
Treatment Strategy          Proportion of  Mean Age Min. Age Max. Age  
            Patients with JR in yrs (+SD) in yrs  in yrs 
   
Standard MTX  78.9  68.42 (+1.7) 67.0  79.5  
Leflunomide+MTX     79.5  68.33 (+1.5) 67.0  77.5  
Infliximab+MTX     77.9  68.26 (+1.5) 67.0  78.0 
Adalimumab+MTX    77.9  68.40 (+1.6) 67.0        75.5    
Etanercept+MTX      76.4  68.58 (+2.0) 67.0  83.5 
Min. Age - Minimum age when patients underwent Joint replacement, Max. Age - Maximum age when 





































Discussion for Phase I Results 
Background 
Cost-effectiveness analysis has become the standard metric for the assessment 
of the clinical and economic value of new treatments (Ruff, 1999).  These analyses 
translate the clinical benefits of any treatment into both lifetime costs and effectiveness 
measures such as quality-adjusted life years (QALYs).  Thus, by applying a long time 
horizon, these analyses account for future benefits and savings or expense.  Also, these 
analyses help decision makers, clinicians, and patients compare relative cost-
effectiveness of alternative treatments (Wong, 2004). 
 
It has become a practice to compare new treatments to standard care so that new 
treatments that are more effective and less costly over a lifetime can be cost saving and 
also dominate the current standard treatments (Gabriel, Tugwell, O’Brien et al., 1999).  
More often, new treatments introduced in the market are more effective but also cost 
more.  To establish their effectiveness against standard treatments, incremental cost-
effectiveness analysis are conducted which takes into account the increased cost of the 
new treatment divided by the increased benefits the new treatment offers. Typically, the 
outcome measures used in these analyses are expressed as the net additional costs to 
increase life expectancy by one discounted QALY.  
 
Tumor Necrosis Factor Inhibitors 
Tumor necrosis factor inhibitors offer important treatment options to patients 
who fail multiple traditional DMARDs.  Results from RCTs conducted in patients that 
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inadequately respond to MTX alone have shown that these new treatments have the 
potential to reduce future disability (Keystone et al., 2004; Maini et al., 1999; Weinblatt 
et al., 2003; Weinblatt et al., 1999).  However, these agents are expensive compared to 
the traditional DMARDs.  Based on the average US wholesale price, adalimumab and 
etanercept cost around $16,000 and infliximab costs $17,000 per year (Drug Topics 
Red Book, 2004).  These costs do not include pre-therapy testing for opportunistic 
infections or monitoring for treatment complications.  Also, a number of patients (26-
34%) discontinue treatment in the first year due to toxicities or ineffectiveness 
(Flendrie, Creemers, Welsing, Den Broeder, & Van Riel, 2003).  A cost-effectiveness 
analysis of these new treatments is thus warranted.  The resulting cost-effectiveness 
ratio will express the relationship between the extra costs and additional benefits of 
these new treatments in comparison with the traditional DMARDs they replace.       
 
Economic Model for RA 
In RA, the health benefits and economic costs of treatments are more evident in 
the longer term.  However, data on the efficacy of TNF inhibitors are limited and only 
available from short-term RCTs.  Therefore, decision analytical modeling is used to 
synthesize short-term clinical trial results with long-term disease epidemiological 
aspects, quality of life, mortality, and resource use (Bansback et al., 2005).  In the last 
few years, a few economic studies assessing the incremental cost-effectiveness of TNF 
inhibitors versus standard therapies have been published.  As discussed in Chapter 2, 
these studies have been limited by their study duration, failing to include withdrawal of 
patients in the first year of treatment due to lack of efficacy or toxicities, or failing to 
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include additional costs due to monitoring or treating for complications in patients 
using TNF inhibitors.  Additionally, no study has evaluated the cost-effectiveness of all 
three TNF inhibitors in RA patients that inadequately respond to MTX. 
 
The current study utilized results from RCTs that were conducted in patients 
that inadequately responded to MTX alone.  Outcome Measures in Rheumatology 
(OMERACT) acknowledge that the underlying characteristics of the clinical trial 
should define the population to which the economic analysis is applicable (Bansback et 
al., 2005).  A hypothetical cohort of 55-year old women was selected as the base-case 
population who had failed two DMARDs, one of which was MTX.  The study model 
used cost per QALY as the outcome measure.   
 
Review of Study Results  
A Markov Model was constructed to evaluate the total costs and effects of five 
treatments: adalimumab plus MTX, etanercept plus MTX, infliximab plus MTX, 
leflunomide plus MTX, and a standard therapy of MTX in patients with RA that 
inadequately respond to MTX alone.  The model was evaluated using a first order 
Monte Carlo simulation.  The base-case simulation model yielded an ICER of 
$49,724/QALY for etanercept plus MTX followed by the next nondominated option of 
leflunomide plus MTX with an ICER of $52,833/QALY.  Infliximab plus MTX was 
dominated by adalimumab plus MTX and adalimumab plus MTX was ruled out 
through extended dominance.  Thus, the net societal economic cost of etanercept plus 
MTX in treatment of patients that inadequately respond to MTX alone is at most 
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$49,724 to increase life expectancy by one quality-adjusted life year, i.e., one year of 
perfect health.    
 
Taking only total costs into account, the standard MTX treatment was the least 
expensive ($82,956 for a lifetime treatment) and etanercept plus MTX was the most 
expensive treatment ($314,895).  The two other TNF inhibitors, infliximab plus MTX 
($189,145) and adalimumab plus MTX ($187,748) were less expensive than etanercept 
plus MTX but were more expensive than leflunomide plus MTX ($116,991).  The total 
QALY gain was the highest in etanercept plus MTX (15.84 QALYs) followed by 
adalimumab plus MTX (13.28 QALYs), leflunomide plus MTX (12.94 QALYs), 
infliximab plus MTX (12.51 QALYs), and standard MTX treatment (12.29 QALYs). 
 
As this study was the first to evaluate the cost-effectiveness of all three TNF 
inhibitors and leflunomide in patients with RA that inadequately respond to MTX 
alone, results were not directly comparable to other studies.  As reported earlier, there 
are few economic studies that have compared each of the TNF inhibitor to a standard 
therapy.  Also, the decision analytic models used in these studies have used disparate 
time horizons, comparators, quantities of drugs, discount rates, and treatment sequences 
making it very difficult to compare the cost-effectiveness ratios between the analyses. 
 
Reports of the cost-effectiveness of TNF inhibitors and leflunomide are 
available from other countries (Bansback et al., 2004; Barton et al., 2004; Brennan et 
al., 2003; Jobanputra et al., 2002; Kobelt et al., 2003; Kobelt et al., 2002).  Different 
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methodologies were employed in each of these studies to extrapolate long-term HAQ 
scores for patient cohorts.  Kobelt and colleagues (2003) and Wong and colleagues 
(2002) used patient level data from infliximab clinical trial (ATTRACT) and 
epidemiological database to calculate Markov transition rates.  Brennan and colleagues 
(2003) utilized clinical data and published annual progression rates to measure mean 
HAQ improvements for both responders and nonresponders of treatment.  Jobanputra 
and others (2002) did not include differential disability progression in the model. 
 
The study by Bansback and others (2004) modeled patients with moderate to 
severe RA who had failed at least two traditional DMARDs and estimated incremental 
QALY versus traditional DMARDs at 1.20 and 1.25 for adalimumab plus MTX and 
etanercept plus MTX, respectively.  The cost-effectiveness was estimated at 40,875 
euros per QALY (US $53,137/QALY) for adalimumab plus MTX and 51,976 euros 
(US $67,568/QALY) for etanercept plus MTX. 
 
Brennan and colleagues (2003) conducted a cost-effectiveness analysis of 
etanercept monotherapy under British Society for Rheumatological guidelines.  The 
study compared a DMARD sequence with etanercept as a third-line agent against the 
same sequence excluding etanercept.  The study reported a cost-effectiveness ratio of 
£16,330/QALY (US $26,000/QALY; costs adjusted to 2004 values) suggesting that 
etanercept was cost-effective when compared with non-biologic agents.  The cost-
effectiveness ratio in the sensitivity analysis ranged from £7,800 to £42,000 (US 
$11,232 to $60,480). 
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The study by Kobelt and colleagues (2002) investigated the cost-effectiveness 
of leflunomide compared to MTX in the UK.  The analyses covered a timeframe of 10 
years.  Leflunomide was reported to have costs of £44,017 (US $63,384) and effects of 
4.307 QALY compared to £44,988 (US $64,782) and effects of 4.158 QALY for MTX.  
Another study by Kobelt and colleagues (2003) evaluated the cost per QALY of 
infliximab plus MTX with MTX alone in patients with advanced disease.  Including 
both direct and indirect costs, the cost per QALY over 10 years was 3, 440 euros (US 
4,953) in Sweden and 34,800 euros (US $50,112) in UK.  The respective QALY gains 
were 0.248 and 0.298.  However, these analyses included markedly different 
assumptions regarding treatment effectiveness, disease progression, and quality 
adjustments.   
 
Studies by Jobanputra and colleagues (2002) and Barton and colleagues (2004) 
assessed the additional costs and QALYs gain associated with the use of either 
etanercept or infliximab as the third DMARD in a sequence of DMARDs.  The first 
study resulted in an ICER of approximately £83,000 (US $130,000; costs adjusted to 
2004 values) per QALY for etanercept and approximately £115,000 (US $180,000; 
costs adjusted to 2004 values) per QALY for infliximab.  The second study 
incorporated the effects of DMARDs on joint replacement, mortality, and QoL in the 
model developed by Jobanputra and colleagues (2002) and reported an ICER of 
approximately £59,289 (US $85,376) per QALY for etanercept and approximately 
£76,233 (US $109,775) per QALY for infliximab was reported.  Wong and colleagues 
(2002) examined costs and QALYs of infliximab plus MTX over a patient’s lifetime 
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using Markov model.  The study reported an ICER of $31,000/QALY (costs adjusted to 
2004 values). 
 
Despite lack of homogeneity in the methodological approaches and different 
model assumptions, these studies do provide a benchmark against which to compare the 
present study results.  The discounted incremental costs per QALY estimates from 
these analyses for different treatments range from $26,000 to $109,755.  Measurement 
of costs in the present study was comprehensive and included costs due to monitoring, 
costs of treating mild/moderate events, costs of treating severe adverse events, 
hospitalization costs and laboratory tests costs.  This may explain the higher ICER of 
etanercept plus MTX compared with results of some of economic studies discussed 
earlier in the section.  In terms of improvement in HRQoL, the incremental QALY 
reported for etanercept was 1.660 (Brennan et al., 2003), 0.214 (Jobanputra et al., 
2002), and 0.248 (Kobelt et al., 2003); 0.116 for infliximab (Jobanputra et al., 2002) 
and 0.290 (Wong et al., 2002).  The incremental QALY gain against standard MTX 
treatment in the present study was 3.55 for etanercept plus MTX, 0.99 for adalimumab 
plus MTX, 0.65 for leflunomide plus MTX, and 0.22 for infliximab plus MTX. 
 
During the last two decades, cost-effectiveness ratios of less than or equal to 
$50,000 per discounted QALY have been considered as acceptable, ratios greater than 
$50,000 and less than or equal to $100,000 per discounted QALY have been considered 
as reasonable, and ratios greater than $100,000 per discounted QALY have been 
considered as unreasonable or high (Maetzel, 2004).  Recent studies in different disease 
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areas have found cost-effectiveness ratios of $60,000 per discounted QALY for chronic 
hemodialysis and $ 1,000,000 for interferon beta for multiple sclerosis (Wong et al., 
2002).  In the present study, the ICER of etanercept plus MTX, and the next 
nondominated treatment, leflunomide plus MTX, fall within the acceptable range of 
$50,000 and $100,000.  In the sensitivity analysis, the base-case results were sensitive 
to variations in utilities and medication costs of etanercept and leflunomide. The lowest 
cost/QALY for etanercept plus MTX and leflunomide plus MTX were $30,371 and 
$43,720, respectively and the highest cost/QALY values were $74,628 and $63,126.  
These ICERs for both treatments remain below the acceptable range of $50,000 and 
$100,000.      
 
There are conflicting reports regarding the effect of RA on the risk of mortality.  
The OMERACT statement recommends that the risk of mortality be included in the 
decision analytical modeling studies.  Wong and colleagues (2002) assumed that an 
increase in disability level was equivalent to a 1.77-fold increase in mortality risk.  
Removing this assumption, the base-case results increased the base-case cost per 
QALY from $30,690 to $35,800 (1998 values).  The study by Brennan and others 
(2003) estimated the impact of the change in HAQ score on mortality via a COX 
proportional hazard regression.  Kobelt and colleagues (2003) did not account for 
increased risk of mortality in their model and used age- and gender-adjusted all cause 
mortality rates. To test the effect of mortality assumption, Jobanputra and colleagues 
(2002) assumed standardized mortality ratios (SMR) of 1.1 and 2.1.  These made no 
difference to the ICERs.  The ICER for etanercept against standard treatment changed 
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from £71,659/QALY to £71,471 with SMR 1.1 and to £71,838 with SMR 2.1.  In the 
present study, the incremental cost per QALY was calculated by adjusting the age-, 
gender-, race-adjusted all cause mortality rates by a factor of two (SMR = 2) to reflect 
the increased risk of mortality due to RA.  The dominance status remained the same 
though the incremental cost per QALY for etanercept plus MTX increased from 
$49,724/QALY to $50,782/QALY and leflunomide plus MTX decreased slightly from 
$52,833/QALY to $51,905/QALY. 
 
 The indirect costs associated from disability associated with rheumatoid 
arthritis are substantial (Callahan, 1998), including unemployment with increasing 
disease duration, decreased productivity, and increased work absenteeism (Wong et al., 
2002).  The inclusion of productivity costs in economic analyses remains contentious 
and even OMERACT states that all direct costs and societal costs should be reported 
separately.  Therefore, the present study reported base-case results separately for directs 
costs and for societal (total costs).  Considering only direct costs, the dominance status 
remained the same for both, all cause mortality rate and RA-adjusted mortality rate.  
The incremental cost per QALY for etanercept plus MTX was $24,333/QALY and 
$24,421/QALY for all cause mortality rate and RA-adjusted mortality rate, 
respectively.  Similarly, the incremental cost per QALY for leflunomide plus MTX was 
$27,717/QALY and $28,127/QALY for all cause mortality rate and RA-adjusted 




The study population included in this analysis was patients with severe RA that 
were refractory to standard therapy.  Due to their disease severity, the indirect costs of 
these patients are expected to be higher for the patients with mild RA or newly 
diagnosed RA (Kavanaugh et al., 1996).  Since the estimation of indirect costs is 
severely limited by data availability, indirect costs in the present study were considered 
to be one to three times that of direct costs.  In the base-case analysis, indirect costs 
were considered equal to direct costs (Wong et al., 2002).  When indirect costs were 
considered as twice that of direct costs, etanercept plus MTX had the lowest ICER 
followed closely by leflunomide plus MTX.  However, when indirect costs were 
considered as three times that of direct costs, leflunomide plus MTX has a lowest ICER 
than etanercept plus MTX.  In both scenarios, infliximab plus MTX and adalimumab 
plus MTX were ruled out by dominance and extended dominance, respectively.  The 
ICER became favorable for leflunomide plus MTX at higher total costs since 
leflunomide plus MTX had lower direct costs compared to etanercept plus MTX.  
However, even after considering high indirect costs, the ICERs of etanercept plus MTX 
and leflunomide plus MTX seemed to be in a reasonable range of $75,000 - $100,000. 
 
One of the main contributors to the high cost-effectiveness ratios may be the 
high acquisition cost of the TNF inhibitors, which if lowered, would make the cost-
effectiveness ratios even more acceptable.  However, no rheumatologist, knowing the 
important role and value of TNF inhibitors would want cost-effectiveness ratios to 
influence the way patients receive these treatments.  A study by Erkan and colleagues 
(2002) demonstrated that economic factors did influence DMARD preferences.  
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However, in addition to the cost of treatment, a number of other factors have been 
found to influence a rheumatologist’s decision-making process regarding choice of 
therapy.  These include patient preference, the disease itself (for example, disease 
duration and symptom severity), the drug chosen (for example, potential adverse 
events, cost, and route of administration), and published evidence documenting the 
overall experience with each drug (Schwartzman et al., 2004; Schwartzman & Morgan, 
2004).  No study has assessed rheumatologist’s prescribing patterns and the factors that 
influence rheumatologist’s choice of a particular TNF inhibitor over less costly 
standard RA treatments.  The lack of information on the actual use of TNF inhibitors by 






Phase II of the study involved a cross-sectional mail survey of randomly  
selected national sample of rheumatologists.  The study assessed the current 
rheumatologists’ prescribing patterns, their laboratory monitoring guidelines, and the 
potential barriers they face in terms of using TNF inhibitors or making a choice among 
the three agents.  The mailing list had a total of 1,970 rheumatologists.  Trainees, non-
clinical, and those in pediatric practices, were excluded from the survey.  A survey 
instrument developed for this study was mailed to each rheumatologist.  Table 31 gives 
the response rate analysis.  Of the 1,970 surveys mailed, 48 were undeliverable due to 
incomplete or incorrect addresses, death or retirement of the rheumatologist.  Thus, 
1,922 rheumatologists were presumably reached by the mailings.  A total of 432 usable 
responses were returned after two mailings for a response rate of 22.5%.  Four surveys 
were excluded from the analysis because they had less than 50% complete item 












Table 31. Response rate  
 
        N       Percent (%) 
 
Original sample size       1,970 
Undeliverable surveys          48 
    Effective Sample Size 1,922           100.0  
Number of questionnaires returned       432  22.5 
Incomplete questionnaire            4 
    Usable Response     428 








The nonresponse survey was mailed to a randomly selected sample of 
rheumatologists who did not respond to the two mailings of the survey.  Of the 200 
nonrespondent surveys mailed, 40 were returned, thus giving a response rate of 20%.  
The reasons cited by the rheumatologists for their nonparticipation in the study are 
listed in Table 32.  The most common reasons cited were: do not respond to mail 
surveys (35%), did not have enough time to complete the survey (30%), the survey was 
too long (15.4%), forgot the survey (10%), no incentive to participate (7.5%), did not 
receive the survey (5%), not interested in such studies (5%), the survey was misplaced 
(7.5%), and other reasons (22.5%). 
 
Demographics and practice-related characteristics of nonrespondents are 
presented in Table 33.  Of the 40 rheumatologists who responded to the non-response 
survey, 61% were males and 39% were females.  The mean age was 46.8 (SD =+8.5) 
years.  The mean number of years in practice as a rheumatologist was 14.6 (SD =+8.7) 
years and the mean number of patients with RA seen per week was 26.3 (SD =+13.1).  
A total of 66.7% described their primary practice site as group-based, 19.4% as solo-
based, 8.3% as university-affiliated hospital, 2.8% as hospital-based, and 2.8% as other.  
Rheumatologists reported using all three agents in patients with varying disease 
severity.  Rheumatologists prescribed all three agents in patients with moderate RA 
(88-100%) and severe RA (88-97%).  Also, some rheumatologists (11-26%) reported 
using these agents in newly diagnosed and mild RA patients (Table 34).      
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Table 32. Reasons for not participating in the study survey 
 
Reasons for Non Participation    N (40)*  Percent (%) 
Do not respond to mail surveys     14  35.0 
Did not have enough time to complete the survey   12  30.0 
The survey was too long        6  15.4  
Forgot the survey         4   10.0 
No incentive to participate        3    7.5  
The survey was misplaced        3    7.5 
Did not receive the survey        2     5.0  
Not interested in such studies       2    5.0  
Other          9  22.5   
* Multiple responses were checked by responders of nonresponse survey, hence total greater than 100% 
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Table 33. Demographic and practice-related characteristics of respondents of the 
non-response survey 
 
Characteristics     N   Percent (%) 
 




Males      22   61.1 
 
Females     14   38.9 
 
Primary practice site 
 
Hospital-based      1     2.8 
 
University affiliated hospital     3     8.3 
 
Solo-based       7   19.4 
 
Group-based     24   66.7 
 
Other        1     2.8 
 
Number of years in practice as a  
rheumatologist (Mean+S.D)    14.6+8.7 
 
Number of patients with RA seen 
per week (Mean+S.D)    26.3+13.1 
 
S.D = Standard deviation, RA = Rheumatoid arthritis 
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Table 34. Patient population in which TNF inhibitors used by respondents of the 
non-response survey* 
 
TNF  Newly Diagnosed Mild RA Moderate RA       Severe RA 
inhibitors  N (%)    N (%)     N (%)   N (%) 
 
Adalimumab  6 (17.6) 7 (20.6) 33 (97.1)       32 (94.1)  
 
Etanercept  9 (26.5) 8 (23.5) 34 (100)       33 (97.1) 
 
Infliximab  4 (11.8) 6 (17.6) 30 (88.2)       30 (88.2) 
 
* Multiple responses were checked by responders of nonresponse survey, hence total greater than 100% 
TNF = Tumor necrosis factor, RA = Rheumatoid arthritis
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  Respondents and nonrespondents were compared on the basis of their 
demographic and practice-related characteristics.  The variables compared were age, 
gender, primary practice site, number of years in practice as a rheumatologist, and 
mean number of patients with RA seen per week.  Independent t-tests and Chi-square 
tests were conducted for comparisons of these variables.  The result of the analysis is 
presented in Table 35.  The respondents and nonrespondents were significantly 
different on age and years of practice.  The nonrespondents were younger and had less 
number of years in practice as a rheumatologist compared to the respondents.  
However, no significant differences were noted between respondents and 
nonrespondents for gender, primary practice site, and average number of patients with 




Table 35. Analysis of non-response bias for demographic and practice-related 
characteristics  
  
Characteristics  Respondents Non-  Test  Significance 
    respondents Statistic P 
 
Age, years (Mean+S.D) 50.9+9.4 46.8+8.5 t=2.492 0.013* 
 
Gender , n (%)       χ2=3.293 0.07 
 
Males   323 (93.6) 22 (6.4)    
 
Females  108 (88.5) 14 (11.5)    
 
Primary practice site, n (%)     χ 2=5.389 0.25 
 
Hospital-based 18 (94.7) 1 (5.3)    
 
University-affiliated 75 (96.2) 3 (3.8) 
hospital    
 
Solo-based  111 (94.1) 7 (5.9)    
 
Group-based  223 (90.3) 24 (1.8)    
 
Other   3 (75)  1 (25)    
 
Number of years in practice as a  
rheumatologist (Mean+S.D) 18.2+9.6 14.6+8.7 t=2.211 0.028* 
    
Number of patients with RA  
seen per week (Mean+S.D) 29.9+20.1 26.3+13.1 t=1.009 0.314 
 
* Significant at p< 0.05, S.D = Standard deviation, RA = Rheumatoid arthritis 
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Demographics and Practice-related Characteristics of Responding 
Rheumatologists 
 
Demographics and practice-related characteristics of respondents are presented 
in Table 36.  Of the 432 respondents, 25.1% were women and 74.9% were men.  Mean 
age in years (S.D) was 50.9 (SD =+9.4), mean number of years in practice as a 
rheumatologist was 18.2 (SD =+9.6), and mean number of patients with RA seen per 
week was 29.9 (SD =+20.1).  Eighteen (4.2%) rheumatologists reported their practice 
site as hospital based, 75 (17.4%) as university-affiliated hospital, 111 (25.8%) as solo 




Table 36. Demographic and practice-related characteristics of respondents  
 
Characteristics     N  Percent (%) 
 




Males      323   74.9 
 
Females     108   25.1 
 
Primary practice site 
 
Hospital-based      18     4.2 
 
University affiliated hospital     75   17.4 
 
Solo-based     111   25.8 
 
Group-based     223   51.9 
 
Other          3     0.7 
 
Number of years in practice as a     
rheumatologist (Mean+S.D)     18.2+9.6 
 
Number of patients with RA  
seen per week (Mean+S.D)    29.9+20.1 
 
S.D = Standard deviation, RA = Rheumatoid arthritis 
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Results for Objective 1 
    The questionnaire asked the respondents to indicate their use of specific TNF 
inhibitors in different groups of patients with RA.  For study purposes, four groups of 
patients were identified based on the severity of the disease: newly diagnosed, mild 
RA, moderate RA, and severe RA.  Rheumatologists reported using all three TNF 
inhibitors in patients with moderate RA (82-90%) and severe RA (94-96%).  Also, 
some rheumatologists (10-18%) reported using these agents in newly diagnosed and 
patients with mild RA (Table 37). 
 
The questionnaire also asked rheumatologists regarding their use of TNF 
inhibitors in patients with severe RA that responded inadequately to methotrexate 
alone.  The response was based on the use of TNF inhibitors reported in clinical 
practice: TNF inhibitor alone, used in combination with one disease modifying anti-
rheumatic drug (DMARD), used in combination with two other DMARDs, TNF 
inhibitors not used, and other treatments or approaches used.  Rheumatologists were 
asked to check either one or more responses based on their use of TNF inhibitors in this 
patient population.  A majority of rheumatologists (n = 392; 91.2%) reported using a 
TNF inhibitor with one other (DMARD), 120 (28%) used a TNF inhibitor with two 
other DMARDs, 73 (17.0%) rheumatologists reported using a TNF inhibitor as 
monotherapy, 11 (2.6%) reported not using any TNF inhibitors in such patients, and 35 




Table 37. Respondents prescribing TNF inhibitors in patients based on the 
severity of the disease* 
 
TNF  Newly Diagnosed Mild RA Moderate RA    Severe RA 
inhibitors  N (%)    N (%)     N (%)         N (%) 
 
Adalimumab  64 (14.8) 54 (12.5) 375 (87.2)     411 (95.4)  
 
Etanercept  77 (17.9) 68 (15.8) 390 (90.5)     416 (96.7) 
 
Infliximab  46 (10.7) 43 (10.0) 357 (82.8)     408 (94.7) 
 
* Multiple responses were checked by responders of nonresponse survey, hence total greater than 100% 
TNF = Tumor necrosis factor, RA = Rheumatoid arthritis 
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  Rheumatologists were asked if they had ever switched any patient from one 
TNF inhibitor to a different TNF inhibitor.  Also, if they had switched patients to a 
different TNF inhibitor, their reasons for switching were elicited using an open-ended 
question.  Over 94% rheumatologists stated switching patients from one TNF inhibitor 
to a different TNF inhibitor in case of a nonresponse.  The following reasons were 
given by the respondents for switching patients from one TNF inhibitors to another: 
lack of efficacy (44.9%), adverse events (20.1%), insurance and reimbursement issues 
(3.7%), differences in the mechanism of action of the three TNF inhibitors (3.5%), 
success of switching based on study reports and case studies (3.5%), allergic reaction 
and infusion-site reaction to infliximab (2.1%), cost (1.9%), and patient preferences 
(1.6%). 
 
Rheumatologists were also asked to indicate the average number of 
prescriptions written per week for each drug.  The average number of prescriptions per 
week reported for adalimumab, etanercept, and infliximab were 3.68 (SD = +5.11), 




Discussion for Objective 1 
Modern RA management stresses the need for an aggressive treatment 
preferably at an early stage of the disease.  The original labeling of the TNF inhibitors 
indicates their use in patients with moderate to severely active RA despite treatment 
with MTX.  However, there are some emerging clinical reports that indicate their 
success in patients who have been recently diagnosed or those who have a mild form of 
the disease (Genovese, Bathon, & Martin, 2002; Smolen, ven der Heijde, Emery et al., 
2004).  While there is a tremendous excitement regarding the potential for disease 
modification in those patients with an early forms of the disease, there are issues such 
as costs and access that restrict the use of these agents in patients with early form of 
disease.  Results of this study show that a majority of rheumatologists are prescribing 
TNF inhibitors for moderate to severe patients as indicated.  However, there appears to 
be some rheumatologists who seem to broaden the official indication of TNF inhibitors 
to patients with early-onset RA. 
 
For the most severe group of patients with RA that inadequately respond to 
MTX alone, it is not known if the TNF inhibitors are being prescribed alone or used in 
combination with other DMARDs, or are being used as a second- or a third-line 
therapy.  Recent results from clinical trials have demonstrated a synergistic effect of 
MTX and TNF inhibitors in reducing signs and symptoms of RA, inhibiting structural 
damage, and improving physical functions in patients with RA (Klareskog et al., 2004; 
Smolen et al., 2004).  Thus, a combination of TNF inhibitors with MTX has become 
somewhat of a standard for patients with aggressive disease (Choy, 2004; Schnabel, 
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2004).  The result of this study is consistent with the reports that TNF inhibitor with 
one DMARD is the most commonly used combination followed by a combination of 
TNF with two DMARDs.  Some rheumatologists reported using TNF inhibitors alone 
while others reported using other treatments or approaches in treating patients with 
severe disease. 
 
Not all patients respond to TNF inhibitors and some who do respond develop 
treatment limiting side-effects.  Since the three TNF inhibitors seem to have similar 
efficacies in RA, an important practical question for clinicians is whether there is a 
rationale for prescribing another TNF inhibitor in case of a failure with the first TNF 
inhibitor or whether this practice only increases treatment costs (van Vollenhoven, 
2004).  The results indicate that an overwhelming majority of rheumatologists switched 
patients from one TNF inhibitor to another.  Major reasons for switching included lack 
of efficacy or adverse events associated with the TNF inhibitor.  Kavanaugh and 
colleagues (2004) have reported that reasons for switching patients from one TNF 
inhibitor to another are varied and include toxicity, loss of efficacy, cost, and 
reimbursement issues.   
 
Other reasons for switching could include the differences in mechanism of 
action of the TNF inhibitors.  Tumor necrosis factor (TNF-α), the proinflammatory 
cytokine, is believed to be an important factor in determining clinical response.  
Etanercept is made of two P75 soluble receptors and is capable of binding to both TNF-
α and TNF- β while infliximab and adalimumab are monoclonal antibodies and specific 
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to TNF-α.  Infliximab is administered intermittently in large doses and after achieving 
peak levels, decrease to undetectable levels after 6 to 8 weeks.  This warrants 
shortening of intervals of infusions in patients who do not respond to the 8-week 
interval.  On the other hand, shorter half life of etanercept and its administration twice a 
week leads to more sustained levels that may be inadequate in patients who require 
more rapid and drastic suppression.  This subset of patient population may benefit most 
from a switch to infliximab (Haraoui, 2004).  However, much remains to be learned 
about the exact mechanisms of these agents and until predictors of response have been 
identified, the use of these agents and switching between them will be governed by 
clinical judgment and accumulated experience.    
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Results for Objective 2 
Rheumatologists ranked, in order of preference, the TNF inhibitors they would 
give to patients in whom one is determined as necessary.  Etanercept was ranked first 
by 292 (68.2%) respondents, adalimumab by 120 (28.2%), and infliximab by 86 
(20.4%) respondents (Table 38).  Of those who ranked etanercept as first choice 
(n=292), 38 (13%) and 33 (11.5%) also ranked adalimumab and infliximab as first 
choice, 159 (54.5%) and 97 (33.2%) ranked adalimumab and infliximab as second 
choice, and 90 (31.0%) and 154 (53.5%) ranked adalimumab and infliximab as third 
choice. 
 
Of those who ranked adalimumab as first choice (n=120), 38 (31.7%) and 32 
(26.7%) also ranked etanercept and infliximab as first choice, 71 (59.2%) and 15 
(12.5%) ranked etanercept and infliximab as second choice, and 11 (9.2%) and 69 
(58.5%) ranked etanercept and infliximab as third choice.  Of those who ranked 
infliximab as first choice (n=86), 32 (37.2%) and 33 (38.4%) also ranked adalimumab 
and etanercept and as first choice, 22 (25.6%) and 32 (37.2%) ranked adalimumab and 
etanercept as second choice, and 32 (37.2%) and 21 (24.4%) ranked adalimumab and 




Table 38. Ranking of TNF inhibitors based on rheumatologist’s preference 
 
TNF inhibitors  Rank 1   Rank 2   Rank 3 
    N (%)   N (%)   N (%) 
 
Adalimumab   120 (28.2)  181 (42.5)  122 (28.6)      
  
Etanercept   292 (68.2)  104 (24.3)    32 (7.5)
        
Infliximab     86 (20.4)  107 (25.4)  223 (53.0)
  




Discussion for Objective 2 
 Etanercept was ranked first by 292 (68.2%) respondents, adalimumab by 120 
(28.2%) and infliximab by 86 (20.4%).  Around 42.5% and 53% of the respondents 
ranked adalimumab and infliximab as their second and third choice TNF inhibitor, 
respectively.  Thus, this indicates a clear preference for etanercept as the first choice 
TNF inhibitor compared to the other two TNF inhibitors among the responding 
rheumatologists.  Thus, the null hypothesis A that rheumatologists do not have any 
preference for any of the TNF inhibitors is rejected.  
 
The analysis revealed that there is a preference for etanercept and that 
infliximab is the third choice agent among the three TNF inhibitors for a majority of the 
rheumatologists.  The preference for etanercept could be due to the fact that it was the 
first TNF inhibitor to be launched in the market in the year 1999 and therefore, has the 
most clinical use experience among the three agents.  Also, data from clinical trials, 
practice experiences, and post-marketing surveillance reports have shown that 










Results for Objective 3 
Rheumatologists who preferred adalimumab, etanercept, or infliximab as their 
first choice agent were compared on the basis of their demographic (age, gender), 
practice-related characteristics (primary practice site, number of years in practice as a 
rheumatologist, and average number of patients with RA seen per week), and perceived 
barriers to prescribing the TNF inhibitors.  Analysis of variance (ANOVA) and Chi-
square tests were conducted to compare these variables.  Significant ANOVAs were 
further investigated by post-hoc Tukey comparisons.  Since the analysis compared 
rheumatologists who preferred adalimumab, etanercept, or infliximab as their first 
choice agent, rheumatologists who ranked all the three TNF inhibitors as their first 
choice agent were excluded from the analysis (n = 32). 
 
Table 39 gives the results of the analysis.  Rheumatologists who preferred 
adalimumab, etanercept, or infliximab as their first choice agent were significantly 
different on gender and number of patients with RA seen per week.  Rheumatologists 
who preferred infliximab as their first choice agent saw more patients with RA per 
week compared with rheumatologists who preferred adalimumab or etanercept as the 
first choice TNF inhibitor.  Also, rheumatologists who preferred infliximab perceived 
support for administration of infusion as a major problem compared with those who 
either preferred adalimumab or etanercept.  Rheumatologists who preferred etanercept 
perceived patient compliance with the agent as a major problem compared with those 
who preferred adalimumab.   
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Table 39. Demographic, practice-related characteristics, and perceived barriers of 
rheumatologists who preferred adalimumab, etanercept, or infliximab as their 
first choice TNF inhibitor  
   
Characteristics  Adalimumab Etanercept Infliximab Stat. Sig.
 n=82  n=253  n=53 
 
Age, years (Mean+S.D)  51.3+9.2 50.6+9.3 51.4+10.1      F=0.293    0.746  
  
Gender, n (%)                         χ 2=14.401   0.001* 
 
Males   66 (22.8) 175 (60.3) 49 (16.9)   
 
Females  16 (16.3) 78 (79.6) 4 (4.1)    
 
Primary Practice Site, n (%)           χ 2=10.333 0.242 
 
Hospital-based  4 (23.5)  13 (76.5) 0 (0)    
 
University-affiliated 9 (13.6)  50 (75.8) 7 (10.6) 
hospital    
 
Solo-based  27 (27)  58 (58)  15 (15) 
    
Group-based  40 (19.8) 131 (64.9) 31 (15.3)   
 
Other   1 (50)  1 (50)  0 (0)  
 
Number of years in practice as a  
rheumatologist (Mean+S.D)  18.4+9.8 17.9+9.6          18.4+9.9         F=0.127     0.881 
    
Number of patients with RA  
seen per week (Mean+S.D) 28.3+18.4a 28.4+18.3b 38.2+28.5a,b   F=5.494  0.004*
  
ANOVA: Significant ANOVA’s were investigated with post-hoc Tukey comparisons 
a,b: Means with same letters are significantly different. 

















Table 39 (contd.). Demographic, practice-related characteristics, and perceived 
barriers of rheumatologists who preferred adalimumab, etanercept, or infliximab 
as their first choice TNF inhibitor 
  
  Adalimumab Etanercept Infliximab Stat. Sig.
   
Factors  (Mean+S.D)  (Mean+S.D)  (Mean+S.D) 
 
Age of Patient   2.3+1.6  2.3+1.6  2.1+1.5       F=0.538    0.584  
 
Costs to Patients  5.9+1.5  6.1+1.4  5.7+1.6       F=1.868    0.156 
 
Efficacy of TNF inhibitors    2.1+1.3  2.4+1.7  2.1+1.3       F=2.091    0.125 
 
Insurance/Formulary coverage 5.0+1.7  4.9+1.9  4.9+1.9       F=0.356    0.701 
 
Patient Compliance  1.8+1.0a 2.2+1.4a 1.9+1.2       F=5.140   0.006* 
 
Patient Preference  2.1+1.5  2.5+1.4  2.5+1.5       F=2.615    0.074 
 
Route of Administration 2.4+1.4  2.7+1.5  2.8+1.5       F=2.082    0.126 
 
Side Effects   2.8+1.2  2.9+1.4  3.2+1.4       F=2.524    0.081 
 
Support for Administration 1.5+0.8b 1.7+1.3c 2.2+1.5b,c    F=6.861   0.001* 
 
Measured on a 7-point scale where 1 = no problem and 7 = major problem 
ANOVA: Significant ANOVA’s were investigated with post-hoc Tukey comparisons 
a,b,c: Means with same letters are significantly different. 
Significant at p< 0.05 
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Discussion for Objective 3 
Based on the analysis, the null hypothesis B that there is no difference in 
demographic, practice-related characteristics, and perceived barriers to prescribing TNF 
inhibitors among rheumatologists who preferred adalimumab, etanercept, or infliximab 
as their first choice agent is rejected.  Gender and number of patients with RA seen per 
week do have an association with prescribing preferences of rheumatologists.  More 
males compared to female rheumatologists showed preference for these agents.  
Rheumatologists who preferred infliximab as their first choice agent saw more patients 
with RA per week compared with rheumatologists who preferred adalimumab or 
etanercept as the first choice TNF inhibitor.  This could be attributed to the difference 
in dosing schedule and route of administration of the three drugs (Schwartzman & 
Morgan, 2004).  Infliximab is administered intravenously (IV) at a dose of 3mg/kg at 
weeks 0, 2, and 6, then every 8 weeks thereafter.  Both adalimumab and etanercept can 
be self-administered subcutaneously (SC).  Thus, patients on infliximab require 
frequent visits to the rheumatologists to get the infusion. 
 
One of the perceived barriers for prescribing infliximab, although a minor 
problem, was the support needed for administering infliximab.  Infliximab is generally 
administered on an outpatient basis and this requires the use of professionally staffed 
clinics and hospital infusion suite.  In addition to the basic equipment necessary for 
administering the infusion, the possibility of an acute infusion reaction to infliximab 




The compliance with etanercept although perceived as a minor barrier was 
significantly different than the other two TNF inhibitor.  This perception could be 
attributed to a number of factors.  It is seen that treatment with assisted IV infusions has 
higher compliance rates than self-administered SC injections.  Results of a survey of 
Canadian patients with RA indicate a preference for IV administration (infliximab) 
over an SC regimen (etanercept) (Schwartzman & Morgan, 2004).  Patients receiving 
etanercept must receive a short training session in self-administered SC injection while, 
as mentioned earlier, infliximab is administered on an outpatient basis by trained staff 
(Gallup, 2001). 
 
Another major reason for compliance being cited as a perceived barrier could be 
due to inequalities in coverage and reimbursement policies.  Infliximab is given 
intravenously and is covered under medical benefits, which are often unlimited or have 
a very high cap (e.g., $ 1,000,000).  Self-injectables like etanercept are covered by 
pharmacy benefits that are limited by the caps (typically $400-$500 per year for 
Medicare patients).  In addition, many managed care organizations institute three-tier 
plans that require high copay (Gallup, 2001).  These reasons could potentially explain 
the lower compliance with etanercept perceived by rheumatologists as compared to 
infliximab.    
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Results for Objective 4 
Adalimumab 
The most prescribed dose for adalimumab was 40 mg every other week.  Nearly 
one-fourth of the rheumatologists used this dose in patients with newly diagnosed and 
mild RA while a majority of rheumatologists indicated using this dose in moderate RA 
(83.7%) and severe RA (74.5%).  For patients with severe RA, one-fifth of the 
rheumatologists indicated using 40 mg of adalimumab every week. 
 
The laboratory tests routinely ordered by the rheumatologists varied with 
respect to the tests ordered and the frequency at which these were ordered.  A majority 
of the rheumatologists ordered complete blood count (88.2%) and purified protein test 
(96.6%).  Purified protein test (PPD) was ordered mostly at baseline (82.7%) and a few 
(15.7%) ordered the test after a year of follow-up.  Antinuclear antibody test (ANA), 
chest radiography, and creatinine were monitored by 30 to 60% of rheumatologists 
(Table 40).   
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Table 40. Laboratory tests ordered for adalimumab and percentage of 
rheumatologists ordering the tests during different weeks 
Tests     N (%)    Weeks (%) 
     0 4 6 8 12 24 52
  
ANA   132 (32.5) 52.3 - 1.6   2.3   3.9 6.3 20.3 
 
CBC   358 (88.2)   2.5 9.9 7.6 22.6 37.3 5.7   2.5 
 
CXR   205 (50.5) 71.0 - - - - - 24.0 
 
Creatinine  247 (61.6)   7.7 6.9 - 22.7 32.8 7.7 - 
 
PPD   392 (96.6) 82.7 - - - - - 15.7 
 





  The most prescribed dose for etanercept was 50 mg every week for newly 
diagnosed (15.3%) and mild RA (14.9%) patients followed by 25 mg twice weekly in 
newly diagnosed (13.7%) and mild RA (13.2%) patients.  Nearly half of the 
rheumatologists reported using etanercept 25 mg twice a week in moderate to severe 
patients while 40% of rheumatologists used a dose of 50 mg every week in patients 
with moderate to severe RA. 
 
Similar to tests for adalimumab, the laboratory tests routinely ordered for 
etanercept varied with respect to the tests ordered and the frequency at which these 
were ordered.  A majority of the rheumatologists ordered complete blood count 
(88.2%) and PPD (96.4%).  Purified protein test was ordered mostly at baseline 
(82.6%) and a few (15.9%) ordered the test after a year of follow-up. Antinuclear 
antibody test (ANA), chest radiography, and creatinine were monitored by 30 to 60% 
of rheumatologists (Table 41).  
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Table 41. Laboratory tests ordered for etanercept and percentage of 
rheumatologists ordering the tests during different weeks 
 
Tests     N (%)    Weeks (%) 
     0 4 6 8 12 24 52
  
ANA   139 (33.6) 53.3 - 1.6   2.3   3.9   9.6 20.7 
 
CBC   365 (88.2) - 10.7 7.4 22.8 - 11.5 - 
 
CXR   209 (50.5) 70.2 - - - - - 23.9 
 
Creatinine  255 (61.6) -   7.5 8.3 22.5 32.0 13.4 - 
 
PPD   398 (96.4) 82.6 - - - - - 15.9 
 






The preferred dose for infliximab was 3 mg/kg in patient population with 
varying disease severity.  Around 17 % rheumatologists prescribed 3 mg/kg in newly 
diagnosed and mild RA patients while 43.4% and 34.2% prescribed 3 mg/kg in 
moderate and severe RA, respectively. 
 
Rheumatologists reported using a range of doses for infliximab with almost 
93% indicating the use of a minimum dose of 3 mg/kg and 67% reporting a maximum 
dose of 5 mg/kg for newly diagnosed patients.  In mild patients, 88% rheumatologists 
reported using a minimum dose of 3 mg/kg and 73% reported a maximum dose of 5 
mg/kg.  The 8-week dosing interval for infliximab infusion was universally used by 
rheumatologists in newly diagnosed (89.3%) and mild patients (88.5%).  In moderate 
patients, 81% of rheumatologists used a minimum dose of 3 mg/kg while a maximum 
dose of 5 mg/kg was used by 52% rheumatologists and a maximum dose of 10 mg/kg 
was used by 19.5% of rheumatologists.  Almost three-fourth of the rheumatologists 
reported a dosing interval of 8 weeks while 13.2% rheumatologists reported a dosing 
interval of 6-8 weeks between infusions. 
 
For severe patients, rheumatologists (64%) used a minimum dose of 3 mg/kg 
and 22% rheumatologists used a minimum dose of 5 mg/kg while 30% and 37% 
reported using a maximum dose of 5 mg/kg and10 mg/kg, respectively.  In severe 
patients, rheumatologists reported using a dosing interval of 8-week (55.1%), 6-8 
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weeks (15.6%), 6-week (11.4%), and 4-8 weeks (9.9%) indicating an increase in the 
frequency of treatment. 
 
The results for laboratory tests ordered and frequency of the tests for infliximab 
were similar to that of adalimumab and etanercept.  Rheumatologists ordered complete 
blood count (89.3%) and PPD (97%).  Purified protein test was ordered mostly at 
baseline (82.3%) and a few (15.6) ordered the test after a year of follow-up. Like the 
PPD test, chest radiograph was ordered by 51.8% rheumatologists with 71.3% ordering 
them at baseline and 21.3% after a year of follow-up.  Antinuclear antibody test (ANA) 
was ordered by 38% of rheumatologists with nearly half of them ordering the test at 




Table 42. Laboratory tests ordered for infliximab and percentage of 
rheumatologists ordering the tests during different weeks 
 
Tests     N (%)    Weeks (%) 
     0 4 6 8 12 24 52
  
 
ANA   152 (38) 52.7 - -   5.4   6.8 14.2 16.2 
 
CBC   357 (89.3) - 10.2   9.0 31.9 29.1   9.6 - 
 
CXR   207 (51.8) 71.3 - - - - - 21.3 
 
Creatinine  252 (63)   6.8   7.2 11.2 29.2 26.0 12.0 - 
 
PPD   387 (97) 82.3 - - - - - 15.6 
 
ANA - Anti-nuclear antibody, CBC - Complete blood count, CXR - Chest radiograph, PPD - Purified 
protein derivative  
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Discussion for Objective 4 
The survey revealed some interesting points regarding the dosing of the TNF 
inhibitors and laboratory tests ordered by the rheumatologists.  Dosing guidelines 
suggest that adalimumab patients are prescribed a dose of 40 mg every other week, 
etanercept patients two doses of 25 mg a week or a new dosage of 50 mg once every 
week.  The recommended dosing for infliximab is 3 mg/kg of body weight for the first 
dose and then at two and six weeks and every eight weeks thereafter.  Patients 
experiencing inadequate response may increase the dose to 10mg/kg; or may receive 
treatment as frequently as every four weeks (Physicians’ Desk Reference, 2002). 
 
The most prescribed dose for adalimumab was 40 mg every other week.  
However, in patients who had a severe form of the disease, rheumatologists reported 
administering 40 mg every week.  For etanercept, both 25 mg twice every week and 50 
mg once a week were being administered.  Rheumatologists reported using a range of 
doses for infliximab from 3mg/kg to 10mg/kg and these doses were administered every 
four to eight weeks.  A number of studies have shown that there are changes in the 
dosing of TNF inhibitors especially with infliximab (Gilbert, Smith, & Ollendorf, 2004; 
Harley, Frytak, & Tandon, 2003).  Possible explanations for changes in the dosage and 
dosing interval include adverse events and safety concerns resulting in decreasing in 
dosages, or poor response to therapy with lower dosages resulting in dosage increases 
or reduction of dosing intervals (Harley et al., 2003). 
 
There are currently no guidelines available for monitoring patients on TNF  
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inhibitors.  The only recommended test is the purified protein derivative (PPD), which 
is done at pretreatment to monitor for tuberculosis.  If the PPD test is positive, chest 
radiography is recommended.  The results of this study indicate that rheumatologists 
are following this recommendation and using PPD monitoring at pretreatment, with 
chest radiography if the PPD is positive.  Results indicate that only 82% were ordering 
PPD and 72% chest radiography, which is recommended if the PPD is positive.  Similar 
results were reported by Yazici and colleagues (2003).  Their study reported that 73% 
and 83% rheumatologists ordered PPD tests and 43% and 50% ordered chest 
radiography for etanercept and infliximab, respectively. 
 
There are no guidelines for blood test monitoring, however, a majority of 
rheumatologists (88-89%) seemed to order complete blood count (CBC) tests for 
patients at varying time interval.  Percentage of rheumatologists ordering CBC tests 
(88-89%) was lower than that reported by Yazici and colleagues (97-98%) (2003).   
Also, creatinine tests (61-63%) reported by rheumatologists in this study were lower 
than that reported by Yazici and colleagues (88-89%) (2003).  Rheumatologists who 
did not order tests such as creatinine and anti-nuclear antibody (ANA) may indicate 
either a lack of belief on part of the rheumatologists to the utility of these tests or a 
belief that all patients do not need these tests.  In summary, rheumatologists seem to be 
following similar laboratory monitoring practices for all the three TNF inhibitors but 
there seems to be no consensus as to how often the tests should be performed.  Thus,  
there is a need to revisit old monitoring guidelines or implement new monitoring 
guidelines for these TNF inhibitors. 
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Results for Objective 5 
The questionnaire asked the respondents to indicate the monitoring guidelines 
they followed when prescribing the three TNF inhibitors to patients with RA.  The 
responses included ACR guidelines, EULAR guidelines, both ACR and EULAR 
guidelines, none, and others.  Based on the analysis, the null hypothesis C that 
rheumatologists are not following any recommended monitoring guidelines for patients 
with RA on adalimumab, etanercept, and infliximab is rejected.  Almost 62% reported 
following ACR guidelines and 5% reported following both ACR and EULAR.  One- 
quarter of the responding rheumatologists reported not following any monitoring 
guidelines for the TNF inhibitors (Table 43). 
 
Discussion for Objective 5 
Guidelines for monitoring of potential toxicity caused by DMARDs have been 
developed by American College of Rheumatism (ACR Guidelines) and European 
League Against Rheumatism (EULAR Guidelines).  However, there are no available 
guidelines for monitoring TNF inhibitors.  It is interesting to note that 62% of the 
rheumatologists reported following ACR guidelines to monitor patients on TNF 
inhibitors and around 25% did not follow any monitoring guidelines.  Since there are 
no established guidelines available for TNF inhibitors, it is possible that 
rheumatologists who reported following monitoring guidelines continued their practice 
based on their experiences with earlier DMARDs, particularly MTX (Yazici et al., 
2003).       
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Table 43. Recommended monitoring guidelines followed by rheumatologists 
 
  ACR  EULAR Both   None               Other 
TNF         (ACR & EULAR)   
inhibitors   N (%)  N (%)  N (%)     N (%) 
 
Adalimumab 257 (62.2) 1 (0.2)  23 (5.6)       106 (25.7)    26 (6.3) 
 
Etanercept 261 (63.2) 1 (0.2)  22 (5.4)       106 (25.7)    23 (5.5) 
        
Infliximab 254 (61.5) 1 (0.2)  22 (5.3)       108 (26.2)    28 (6.8) 
 




Results for Objective 6 
Rheumatologists who followed ACR monitoring guidelines were compared to 
those who reported not following any monitoring guidelines on demographic and 
practice-related characteristics.  Independent t-tests and Chi-square tests were 
conducted for comparisons of these variables.  The results of the analysis are presented 
in Table 44. 
 
Rheumatologists who followed ACR monitoring guidelines were significantly 
different on age, gender, and number of years in practice compared to rheumatologists 
who did not follow any monitoring guidelines.  Rheumatologists who followed 
monitoring guidelines were younger and had practiced as a rheumatologist for fewer 
years as compared to those who did not follow any guidelines.  A higher proportion of 
males followed guidelines more than females. 
 
Rheumatologists who used monitoring guidelines when prescribing each of the 
TNF inhibitors were compared to those who did not follow any guidelines on perceived 
barriers to prescribing TNF inhibitors.  There was no significant difference between the 
two groups in all the three TNF inhibitors on perceived barriers to prescribing these 
agents.     
 




Table 44. Demographic, practice-related characteristics, and perceived barriers of 
rheumatologists who followed monitoring guidelines compared to those who do 
not follow any monitoring guidelines 
 Characteristics  Follow  Don’t Follow Test  Significance 
     Guidelines Guidelines Statistic P 
 
Age, years (Mean+S.D) 
  50.2+9.1 52.9+2.6 t=2.546 0.012* 
 
Gender, n (%)       χ 2=7.223 0.007* 
 
Males   188 (67.1) 92 (32.9)    
 
Females  73 (82)  16 (18)    
 
Primary Practice Site, n (%)     χ 2=7.881 0.096 
 
Hospital-based 9 (56.3) 7 (43.8)    
 
University-affiliated 48 (77.4) 14 (22.6) 
hospital    
 
Solo-based  60 (61.9) 37 (38.1)    
 
Group-based  142 (74.3) 49 (25.7)    
 
Other   2 (66.7) 1 (33.3)    
 
Number of years in practice as a  
rheumatologist (Mean+S.D) 17.5+9.2 20.2+9.8 t=2.467 0.015* 
    
Number of patients with RA  
seen per week (Mean+S.D) 30.4+21.1 30.3+19.3 t=-0.061 0.951 
 
* Significant at p< 0.05, S.D = Standard deviation, RA = Rheumatoid arthritis 
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Table 44 (contd.). Demographic, practice-related characteristics, and perceived barriers of rheumatologists who followed 
monitoring guidelines compared to those who do not follow any monitoring guidelines 
 
 
Characteristics   Adalimumab    Etanercept    Infliximab   
   Follow  Don’t follow   Follow  Don’t follow   Follow  Don’t follow 
    Mean (+SD) Mean (+SD)  Mean (+SD) Mean (+SD)  Mean (+SD) Mean (+SD) 
   
 
Age of Patient   2.46 (+1.7)  2.13 (+1.6)  2.30 (+1.6)  2.03 (+1.5)  2.64 (+1.8)  2.31 (+1.6) 
Costs to the Patient  5.97 (+1.5)  6.11 (+1.3)  6.02 (+1.4)  6.09 (+1.3)  5.49 (+1.8)  5.37 (+1.9) 
Efficacy of TNF  
inhibitors   2.58 (+1.5)  2.69 (+1.7)  2.31 (+1.5)  2.60 (+1.7)  2.54 (+1.5)  2.80 (+1.7) 
 
Insurance/Formulary 
coverage   5.07 (+1.8)  5.00 (+1.6)  4.87 (+1.9)  4.86 (+1.7)  4.62 (+2.0)  4.32 (+1.9) 
 
Patient compliance  2.17 (+1.3)  2.34 (+1.6)  2.31 (+1.4)  2.33 (+1.6)  2.27 (+1.6)  2.16 (+1.5) 
 
Patient Preference  2.36 (+1.4)  2.53 (+1.6)  2.58 (+1.4)  2.64 (+1.5)  3.05 (+1.5)  2.21 (+1.6) 
Route of Administration 2.51 (+1.4)  2.60 (+1.5)  2.64 (+1.4)  2.69 (+1.5)  3.58 (+1.7)  3.62 (+1.7) 
 
Side Effects   2.93 (+1.4)  3.07 (+1.4)  2.73 (+1.4)  2.90 (+1.3)  3.72 (+1.5)  3.88 (+1.4) 
 
Support for Administration 1.72 (+1.3)  1.67 (+1.3)  1.73 (+1.2)  1.68 (+1.3)  2.61 (+1.8)  2.76 (+1.9) 
 
SD = Standard Deviation 
Measured on a 7-point scale where 1=no problem and 7=major problem 
Independent t-test, significant at p< 0.05
 
 
Discussion for Objective 6 
Based on the analysis, the null hypothesis D that there is no difference in 
demographic and practice-related characteristics between rheumatologists who follow 
guidelines and those did not follow any guidelines is rejected.  The study results 
indicated that rheumatologists who followed monitoring guidelines were younger and 
had fewer years in practice compared to those who did not follow ant guidelines.  This 
is consistent with previous reports that showed that younger physicians are more likely 
to adhere to guidelines in other disease areas such as hypertension (Fernandes, 
Madhavan, Amonkar, Dell, Islam, & Scott, 2003).  
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Results for Objective 7 
  Figure 7 lists the factors that rheumatologists perceived as problematic 
regarding the use of specific TNF inhibitors in patients with RA.  A repeated measure 
ANOVA was conducted for comparisons of these variables.  The results of the analysis 
are presented in Table 45. 
 
There was no perceived difference seen in the patient compliance with these 
agents (F = 0.984, p = 0.322).  Age of the patient (F = 4.052, p = 0.045) was perceived 
as a minor problem with the perception being the highest for infliximab followed by 
adalimumab and etanercept.  Efficacy of the TNF inhibitors (F = 4.029, p = 0.049) was 
also perceived as a minor problem with etanercept being considered the most 
efficacious among the three agents.  Costs to the patient (F = 42.612, p = 0.000) and 
insurance or formulary coverage (F = 39.799, p = 0.000) were perceived as a major 
problem with etanercept and adalimumab being perceived as highly expensive and 
lacking insurance coverage as compared with infliximab. 
 
Patient preference for the TNF inhibitor (F = 47.343, p = 0.000) and preference 
for route of administration (F = 73.834, p = 0.000) was the highest for adalimumab, 
followed by etanercept and infliximab.  Side effects of TNF inhibitor (F = 112.247, p = 
0.000) was perceived as a major problem for infliximab, followed by adalimumab and 
least for etanercept.  Finally, support for administering infusions (F= 85.209, p = 0.000) 
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                Measured on a 7-point scale, where 1 = no problem and 7 = major problem 
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Table 45. Perceived barriers to prescribing different TNF inhibitors * 
 
Factors   Adalimumab  Etanercept  Infliximab 
    Mean+SD  Mean+SD  Mean+SD 
 
Age of patient   2.32+0.9a  2.20+0.9b  2.40+0.9a, b 
 
Costs to the patient  6.12+0.8c  6.11+0.8d  5.57+0.11c, d 
 
Efficacy of this TNF 
inhibitor   2.64+0.09e  2.47+0.09e  2.60+0.09 
 
Insurance/Formulary   
coverage   5.16+0.10f  4.95+0.11f  4.62+0.12f 
 
Patient compliance 
with this therapy  2.25+0.08  2.30+0.08  2.21+0.09 
 
Patient preference for 
this TNF inhibitor  2.38+0.08g  2.60+0.08g  3.10+0.1g 
 
Route of administration 
of this TNF inhibitor  2.55+0.09h  2.71+0.08h  3.62+0.1h 
 
Side effects of this 
TNF inhibitor   3.01+0.09i  2.88+0.08i  3.80+0.09i 
 
Support for administering 
Infusions   1.71+0.08j  1.71+0.07k  2.72+0.1j, k 
 
* Measured on a 7-point scale where 1 = no problem and 7 = major problem 
SD = standard deviation  
Repeated Measures of Analysis of Variance with post-hoc Tukey comparisons 
a,b,c,d,e,f,g,h,I,j,k, Means with same letters are significantly different at p<0 .05 




Discussion for Objective 7  
Based on the analysis, the null hypothesis E that there are no significant 
differences in rheumatologists’ perception of barriers (insurance coverage, route of 
administration, patient compliance, side effects, costs to the patient, age of the patient, 
efficacy of the drugs, and support needed for administration of drugs) to prescribing the 
three TNF inhibitors is rejected.  Two factors (costs to the patient and insurance or 
formulary coverage) were perceived as major barriers in prescribing the TNF inhibitors.  
Among the three agents, the perception was a little lower for infliximab.  The average 
wholesale price of these agents for a year of therapy is approximately $16,000 
(Kavanaugh et al., 2004).  Also, as discussed earlier, infliximab, etanercept, and 
adalimumab have different routes of administration, which has resulted in different 
coverage and reimbursement policies.  Infliximab, which is administered intravenously, 
is covered under medical benefits while etanercept and adalimumab are administered 
subcutaneously and are covered only under pharmacy benefits.  In addition, due to the 
tier system of the managed care organizations, patients are required to pay higher copay 
or sometimes pay the entire cost of etanercept or adalimumab (Gallup, 2001). 
 
Efficacy of TNF inhibitors, side effects of these agents, and age of patient 
eligible for these agents were perceived as less problematic.  Etanercept was considered 
as most efficacious with less perceived side effects as compared to adalimumab and 
infliximab.  These TNF inhibitors have been shown to achieve a marked improvement 
in outcomes in patients with RA and also found to be well tolerated.  There are a few 
side effects reported such as injection-and infusion-site reaction and infections.  Largest 
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clinical experience among the three agents exists with etanercept since it was the first to 
be launched in the market. Also, data from clinical trials, practice experience, and post-
marketing surveillance reports have shown that etanercept is effective and safe 
(Fleischmann & Yocum, 2004). 
 
Rheumatologists perceived patient preference and route of administration as 
less problematic in prescribing these agents.  Adalimumab was perceived to be least 
problematic in terms of patient preference and route of administration as compared to 
the other two agents.  The patient preference for adalimumab could be high because of 
the differences in route of administration of these agents.  Adalimumab and etanercept 
are self-administered as subcutaneous injections while infliximab is administered as an 
infusion.  Adalimumab has a dosing schedule of 40 mg every other week as compared 
to 25 mg twice a week for etanercept and a loading dose at baseline, two, six and every 
eight weeks for infliximab.  This might influence better outcomes in patient with RA 
although further research is needed to evaluate this possibility. 
 
Finally, support for administering infusions although perceived as a minor 
problem, was higher for infliximab as compared to the other two agents.  Infliximab is 
administered as an infusion on an outpatient basis and requires the use of professional 
staff.  In addition, it also requires emergency personnel and equipment to monitor any 
untoward acute infusion reactions.  Etanercept and adalimumab, on the other hand, are 
self-administered by patients and do not require additional staff to administer or 





SUMMARY AND CONCLUSIONS 
 
This chapter provides a review of the study findings, draws conclusions, 
presents implications of the study findings, lists limitations of each phase of the study, 




 Tumor necrosis factor (TNF) inhibitors offer important treatment options to 
patients with RA and are essential to patients that inadequately respond to MTX alone.  
With the healthcare expenditures rising due to ageing population and technological 
advances, it is becoming important to assess the “value for money” for these new drugs 
that are relatively expensive compared to the traditional DMARDs, but then also seem 
to provide more health benefits to the patients.  A few pharmacoeconomic evaluations 
have been conducted with TNF inhibitors in patients with RA who had an inadequate 
response to MTX.  However, most of the studies have failed to include the withdrawal 
rates of patients, adverse effects caused by the TNF inhibitors or a decrease in the 
future risk of disability, thereby potentially biasing the cost-effectiveness ratios.  Also, 
there are no pharmacoeconomic studies that have compared all three TNF inhibitors 
(adalimumab, etanercept, and infliximab) and leflunomide. 
 
Thus, the goal of this phase of the study was to conduct an incremental cost-
effectiveness analysis of TNF inhibitors (adalimumab, etanercept, and infliximab) and 
leflunomide used in combination with MTX in the treatment of patients with RA that 
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inadequately respond to MTX alone.  In particular, the goal was to quantify the cost per 
discounted quality-adjusted life year (QALY) gained through the use of etanercept, 
adalimumab, infliximab, or leflunomide in combination with MTX compared with the 
standard MTX treatment.  The method involved modeling clinical pathways, defining 
comparators and synthesizing evidence from a range of sources to quantify the model 
parameters.  
 
Conclusions for Phase I  
 The results suggest that the combination of etanercept and MTX should be 
considered cost-effective when compared against traditional DMARDs (leflunomide 
plus MTX and standard MTX treatment) and the combination of other two TNF 
inhibitors with MTX (adalimumab and infliximab) in patients with RA that 
inadequately respond to MTX alone.  The one-way and probabilistic sensitivity 
analyses suggest that this conclusion is relatively robust to the model assumptions 
including increased risk of mortality due to RA, consideration of only direct costs, 
different estimates of indirect costs or exclusion of hospitalization costs.  The results 
also suggest that the combination of leflunomide and MTX is the second most cost-
effective option in patients with RA that inadequately respond to MTX alone.  This 
treatment was the most cost-effective when the indirect costs were valued at three times 
that of the direct costs.  In a base-case analysis, adalimumab plus MTX and infliximab 
plus MTX cost more and had a higher ICER than leflunomide plus MTX.  Therefore, 




Etanercept plus MTX provided more health benefits (15.84 QALYs) and was 
more costly than standard MTX treatment, with resulting cost-effectiveness ratios of 
$49,724/QALY.  The second most cost-effective treatment was leflunomide plus MTX 
with an ICER of $52,833/QALY.  The lowest cost/QALY for etanercept plus MTX and 
leflunomide plus MTX were $30,371/QALY and $43,720/QALY, respectively.  The 
highest cost/QALY values for etanercept plus MTX and leflunomide plus MTX were 
$74,628/QALY and $63,126/QALY, respectively.  These ICERs for both the 
treatments remained within the acceptable range of $50,000 and $100,000 as compared 




Even though infliximab, etanercept, and adalimumab belong to the same class 
of drugs, they have distinct clinical, pharmacokinetic, and pharmacodynamic properties 
that must be considered when selecting any one of them for therapy.  These drugs have 
the potential to reduce future disability and cause remission in RA; however, the high 
acquisition cost of these agents coupled with intensive monitoring required for 
toxicities seem to be the treatment-limiting factors.  Since the TNF inhibitors have 
recently been introduced in the market, there is not enough data available regarding the 
use of these drugs by rheumatologists.  Very little information is available regarding 
rheumatologists practice patterns, laboratory monitoring practices, and barriers they 
perceive in prescribing these agents.  This information can only be clarified with the 
availability of data from evaluation of physician practice experiences.  Thus, the goal of 
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phase II of the study was to survey a national sample of rheumatologists and assess 
their practice patterns with respect to the use of these three agents. 
 
Conclusions for Phase II 
 The conclusions of this phase of the study are presented based on the objectives 
proposed in the study. 
 
Objective 1:  Prescribing patterns for the three TNF inhibitors: adalimumab, 
etanercept, and infliximab. 
 As expected, rheumatologists were prescribing the TNF inhibitors in patients 
with moderate to severe RA.  An important finding was that some rheumatologists had 
broadened the official indication of these agents to patients with early-onset RA.  In 
patients with severe RA that inadequately responded to MTX alone, rheumatologists 
reported using a combination of TNF inhibitor with a traditional DMARD indicating a 
preference for combination treatments in patients with severe disease.  Another finding 
was that a majority of rheumatologists reported switching patients from one TNF 
inhibitor to another TNF inhibitor due to lack of efficacy or adverse events of the first 
one. 
 
Objective 2:  Rheumatologists’ preference for a particular TNF inhibitor. 
The null hypothesis aimed to investigate that there is no preference for any 
particular TNF inhibitor.  The finding of the survey showed a preference for etanercept 
followed by adalimumab and infliximab. 
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Objective 3:  Rheumatologist characteristics and perceived barriers in prescribing 
TNF inhibitors and preference for a particular TNF inhibitor. 
The null hypothesis aimed to investigate that there is no relationship of 
preference for a particular TNF inhibitor and demographic, practice-related 
characteristics, and perceived barriers in prescribing TNF inhibitors.  The study 
revealed that male rheumatologists preferred these agents to females.  Also, 
rheumatologists who preferred infliximab saw more patients per week compared to 
other two TNF inhibitors.  Rheumatologists who preferred infliximab perceived the 
need for additional support for administration of infliximab compared with etanercept 
and adalimumab.  Rheumatologists who preferred etanercept perceived patient 
compliance as a barrier compared to those who preferred adalimumab.  However, both 
perceptions were considered as minor problems. 
 
Objective 4:  Laboratory monitoring practices and the frequency of tests ordered for 
patients on TNF inhibitors. 
 The complete blood count tests and the purified protein derivative tests were 
ordered by a majority of the rheumatologists for all three TNF inhibitors.  The anti-
nuclear antibody tests and creatinine tests were ordered by only one-third to half of the 
rheumatologists.  Also, there was a wide variation in terms of frequency at which these 
tests were ordered.  The most commonly used doses for adalimumab and etanercept 
were 40 mg every other week and 25 mg twice every week, respectively.  A range of 




Objective 5: Recommended monitoring guidelines for patients with RA on adalimumab, 
etanercept, and infliximab. 
A majority of rheumatologists reported following ACR monitoring guidelines.  
Since there are no established monitoring guidelines for TNF inhibitors, it is believed 
that rheumatologists were using guidelines based on their past experiences with 
traditional DMARDs.  Another finding was that one-fourth of the rheumatologists did 
not follow any monitoring guidelines for patients who used TNF inhibitors. 
 
Objective 6:  Rheumatologist characteristics and perceived barriers in prescribing 
TNF inhibitors and monitoring guidelines. 
The null hypothesis aimed to investigate that there is no relationship of 
adherence to monitoring guidelines and demographic, practice-related characteristics, 
and perceived barriers in prescribing TNF inhibitors.  Rheumatologists who followed 
monitoring guidelines were a little younger and had fewer years of practice.  Although 
the results were significantly different indicating a difference in age and years of 
practice between those who follow guidelines and those who don’t, it only remains to 
be seen if a difference of two years is relevant in clinical practice. 
 
Objective 7:  Perceived barriers in prescribing TNF inhibitors. 
Costs to patients and insurance coverage were perceived as major problems and 
patient preference, route of administration, and side effects were perceived as minor 
problems.  Among the three TNF inhibitors, the perception for costs to patients and 
insurance coverage was a little lower for infliximab compared to etanercept and 
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adalimumab.  For factors like patient preference, route of administration, and side 




Implications of Study Findings 
 
The study was undertaken to assess the cost-effectiveness of TNF inhibitors in 
patients that inadequately respond to MTX alone.  The study also aimed to assess the 
prescribing patterns and laboratory monitoring practices of rheumatologists using TNF 
inhibitors.  The study findings should be useful to decision makers such as payers and 
prescribers. 
 
Implications to the Payers 
  The study results indicate that the combination of etanercept and MTX is the 
most cost-effective option in patients with RA that inadequately respond to MTX alone. 
Also, the survey results indicate that rheumatologists prefer etanercept to infliximab 
and adalimumab for a variety of reasons, including method of administration and 
adverse-events profile.  Patients with greater disease severity incur high costs and these 
new therapies can have long-term savings by preventing functional decline and 
subsequent hospitalization and surgery in these patients.  Even though the long-term 
impact of these agents on joint damage cannot be determined with certainty at present, 
a reduced risk of surgery will reduce the demand for orthopedic services.  However, the 
disparity in reimbursement based on different routes of administration for these 
medications underscores the need for investing in long-term positive outcomes through 
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aggressive treatment of RA.  Managed care organizations need to consider these issues 
when making formulary and coverage decisions. 
 
 The study findings also indicate that there are no established treatment 
guidelines for these agents.  Rheumatologists are prescribing these agents to patients in 
mild RA and also switching patients from one TNF inhibitor to another without much 
evidence available regarding the usefulness of this practice.  The practice of switching 
may be effective but if not, it may be a waste of time and money.  Thus, there is a need 
to develop strategies to increase the appropriate prescribing and monitoring of these 
agents till sound evidence are available supporting the usefulness of switching TNF 
inhibitors or using these agents in patients with early forms of the disease.   
  
Implications to the Prescribers 
The use of TNF inhibitors to treat RA has implications for current practices in 
rheumatology.  The widespread use of etanercept and adalimumab would place a 
greater demand on outpatient services.  This would include increased involvement of 
health care providers like nurses to teach patients to self-administer injections and to 
provide disease and drug monitoring services.  The widespread use of infliximab will 
lead to greater utilization of rheumatology facilities and support staff.  Currently there 
are no monitoring guidelines available and there is a wide variation in laboratory 
monitoring practices among rheumatologists.  Thus, interested practitioners, 
manufacturers, and policymakers should revisit old monitoring guidelines or perhaps 
implement new monitoring guidelines for the use of these newer agents.  
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Limitations of the Study 
 
Both phases of the study have some limitations and these are discussed in the 
following section.  These limitations need to be considered when deriving inferences 
from the reported results. 
 
Limitations of Phase I 
 
1. The main limitation relates to available data.  An ideal source would have been 
a very long-term, randomized study with a large sample size examining the 
efficacy and resources utilized by all the therapeutic options in patients with RA 
that inadequately respond to MTX alone.  In the absence of such a study, 
evidence had to be assembled from a range of sources and these sources have 
their advantages and disadvantages from a health economic perspective.  Thus, 
the results of any modeling study need to be treated with some degree of 
caution. 
 
2. The base-case analysis in the decision analytic model assumes that the baseline 
characteristics of the study patients across RCTs are comparable based on their 
close similarities in important baseline demographic and clinical characteristics.  
It is a general view that absolute comparability across different treatments can 
be established through randomization.  Currently, such data does not exist and it 
is doubtful whether all the treatment options considered in the analysis would be 
evaluated using a single head-to-head randomized controlled clinical trial in the 




3. The efficacy data for each treatment option except for adalimumab plus MTX 
and standard MTX treatment comes from a single respective RCT.  Therefore, 
there will be generalizability issues with the base-case estimates used in the 
Phase I of the study.  However, sensitivity analyses were conducted to address 
this limitation and the results obtained seemed to be robust at different values of 
input parameters. 
 
4. The three TNF inhibitors and leflunomide have different modes of 
administration.  Since no data is available indicating differing rates of 
compliance among the different TNF inhibitors and leflunomide in patients with 
RA, the potential impact of compliance was not considered in the model.  The 
model assumed 100% compliance.  This assumption was necessary to fully 
quantify the costs and consequences of introducing these agents under ideal 
conditions.  However, it would be important to see whether the ICERs change 
when compliance is introduced in the model. 
 
5. It was assumed that patients who did not respond to the treatments were 
switched to palliative care.  Currently, there is no data to show the actual 
distribution of time a patient spends on each of these drugs.  Also, in actual 
clinical settings, if the patient fails to respond to one agent, rheumatologists may 
switch the patient to a different DMARD or a TNF inhibitor.  Thus, a sequential 
use of DMARDs could have been a better comparator.  Given the complexity of 
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treatment regimens, it is very difficult to decide on the sequences of DMARDs 
and also the placement of TNF inhibitors in these regimens.   
 
Limitations of Phase II 
 
1. This phase of the study was a mail survey and therefore all the limitations of a 
mail survey will be inherent in this study.  Some of these limitations include 
measurement errors due to respondents not understanding the instructions or 
items, and recall bias, which can affect the accuracy of inferences drawn from 
the survey responses. 
 
2. Even though the survey instrument has face and content validity, it has not been 
otherwise validated. 
 
3. The nonresponse bias analysis revealed differences in some variables such as 
age and years in practice between respondents and nonrespondents.  Caution 
should, therefore, be exercised when extrapolating the findings to the entire 
rheumatologist population. 
 
Recommendations for Future Research 
 
The model presented in the study was populated using different data sources 
and each of the sources had their own strengths and limitations.  The majority of data 
came from clinical trials which are conducted under controlled conditions and therefore 
do not reflect the real clinical setting.  Future studies should try and incorporate data in 
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the model from observational study.  For example, various TNF registries have been 
established all over world.  It is too early to get such a data from the registry however, 
in the future; these might provide refinement of estimates such as response rates, 
withdrawal rates, and long-term disability progression.  These data can also be useful in 
estimating the compliance of different drugs.  Other priorities for future research should 
include estimating costs associated with RA incurred by patients and their families, 
including a fuller coverage of adverse events of TNF inhibitors and other traditional 
DMARDs. 
 
Strategies for treating RA are potentially very complex and could include 
combination treatments, triple therapies, or a sequence of drugs.  A number of events 
such as joint replacement, hospitalization, switching due to lack of efficacy or adverse 
events take place in a patient’s lifetime.  An advanced modeling technique such as 
discrete event simulation can be used to represent such structure and produce a realistic   
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APPENDIX A: FIRST COVER LETTER 
 




 We are writing to seek your opinions on an important class of drugs that you 
use in your practice. Tumor Necrosis Factor (TNF) inhibitors such as adalimumab, 
etanercept, and infliximab, have advanced the treatment of Rheumatoid Arthritis. 
Clinical trials with these drugs have shown that they may be more effective than 
traditional agents because of their ability to prevent or control joint damage as well as 
diminish pain. However, these drugs have been only recently introduced in the market, 
and there are numerous questions regarding their appropriate dosage, monitoring 
schedules, and target population.   
  
The objective of the current research study is to assess the current treatment 
practices of rheumatologists who use TNF inhibitors in patients with Rheumatoid 
Arthritis. This research study is part of a doctoral (Ph.D.) dissertation project and is 
being undertaken and funded by the West Virginia University School of Pharmacy. 
Information obtained from this research study will be useful in determining common 
practices and issues associated with the use of TNF inhibitors.  
 
Your name was randomly selected from a national list of rheumatologists. We 
hope that you will participate by completing the attached questionnaire that asks about 
your current treatment practices and experiences using TNF inhibitors in patients with 
Rheumatoid Arthritis. The approximate time to complete the questionnaire is 5-10 
minutes. To assure confidentiality, your responses will be coded and your name will 
not appear in any data analysis or research reports.  Therefore, we assure you of as 
much confidentiality as legally possible. Your participation in this research study is 
voluntary.  You do not need to answer all questions even though we would prefer that 
you do.  
 
  Your response will provide valuable information and is critical to the success of 
the research study. Please return the completed survey in the enclosed postage-paid 
business reply envelope.   
 
  If you have any questions or concerns, please do not hesitate to contact Khalid 
Kamal at (304) 293-1442 or Dr. Suresh Madhavan at (304) 293-1652 at the West 





Khalid Kamal, M.S.     Suresh Madhavan, Ph.D. 





APPENDIX B: SECOND COVER LETTER 
 




About two weeks ago, we sent you a survey asking you about your current 
treatment practices and experiences using Tumor Necrosis Factor (TNF) inhibitors in 
patients with Rheumatoid Arthritis. If you have already completed and returned the 
survey, we thank you for your time and participation. If you have not completed the 
survey, we request you to kindly do so.  
 
  We understand that you are busy or may not have received the initial survey. 
However, your views are extremely important to us, and the information obtained from 
this research study would be very useful in determining common practices and issues 
associated with the use of TNF inhibitors. Therefore, we are again sending you this 
survey and would appreciate it if you will take a few minutes to complete the survey 
and return it in the postage-paid business reply envelope. 
 
  This research study is part of a doctoral (Ph.D.) dissertation project and is being 
undertaken and funded by the West Virginia University School of Pharmacy. To assure 
confidentiality, your responses will be coded and your name will not appear in any data 
analysis or research reports.  Therefore, we assure you of as much confidentiality as 
legally possible. Your participation in this research study is voluntary. You do not need 
to answer all questions even though we would prefer that you do.  
 
  If you have any questions or concerns, please do not hesitate to contact Khalid 
Kamal at (304) 293-1442 or Dr. Suresh Madhavan at (304) 293-1652 at the West 







Khalid Kamal, M.S.     Suresh Madhavan, Ph.D. 






































INSTRUCTIONS: The first section of the questionnaire gathers prescribing information on specific Tumor 
Necrosis Factor (TNF) inhibitors [adalimumab (Humira®), etanercept (Enbrel®), and infliximab (Remicade®)] 




1.  In what patient population do you normally use the following TNF inhibitor/s: adalimumab 
(Humira®), etanercept (Enbrel®), and infliximab (Remicade®): (Please check all that apply) 
 
             Patient Population 
TNF inhibitors       Newly Diagnosed    Mild RA Moderate RA       Severe RA                            
 
Adalimumab (Humira®)               ⁪          ⁪          ⁪   ⁪ 
Etanercept (Enbrel®)                 ⁪          ⁪          ⁪   ⁪ 
 Infliximab (Remicade®)       ⁪          ⁪          ⁪   ⁪ 
 
2. I do not use TNF inhibitors   ⁪   (If you have checked this box, please go to Section C) 
 
3.  In patients diagnosed with Rheumatoid Arthritis in whom you determine a TNF inhibitor is necessary, 
which TNF inhibitor are you most likely to prescribe? (Please rank in the order of preference with 1 
being your first choice)   
TNF Inhibitor        Rank 
 
Adalimumab (Humira®)   ________ 
Etanercept  (Enbrel®)   ________ 
Infliximab (Remicade®)   ________ 
 
 
4.  In patients who have severe RA and who have failed to respond to methotrexate, please indicate how 
you would use a TNF inhibitor: (Please check all that apply) 
 
     ⁪ TNF inhibitor alone       ⁪ TNF inhibitor and one other DMARD  
     ⁪ TNF inhibitor and 2 other DMARDs    ⁪ No TNF inhibitor     
     ⁪ Other treatment or approach (please specify) _______________     
 
5. a. In your practice, have you ever switched any patient from one TNF inhibitor to a different TNF 
inhibitor due to inadequate response or side effects? 
 
        ⁪ No      ⁪ Yes 
 
    b. If yes, please indicate in general, your reason(s) for switching______________________________ 
 





        








INSTRUCTIONS: The following questions are regarding the use of [adalimumab (Humira®), etanercept 
(Enbrel®), and infliximab (Remicade®)] in your practice. Please answer the questions carefully.  All responses will 
be kept confidential. 
1. The following questions are regarding the use of Adalimumab (Humira®) 
 
a.  Please indicate the typical dose and frequency of dosing of adalimumab (Humira®) that you use for   
     patients  with RA in your practice.   
 
     Dose for newly diagnosed RA                                          ____________  mg every_________ week 
     Dose for mild RA                                                              ____________  mg every_________ week       
     Dose for moderate RA                                                      ____________  mg every _________ week 
     Dose for severe RA                                                           ____________  mg every _________ week 
 
b. Which laboratory tests do you routinely order for adalimumab (Humira®) and how frequently do you  
     order these tests? (Please check all that apply) 
 
       Tests       Tests ordered  How frequently? 
  
    Antinuclear Antibody test (ANA)           ⁪   Every  ________ week(s) 
    Complete blood cell count (CBC)          ⁪   Every  ________ week(s) 
    Chest radiography            ⁪   Every  ________ week(s) 
    Creatinine             ⁪   Every  ________ week(s) 
    Purified protein derivative (PPD)          ⁪   Every  ________ week(s) 
      
2. The following questions are regarding the use of Etanercept (Enbrel®) 
 
a.  Please indicate the typical dose and frequency of dosing of etanercept (Enbrel®) that you use for  
     patients with RA in your practice.         
 
     Dose for newly diagnosed RA                                          ____________  mg every_________ week 
     Dose for mild RA                                                              ____________  mg every_________ week       
     Dose for moderate RA                                                      ____________  mg every _________ week 
     Dose for severe RA                                                           ____________  mg every _________ week
  
b. Which laboratory tests do you routinely order for etanercept (Enbrel®) and how frequently do you  
     order these tests? (Please check all that apply) 
 
             Tests       Tests ordered  How frequently? 
  
    Antinuclear Antibody test (ANA)           ⁪   Every  ________ week(s) 
    Complete blood cell count (CBC)          ⁪   Every  ________ week(s) 
    Chest radiography            ⁪   Every  ________ week(s) 
    Creatinine             ⁪   Every  ________ week(s) 
    Purified protein derivative (PPD)          ⁪   Every  ________ week(s) 
   
3. The following questions are regarding the use of Infliximab (Remicade®) 
 
a.  Please indicate the typical dose and frequency of dosing of infliximab (Remicade®) that you use for  
     patients with RA in your practice.   
 
     Dose for newly diagnosed RA                                          ____________  mg every_________ week 
     Dose for mild RA                                                              ____________  mg every_________ week       
     Dose for moderate RA                                                      ____________  mg every _________ week 
     Dose for severe RA                                                           ____________  mg every _________ week 
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b. Which laboratory tests do you routinely order for infliximab (Remicade®) and how frequently do you  
     order these tests? (Please check all that apply) 
 
    Antinuclear Antibody test (ANA)           ⁪   Every  ________ week(s) 
    Complete blood cell count (CBC)          ⁪   Every  ________ week(s) 
    Chest radiography            ⁪   Every  ________ week(s) 
    Creatinine             ⁪   Every  ________ week(s) 
    Purified protein derivative (PPD)          ⁪   Every  ________ week(s) 
 
4. Please indicate the extent to which you feel each of the following factors are problematic to using 
specific TNF inhibitors in patients with Rheumatoid Arthritis. Circle the number on the continuum 
between 1 and 7 (1=no problem and 7=major problem) that best describes your opinion for each 
specific TNF inhibitor.   
 
   Adalimumab (Humira®)     Etanercept (Enbrel®)     Infliximab (Remicade®) 
 
Factors                       No                      Major          No                   Major     No                 Major 
                                  Problem             Problem       Problem          Problem     Problem        Problem 
 
Age of patient             1   2   3   4   5   6   7     1   2   3   4   5   6   7     1   2   3   4   5   6   7 
 
Costs to the patient     1   2   3   4   5   6   7     1   2   3   4   5   6   7     1   2   3   4   5   6   7 
 
Efficacy of this TNF  
inhibitor in your        
experience    1   2   3   4   5   6   7     1   2   3   4   5   6   7     1   2   3   4   5   6   7 
 
Insurance / Formulary 
coverage         1   2   3   4   5   6   7     1   2   3   4   5   6   7     1   2   3   4   5   6   7 
 
Patient compliance  
with this therapy          1   2   3   4   5   6   7     1   2   3   4   5   6   7     1   2   3   4   5   6   7 
 
Patient preference for  
this TNF inhibitor  1   2   3   4   5   6   7     1   2   3   4   5   6   7     1   2   3   4   5   6   7 
 
Route of administration 
of this TNF inhibitor 1   2   3   4   5   6   7     1   2   3   4   5   6   7     1   2   3   4   5   6   7 
 
Side-effects of this  
TNF inhibitor  1   2   3   4   5   6   7     1   2   3   4   5   6   7     1   2   3   4   5   6   7 
          
Support for administering 














       
   
   
INSTRUCTIONS: This section of the questionnaire gathers information about you and your practice.  
Section C 
 
1. Age _________Years   
 
2. Gender:  ⁪ Male   ⁪  Female 
 
3. Number of years in practice as a rheumatologist:  ______________ Years  
 
4. Your primary practice site is: 
 
    ⁪ Hospital based      ⁪ University-affiliated Hospital      ⁪ Solo, Office-based     ⁪ Group, office-based 
 
    ⁪ Others, please specify _________________ 
 
5. Average number of RA patients seen per week _____________ 
 
6. Average number of prescriptions written per week for each drug:   
 
Adalimumab (Humira®) ________ 
Etanercept  (Enbrel®) ________ 
Infliximab (Remicade®)     ________ 
 
7. Please indicate which of the following monitoring guidelines you follow for patients with RA on 
adalimumab (Humira®), etanercept (Enbrel®), or infliximab (Remicade®)?  
 
    ACR EULAR    ACR & EULAR        None   Other  
                                 (Please specify) 
 
    Adalimumab (Humira®)   ⁪        ⁪   ⁪       ⁪ 
    Etanercept (Enbrel®)   ⁪        ⁪   ⁪       ⁪ 
















****THANK YOU FOR YOUR TIME AND ASSISTANCE!**** 
 
Please return the completed survey in the enclosed business reply envelope. 
219 
 
APPENDIX D: NON-RESPONSE SURVEY 
 
 







During the past two months you may have received two or three mailings of a questionnaire 
asking you about your current treatment practices and experiences using Tumor Necrosis 
Factor (TNF) inhibitors in patients with Rheumatoid Arthritis. We realize that you have been 
very busy and have chosen not to answer the survey. Since your views are extremely important 
to us, we would like to know your reason for not responding to this survey and some key 
information for the research study.  
 
  
This research study is part of a doctoral (Ph.D.) dissertation project and is being undertaken and 
funded by the West Virginia University School of Pharmacy. Your participation in this research 
study is voluntary. You do not need to answer all questions even though we would prefer that 
you do. Your responses will be coded, and your name will not appear in any data analysis or 
research reports.  Therefore, we assure you of as much confidentiality as legally possible.  
 
   
Please answer the few questions below and mail it to us in the postage-paid business reply 
envelope. If you have any questions or concerns, please do not hesitate to contact us at (304) 






Khalid Kamal, M.S.    Suresh Madhavan, Ph.D. 
Ph.D. Candidate     Professor and Chairperson 
 
 
Q1. I did not respond to the survey because: 
     
I did not receive it      I do not respond to mail surveys 
     Forgot the survey     The survey was too long 
     I did not have enough time to complete it  The survey was confusing 
     The survey was misplaced    I am not interested in such studies 
     Survey was biased      No incentive to complete it 
    Topic was irrelevant     Other reasons (Please      





Q2. In what patient population do you normally use the following TNF inhibitor/s: 
adalimumab (Humira®), etanercept (Enbrel®), and infliximab (Remicade®): (Please check 
all that apply) 
 
        Patient Population 
TNF inhibitors     Newly Diagnosed     Mild RA    Moderate RA       Severe RA 
 Adalimumab (Humira®)           ⁪  ⁪          ⁪    ⁪ 
 
 Etanercept (Enbrel®)      ⁪  ⁪          ⁪    ⁪ 
 
Infliximab (Remicade®)      ⁪  ⁪          ⁪    ⁪ 
 
 
Q3. I do not use TNF inhibitors       ⁪  
 
 
Q4. Demographics:  
  
        1. Age _________Years   
 
          2. Gender:       ⁪ Male   ⁪  Female 
 
          3. Number of years in practice as a rheumatologist:  ______________ Years 
 
          4. Your primary practice site is: 
 
             ⁪ Hospital based           ⁪ University-affiliated Hospital      ⁪ Solo, Office-based     
               
               ⁪ Group, office-based    ⁪ Others, please specify _________________ 
 









103 Ellen Lane               Phone: (304) 598-5670 
Morgantown               Cellular: (304) 685-5984 
WV 26505                        Email: kkamal@hsc.wvu.edu 
 
PROFESSIONAL PROFILE 
Highly motivated candidate with diverse educational, work, research, and teaching 
experiences in the field of health economics and outcomes research  
 
Areas of Expertise 
• Decision modeling, epidemiology, pharmacoeconomics, survey research, and 
health services marketing 
• Strong writing, research, and communications skills 
• Strong background in computer applications and statistical skills    
• Successful experiences in pharmaceutical sales and marketing  
 
ACADEMIC CREDENTIALS 
08/1999 - 05/2005   
Doctor of Philosophy (Ph.D.) in Pharmaceutical Sciences 
Major Area: Health Economics and Outcomes Research 
Department of Pharmaceutical Systems & Policy, West Virginia University 
Dissertation: Assessing the cost-effectiveness of tumor necrosis factor inhibitors 
and prescribing practices of rheumatologists in patients with 
rheumatoid arthritis  
Major Advisor: Suresh Madhavan, MBA, PhD     
GPA: 3.71 
 
08/1999 - 12/2000 
Certificate in Health Care Administration, Department of Public Administration,  
West Virginia University 
 
07/1994 - 06/1996 
      Masters in Pharmacology (MS), University of Bombay, India  
 
06/1990 - 06/1994 
      Bachelor of Pharmacy (B. Pharm), University of Bombay, India 
 
WORK / RESEARCH EXPERIENCE 
06/2000 - 09/2004  
CDC-funded Prevention Research Center, West Virginia University 
Research Assistant 
Developed evaluation measures, performed data analysis, assisted in writing grants 






08/2003 - 06/2004 
Health Education Assessment Project in West Virginia 
Research assistant on a study funded by the West Virginia Department of 
Education. The project involved analyzing and reporting the first statewide 
assessment of health education. Developed analytical plan and assisted in 
preparation of report and publication of study results 
 
05/2003 - 08/2003   
GlaxoSmithKline (Global Health Outcomes), RTP, NC 
Summer Intern 
Selected Projects: 
• Impact of treatment for allergic rhinitis on asthma-related health care utilization 
- Developed conceptual framework, methodology, and data analysis plan using 
retrospective claims database  
• Economic burden of illness among patients with allergic rhinitis and comorbid 
asthma 
- Developed concept proposal and assisted in vendor evaluation  
- Performed comprehensive evaluation of quality of life instruments, patient 
preference, and productivity measures 
• Economic and humanistic outcomes in multiple sclerosis 
- Developed a comprehensive report for economic and quality of life studies in 
support of product launch decision  
 
07/2001 - 05/2002  
Pharmacy & Immunization Services: Pharmacists’ Participation and Impact 
Research assistant on a study funded by the American Pharmacists Association 
(APhA) to assess pharmacists’ involvement in immunization services. Assisted in 
development of survey questionnaire, data collection, analyses and publication of 
the study results 
 
07/1996 - 06/1999  
Universal Medicare Ltd, Mumbai, India 
• Product Management    12/1997 - 06/1999 
Successfully coordinated all aspects of product launch including annual 
marketing plans, situation analysis, competitive evaluation, sales planning, 
promotions, and pricing 
• Area Sales Manager      12/1996 - 11/1997 
Managed six sales representatives that consistently met or exceeded company 
sales goals 
• Medical Sales Representative    07/1996 - 11/1996 







08/1999 - 05/2000, 10/2004 - Present 
Graduate Teaching Assistant, School of Pharmacy, West Virginia University 
• Pharmacy as a Profession: Responsibilities included lecturing, grading, 
managing course materials, and facilitating student projects 
• Pharmacy Care Lab and Patient Health Education: Responsibilities included 
conducting skills exercises, evaluating student verbal and non-verbal patient 
consultation skills, grading, and managing course materials 
 
RELEVANT COURSES COMPLETED 
Health Outcomes:   Pharmacoeconomics, Outcomes and Quality of Life 
Assessment, Decision Analysis in Healthcare, Econometrics, 
Project Analysis and Evaluation, Health Behavior Theories 
Research Methods: Epidemiology, Survey Research, Qualitative Methods 
Statistical Methods: Data Management and Analyses, Multivariate Analysis, 
Regression Techniques 
Health Administration:  Healthcare Organizations and Operations, Health Systems, 
Managed Care  
Marketing:                     Health Services Marketing, Consumer Behavior 
 
COMPUTER SKILLS 
Statistical packages:             SPSS, SAS, STATA 
Decision analysis software: DATA TreeAge, @ RISK, Precision Tree 
Other:             MS Office, Microsoft FrontPage, Microsoft Visio 
 
PUBLICATIONS 
Tompkins NO, Kamal KM, Chapman D. West Virginia Health Education Assessment 
Project. Journal of School Health 2005;75(6):193-198 
 
Kamal KM, Miller LA. Psychosocial factors and asthma. (Letter). American Journal 
of Respiratory and Critical Care Medicine 2004;169(11):1253-54 
 
Orsini L, Limpa-Amara S, Crown WH, Stanford RH, Kamal KM. Asthma 
hospitalization risk and costs for patients treated with fluticasone propionate versus 
montelukast. Annals of Asthma, Allergy and Immunology 2004;92:523-529 
 
Dino GA, Kamal KM, Kalsekar ID, Fernandes AW, Horn KA. Stages of change and 
smoking cessation outcomes in adolescents. Addictive Behavior 2004;29(5):935-40 
 
Kamal KM, Madhavan SS, Maine LL. Pharmacy and immunization services: 
Pharmacists’ participation and impact. Journal of American Pharmaceutical 
Association 2003;43(4):470-82 
 
Kamal KM, Madhavan SS, Amonkar MM. Determinants of adult influenza and 







Kamal KM, Madhavan SS, Maine LL. Pharmacists and immunization services: Impact 
of American Pharmaceutical Association’s (APhA) Immunization Training 
Certification Program. American Journal of Pharmaceutical Education 
2003;67(4):article 124 
 
Kamal KM, Madhavan SS, Maine LL.  Pharmacists and immunization services: 
Impact of American Pharmaceutical Association’s (APhA) Immunization Training 
Certification Program. (Abstract). Journal of American Pharmaceutical Association 
2003;43(2):314 
 
Kamal KM, Madhavan SM, Amonkar MM. Determinants of adult influenza and 
pneumonia immunization rates. (Abstract). Journal of American Pharmaceutical 
Association 2001; 41(2):320 
 
Nair AM, Mungantiwar AA, Kamal KM, Saraf MN. Modulation of invitro 
anaphylaxis by furosemide. Indian Journal of Pharmacology 1997;29:182-186 
 
Nair AM, Mungantiwar AA, Kamal KM, Saraf MN. Antiallergic potential of 
furosemide. Indian Journal of Experimental Biology 1997;35:466-469 
 
Kamal KM, Madhavan SM, Hornsby JA, Miller LA, Scott V, Kavookjian J.  Survey of 
current treatment practices of rheumatologists in prescribing tumor necrosis factor 
inhibitors in patients with rheumatoid arthritis (in preparation for Arthritis and 
Rheumatism) 
 
Kamal KM, Miller LA, Madhavan SM, Kavookjian J.  Alternative decision analysis 
modeling in the economic evaluation of tumor necrosis factor inhibitors in patients with 
rheumatoid arthritis (in preparation for Seminars in Arthritis and Rheumatism) 
 
Tessaro I, Campbell MK, Kamal KM, Benedict S, Kelsey K, DeVellis B. Factors 
associated with breast and cervical cancer screening in a population of working women 
(in preparation) 
 
SELECTED SCIENTIFIC PRESENTATIONS  
Kamal KM, Miller LA, Madhavan SM, Kavookjian J.  Alternative decision analysis 
modeling in the economic evaluation of tumor necrosis factor inhibitors in patients with 
rheumatoid arthritis. The annual meeting of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR), Washington, D.C., May 2005 
 
Kamal KM, Madhavan SM, Hornsby JA.  Survey of current treatment practices of 
rheumatologists in prescribing tumor necrosis factor inhibitors in patients with 
rheumatoid arthritis. The annual meeting of the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR), Washington, D.C., May 2005  
 
Kamal KM, Kalsekar I, Fernandes A, Horn K, Dino G. Stage of change and smoking 
cessation outcomes in adolescents. Presented at the annual meeting of the National 




Hassan M, Kamal KM, Mody R, and Amonkar M. Breast and cervical cancer 
screening among obese women in the United States. Presented at the annual meeting of 
American Public Health Association, Atlanta, GA, October 2001 
 
Kamal KM, Madhavan SM, Amonkar MM. Predictors of influenza immunization rates 
in adults aged 50-64 years and 65 years and above. Presented at the annual meeting of 






Treasurer of WVU-ISPOR student chapter (2002 - 2003) 
Secretary of WVU-ISPOR student chapter (2001 - 2002) 
Recipient of Graduate Research Award, School of Pharmacy, WVU (2001- 2002) 
Recipient of All India Council of Technical Education Junior Research Fellowship 
(1994 - 1996) 
Member of Rho Chi Honor Society 
Member of International Society for Pharmacoeconomics & Outcomes Research 
(ISPOR) 
Member of American Pharmacists Association (APhA)  
 
REFERENCES 
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